FOLFIRI Followed by FOLFOX6 or the Reverse Sequence
Randomized GERCOR Study

Journal of Clinical Oncology

22, 229-237

DOI: 10.1200/jco.2004.05.113

Citation Report

#	Article	IF	Citations
1	Principles of intra-arterial infusional chemotherapy in the treatment of liver metastases from colorectal cancer. , 0, , 52-64.		0
2	Messenger RNA expression of TS and ERCC1 in colorectal cancer and matched liver metastasis. International Journal of Oncology, 1992, 33, 1257.	1.4	2
3	Comparison between intravenous and oral postoperative adjuvant immunochemotherapy in patients with stage II colorectal cancer. Oncology Reports, 1994, 20, 1189.	1.2	0
4	ASCO Annual Meeting 2004, New Orleans Opzioni Terapeutiche Nel Carcinoma Del Colon-Retto. Tumori, 2004, 90, 13-27.	0.6	0
5	Impatto Della Letteratura Sulla Pratica Clinica. Tumori, 2004, 90, 1-10.	0.6	0
9	Can we individualise chemotherapy for colorectal cancer?. Annals of Oncology, 2004, 15, 996-999.	0.6	5
12	Use of Surgery Among Elderly Patients With Stage IV Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 3475-3484.	0.8	213
13	A Randomized Trial Comparing Defined-Duration With Continuous Irinotecan Until Disease Progression in Fluoropyrimidine and Thymidylate Synthase Inhibitorâ€"Resistant Advanced Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 3023-3031.	0.8	42
14	Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 1177-1179.	0.8	47
15	Current perspectives in the treatment of metastatic colorectal cancer. Annals of Oncology, 2004, 15, iv43-iv53.	0.6	8
16	First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Annals of Oncology, 2004, 15, 1766-1772.	0.6	99
17	Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Annals of Oncology, 2004, 15, 933-939.	0.6	279
18	First-line treatment options for patients with metastatic colorectal cancer. Nature Clinical Practice Oncology, 2004, 1, 70-71.	4.3	3
19	Cetuximab: an IgG1 monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours. Expert Opinion on Pharmacotherapy, 2004, 5, 1621-1633.	0.9	61
20	Survival of Patients With Advanced Colorectal Cancer Improves With the Availability of Fluorouracil-Leucovorin, Irinotecan, and Oxaliplatin in the Course of Treatment. Journal of Clinical Oncology, 2004, 22, 1209-1214.	0.8	1,007
21	New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Annals of Oncology, 2004, 15, 1453-1459.	0.6	91
22	Tailored Chemotherapy for Colorectal Cancer: A New Approach to Therapy. Cancer Investigation, 2004, 22, 762-773.	0.6	16
23	Developments in combination chemotherapy for colorectal cancer. Expert Review of Anticancer Therapy, 2004, 4, 627-637.	1.1	4

#	Article	IF	Citations
24	The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer. Journal of Clinical Oncology, 2004, 22, 1420-1429.	0.8	153
25	Evidence-based update of chemotherapy options for metastatic colorectal cancer. ANZ Journal of Surgery, 2004, 74, 781-787.	0.3	8
26	A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma. British Journal of Cancer, 2004, 90, 1710-1714.	2.9	31
27	Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. British Journal of Cancer, 2004, 91, 1442-1446.	2.9	15
29	Perspectives in the treatment of colorectal cancer. Seminars in Oncology, 2004, 31, 14-18.	0.8	23
30	Angiogenesis inhibitors in the treatment of colorectal cancer. Seminars in Oncology, 2004, 31, 10-16.	0.8	52
31	Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. BMC Cancer, 2004, 4, 38.	1.1	26
32	Whatâ€™s new in colon and rectal surgery. Journal of the American College of Surgeons, 2004, 199, 917-923.	0.2	6
33	Chemotherapy in metastatic colorectal cancer. Techniques in Coloproctology, 2004, 8, s43-s46.	0.8	9
34	Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies. European Surgery - Acta Chirurgica Austriaca, 2004, 36, 317-321.	0.3	11
35	Medical treatment of advanced colorectal carcinoma. Clinical and Translational Oncology, 2004, 6, 245-257.	1.2	0
37	Integration of novel agents in the treatment of colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S32-9.	1.1	29
38	Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2004, 54 Suppl 1, S57-64.	1.1	17
39	Regional therapy of liver metastases. Current Treatment Options in Oncology, 2004, 5, 427-437.	1.3	0
40	Roles of Infusional High-Dose 5-Fluorouracil with Leucovorin in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, 204-205.	1.0	0
41	Colorectal cancer in 2003: state of the art and new developments. European Journal of Cancer, Supplement, 2004, 2, 1-2.	2.2	0
42	Level of evidence of irinotecan clinical trials and recent data in colorectal cancer. European Journal of Cancer, Supplement, 2004, 2, 3-7.	2.2	2
43	What have we learned and where are we going in the treatment of colorectal and gastric cancer?. European Journal of Cancer, Supplement, 2004, 2, 59-62.	2.2	0

#	Article	IF	Citations
44	Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer. New England Journal of Medicine, 2004, 350, 2343-2351.	13.9	3,268
45	A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. British Journal of Cancer, 2004, 91, 344-354.	2.9	346
46	Phase III Study of Mitomycin-C with Protracted Venous Infusion or Circadian-Timed Infusion of 5-Fluorouracil in Advanced Colorectal Carcinoma. Clinical Colorectal Cancer, 2004, 3, 235-242.	1.0	29
47	A Retrospective Study of Resection of Pulmonary Metastases in Patients wit Advanced Colorectal Cancer: The Development of a PreoperativeChemotherapy Strategy. Clinical Colorectal Cancer, 2004, 4, 101-106.	1.0	25
48	Topoisomerase I Inhibitors in the Treatment of Gastrointestinal Cancer: From Intravenous to Oral Administration. Clinical Colorectal Cancer, 2004, 4, 163-180.	1.0	15
49	Current Approaches to First-Line Treatment of Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S9-S15.	1.0	7
50	Oxaliplatin plus Oral Fluoropyrimidines in Colorectal Cancer. Clinical Colorectal Cancer, 2004, 4, S37-S42.	1.0	14
51	Two Steps Forward in the Treatment of Colorectal Cancer. New England Journal of Medicine, 2004, 350, 2406-2408.	13.9	99
53	Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancer. Cancer Treatment Reviews, 2004, 30, 715-720.	3.4	4
54	Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. European Journal of Cancer, 2004, 40, 1812-1824.	1.3	24
56	Hepatic arterial chemotherapy for colorectal cancer liver metastases: a review of advances in 2003. Current Opinion in Oncology, 2004, 16, 378-384.	1.1	13
57	Prospective multicenter phase II study of irinotecan as third-line therapy in metastatic colorectal cancer and progression after bolus and infusional 5-fluorouracil. Anti-Cancer Drugs, 2004, 15, 473-477.	0.7	5
58	Bevacizumab in combination with irinotecan plus fluorouracil plus leucovorin chemotherapy prolongs survival but increases adverse events in people with metastatic colorectal cancerâ˜†, â˜†â˜†, â˜†â˜†â˜†Abstracted from: Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335â€“42. Cancer Treatment Reviews, 2004, 30, 715-720.	3.4	8
59	Systemic or Regional Chemotherapy for Liver Metastases from Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2004, 10, 271-279.	1.0	3
60	Stellenwert der intensivierten Chemotherapie und der neuen Substanzen in der adjuvanten und palliativen Situation beim kolorektalen Karzinom. Visceral Medicine, 2005, 21, 145-150.	0.5	0
61	Efficacy and Tolerability of Oxaliplatin Plus Irinotecan 5-Fluouracil and Leucovorin Regimen in Advanced Stage Colorectal Cancer Patients Pretreated With Irinotecan 5-Fluouracil and Leucovorin. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 565-569.	0.6	11
62	Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anti-Cancer Drugs, 2005, 16, 1017-1021.	0.7	22
63	A Phase I/II Study of Trimetrexate and Capecitabine in Patients With Advanced Refractory Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 439-444.	0.6	5

#	Article	IF	Citations
64	Insulinlike Growth Factor-I???Mediated Migration and Invasion of Human Colon Carcinoma Cells Requires Activation of c-Met and Urokinase Plasminogen Activator Receptor. Annals of Surgery, 2005, 241, 748-758.	2.1	54
66	Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. Anti-Cancer Drugs, 2005, 16, 39-45.	0.7	9
67	Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer. Anti-Cancer Drugs, 2005, 16, 31-38.	0.7	1
68	Phase I dose escalation study of oxaliplatin combined with oral tegafur???uracil and leucovorin in patients with advanced gastric cancer. Anti-Cancer Drugs, 2005, 16, 47-51.	0.7	4
69	New Drugs for Colorectal Cancer (Irinotecan, Oxaliplatin, Raltitrexed) Meet Expectations in Routine Practice: A Single Center's Experience Before and After Their Introduction. International Journal of Gastrointestinal Cancer, 2005, 35, 069-076.	0.4	2
70	Systemic Therapy for Colorectal Cancer. New England Journal of Medicine, 2005, 352, 476-487.	13.9	1,034
71	Phase II randomised trial of raltitrexedâ€“oxaliplatin vs raltitrexedâ€“irinotecan as first-line treatment in advanced colorectal cancer. British Journal of Cancer, 2005, 93, 1230-1235.	2.9	31
72	Pharmacogenetic influences on treatment response and toxicity in colorectal cancer. Seminars in Oncology, 2005, 32, 113-119.	0.8	17
73	Chemotherapy for advanced colorectal cancer: Letâ€™s not forget how we got here (until we really) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.8	16
74	Cyclooxygenase-2 inhibition in colorectal cancer: Boom or bust?. Seminars in Oncology, 2005, 32, 69-75.	0.8	22
75	Front-Line Therapy for Advanced Colorectal Cancer: Emphasis on Chemotherapy. Seminars in Oncology, 2005, 32, 40-42.	0.8	22
76	Second-Line Treatment of Patients With Metastatic Colorectal Cancer. Seminars in Oncology, 2005, 32, 48-54.	0.8	17
77	Metastatic Colorectal Cancer: First- and Second-Line Treatment in 2005. Seminars in Oncology, 2005, 32, 15-20.	0.8	16
80	Regional and Systemic Chemotherapy for Primary Hepatobiliary Cancers and for Colorectal Cancer Metastatic to the Liver. Seminars in Radiation Oncology, 2005, 15, 284-298.	1.0	18
81	Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer, 2005, 5, 116.	1.1	133
82	Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma. Cancer, 2005, 104, 1871-1884.	2.0	33
83	Treatment strategy for patients with colorectal cancer and synchronous irresectable liver metastases. British Journal of Surgery, 2005, 92, 1155-1160.	0.1	189
86	Severe chemotherapy-induced diarrhea in patients with colorectal cancer: a cost of illness analysis. Supportive Care in Cancer, 2005, 13, 318-324.	1.0	30

#	Article	IF	Citations
88	Chemotherapy of metastatic colorectal cancer. Current Treatment Options in Gastroenterology, 2005, 8, 239-247.	0.3	9
89	Second-line therapy for advanced colorectal cancer. Current Colorectal Cancer Reports, 2005, 1, 7-12.	1.0	0
90	Optimizing adjuvant therapy for colon cancer: Ongoing investigations. Current Colorectal Cancer Reports, 2005, 1, 27-33.	1.0	0
91	The integration of biologic agents into the current systemic management of rectal cancer. Current Colorectal Cancer Reports, 2005, 1, 58-62.	1.0	0
92	First-line therapy for advanced colorectal cancer. Current Oncology Reports, 2005, 7, 167-172.	1.8	5
93	Second-line therapy for advanced colorectal carcinoma. Current Oncology Reports, 2005, 7, 173-180.	1.8	3
94	Chemoradiotherapy for gastrointestinal cancers. Current Oncology Reports, 2005, 7, 196-202.	1.8	0
95	Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX 6 and 7) Regimens for Colorectal Cancer. Hospital Pharmacy, 2005, 40, 662-736.	0.4	2
96	Phenotype of Peripheral Blood Leukocytes and Survival of Patients with Metastatic Colorectal Cancer. International Journal of Biological Markers, 2005, 20, 126-133.	0.7	4
97	Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches. Frontiers in Bioscience - Landmark, 2005, 10, 3042.	3.0	20
102	Asco 2005: Progressi Con Oxaliplatino Nel Trattamento Dei Tumori Del Colon-Retto. Tumori, 2005, 91, 1-12.	0.6	0
104	Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer. , 2005, , 209-228.		1
105	New Chemotherapeutic Strategies in Colorectal Cancer. , 2005, 165, 250-259.		12
106	ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of advanced colorectal cancer. Annals of Oncology, 2005, 16, i18-i19.	0.6	18
107	Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin as First-line Therapy for Advanced Colorectal Cancer. Japanese Journal of Clinical Oncology, 2005, 35, 214-217.	0.6	6
108	Advanced Colorectal Cancer: Current Treatment and Nursing Management With Economic Considerations. Clinical Journal of Oncology Nursing, 2005, 9, 541-552.	0.3	22
109	Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?. Annals of Oncology, 2005, 16, 845-846.	0.6	16
110	CHEMORADIOTHERAPY FOR COLORECTAL CANCER. Gut, 2005, 54, 1194-1202.	6.1	76

#	Article	IF	Citations
111	Combined Therapy with Weekly Irinotecan, Infusional 5â€Fluorouracil and the Selective COXâ€2 Inhibitor Rofecoxib Is a Safe and Effective Secondâ€Line Treatment in Metastatic Colorectal Cancer. Oncologist, 2005, 10, 710-717.	1.9	24
112	Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: An Acta Oncologica expert report. Acta OncolÃ³gica, 2005, 44, 203-217.	0.8	44
113	An Increasingly Common Challenge: Management of the Complete Responder With Multi-Focal Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 1799-1802.	0.8	12
114	Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean Cancer Study Group Trial. Acta OncolÃ³gica, 2005, 44, 230-235.	0.8	28
115	The handling of metastatic colorectal cancer. Annals of Oncology, 2005, 16, ii141-ii143.	0.6	2
116	A Role for Hepatic-Directed Chemotherapy in Colorectal Liver Metastases. Journal of Clinical Oncology, 2005, 23, 4815-4817.	0.8	6
117	Oxaliplatin plus high-dose folinic acid and 5-fluorouracil i.v. bolus (OXAFAFU) versus irinotecan plus high-dose folinic acid and 5-fluorouracil i.v. bolus (IRIFAFU) in patients with metastatic colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase III trial. Annals of Oncology, 2005, 16, 878-886.	0.6	41
118	Guanylyl cyclase C: a molecular marker for staging and postoperative surveillance of patients with colorectal cancer. Expert Review of Molecular Diagnostics, 2005, 5, 701-713.	1.5	60
119	Hepatic Arterial Oxaliplatin Infusion Plus Intravenous Chemotherapy in Colorectal Cancer With Inoperable Hepatic Metastases: A Trial of the Gastrointestinal Group of the FÃ©dÃ©ration Nationale des Centres de Lutte Contre le Cancer. Journal of Clinical Oncology, 2005, 23, 4881-4887.	0.8	215
120	Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dellâ€™Italia Meridionale. Journal of Clinical Oncology, 2005, 23, 4866-4875.	0.8	693
121	ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6212-6217.	3.2	224
122	Whither Irinotecan?. Journal of Clinical Oncology, 2005, 23, 4811-4814.	0.8	13
123	A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. Annals of Oncology, 2005, 16, 1123-1132.	0.6	77
124	Treatment of liver metastases of colorectal cancer. Annals of Oncology, 2005, 16, ii144-ii149.	0.6	63
125	Rapid Evolution in Colorectal Cancer: Therapy Now and Over the Next Five Years. Oncologist, 2005, 10, 4-8.	1.9	12
126	Chemo-Immunotherapy of Metastatic Colorectal Carcinoma With Gemcitabine Plus FOLFOX 4 Followed by Subcutaneous Granulocyte Macrophage Colony-Stimulating Factor and Interleukin-2 Induces Strong Immunologic and Antitumor Activity in Metastatic Colon Cancer Patients. Journal of Clinical Oncology, 2005, 23, 8950-8958.	0.8	161
127	Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Journal of Clinical Oncology, 2005, 23, 3545-3551.	0.8	96
128	Phase II Trial of High-Dose Conformal Radiation Therapy With Concurrent Hepatic Artery Floxuridine for Unresectable Intrahepatic Malignancies. Journal of Clinical Oncology, 2005, 23, 8739-8747.	0.8	308

#	Article	IF	Citations
129	Radiofrequency Ablation of Colorectal Liver Metastases: Where Are We Really Going?. Journal of Clinical Oncology, 2005, 23, 1342-1344.	0.8	35
130	Oxaliplatin, Folinic Acid and 5-Fluorouracil (FOLFOX-4) Combination Chemotherapy as Second-line Treatment in Advanced Colorectal Cancer Patients with Irinotecan Failure: A Korean Single-center Experience. Japanese Journal of Clinical Oncology, 2005, 35, 531-535.	0.6	20
131	Targeting Signal Transduction Pathways in Colorectal Cancerâ€"More Than Skin Deep. Journal of Clinical Oncology, 2005, 23, 5374-5385.	0.8	71
132	Neoadjuvant Chemotherapy Before Liver Resection for Patients With Unresectable Liver Metastases From Colorectal Carcinoma. Journal of Clinical Oncology, 2005, 23, 2038-2048.	0.8	292
133	Critical Evaluation of Current Treatments in Metastatic Colorectal Cancer. Oncologist, 2005, 10, 250-261.	1.9	130
134	The development of clinical research in CRC. Annals of Oncology, 2005, 16, iv37-iv43.	0.6	14
135	Phase III trials in oncology: setting standards of care?. Nature Clinical Practice Oncology, 2005, 2, 426-427.	4.3	4
136	Current stage-specific chemotherapeutic options in colon cancer. Expert Review of Anticancer Therapy, 2005, 5, 695-704.	1.1	10
138	Adjuvant Therapy of Colon Cancer: Current Status and Future Developments. Clinics in Colon and Rectal Surgery, 2005, 18, 224-231.	0.5	5
139	Clinical Pharmacology Issues Relevant to the Dosing and Toxicity of Chemotherapy Drugs in the Elderly. Oncologist, 2005, 10, 602-612.	1.9	56
140	Molecular markers that predict response to colon cancer therapy. Expert Review of Molecular Diagnostics, 2005, 5, 353-375.	1.5	37
141	Overall Survival of Patients With Advanced Colorectal Cancer Correlates With Availability of Fluorouracil, Irinotecan, and Oxaliplatin Regardless of Whether Doublet or Single-Agent Therapy Is Used First Line. Journal of Clinical Oncology, 2005, 23, 9441-9442.	0.8	226
142	Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British Journal of Cancer, 2005, 92, 832-837.	2.9	21
143	Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab. Journal of Clinical Oncology, 2005, 23, 4853-4855.	0.8	164
144	Carboxylesterase Isoform 2 mRNA Expression in Peripheral Blood Mononuclear Cells Is a Predictive Marker of the Irinotecan to SN38 Activation Step in Colorectal Cancer Patients. Clinical Cancer Research, 2005, 11, 6901-6907.	3.2	34
145	The Role of 5-Fluorouracil (5-FU) Reintroduction with Irinotecan or Oxaliplatin in Truly 5-FU-Refractory Advanced Colorectal Cancer Patients. Oncology, 2005, 68, 212-216.	0.9	4
146	Thymidylate Synthase Expression in Colorectal Cancer: The Never-Ending Story. Journal of Clinical Oncology, 2005, 23, 2108-2108.	0.8	1
147	OncoSurge: A Strategy for Improving Resectability With Curative Intent in Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 7125-7134.	0.8	245

#	Article	IF	Citations
148	Antibodyâ€Based Therapies for Colorectal Cancer. Oncologist, 2005, 10, 701-709.	1.9	42
150	Intensive Systemic Chemotherapy Combined With Surgery for Metastatic Colorectal Cancer: Results of a Phase II Study. Journal of Clinical Oncology, 2005, 23, 502-509.	0.8	71
152	Effect of p53 Status and STAT1 on Chemotherapy-Induced, Fas-Mediated Apoptosis in Colorectal Cancer. Cancer Research, 2005, 65, 8951-8960.	0.4	64
153	Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Annals of Oncology, 2005, 16, 425-429.	0.6	145
154	Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Annals of Oncology, 2005, 16, 869-877.	0.6	62
155	Novel targeted therapies in the treatment of gastric and esophageal cancer. Annals of Oncology, 2005, 16, 1740-1748.	0.6	69
156	Systemic Therapy for Metastatic Colorectal Cancer: Current Options, Current Evidence. Journal of Clinical Oncology, 2005, 23, 4553-4560.	0.8	281
157	Phase II Study of Irinotecan, Leucovorin, 5-Fluorouracil and Tegafur/Uracil for Metastatic Colorectal Cancer. Journal of Chemotherapy, 2005, 17, 224-227.	0.7	1
158	First-Line Treatment with Irinotecan and Raltitrexed in Metastatic Colorectal Cancer. Oncology, 2005, 68, 58-63.	0.9	11
159	Continuous Infusion of Oxaliplatin plus Chronomodulated Capecitabine in 5-Fluorouracil- and Irinotecan-Resistant Advanced Colorectal Cancer Patients. Oncology, 2005, 69, 27-34.	0.9	24
160	Combination of Irinotecan (CPT-11) plus 5-Fluorouracil and Leucovorin (FOLFIRI Regimen) as First Line Treatment for Elderly Patients with Metastatic Colorectal Cancer: A Phase II Trial. Oncology, 2005, 69, 384-390.	0.9	61
161	A Phase I Pharmacologic and Pharmacogenetic Trial of Sequential 24-Hour Infusion of Irinotecan Followed by Leucovorin and a 48-Hour Infusion of Fluorouracil in Adult Patients with Solid Tumors. Clinical Cancer Research, 2005, 11, 4144-4150.	3.2	5
162	Colorectal cancer. Lancet, The, 2005, 365, 153-165.	6.3	1,030
164	Advances in the Treatment of Metastatic Colorectal Cancer. Oncologist, 2005, 10, 40-48.	1.9	93
165	StratÃ©gies thÃ©rapeutiques dans les cancers colorectaux. Actualites Pharmaceutiques Hospitalieres, 2005, 1, 15-23.	0.1	0
166	90Y Microsphere (TheraSphere) Treatment for Unresectable Colorectal Cancer Metastases of the Liver: Response to Treatment at Targeted Doses of 135â€“150 Gy as Measured by [18F]Fluorodeoxyglucose Positron Emission Tomography and Computed Tomographic Imaging. Journal of Vascular and Interventional Radiology, 2005, 16, 1641-1651.	0.2	162
167	Prognostic Impact of Race and Ethnicity in the Treatment of Colorectal Cancer. Medical Clinics of North America, 2005, 89, 1045-1057.	1.1	5
168	Improving Rectal Cancer Outcomes with Chemotherapy. Seminars in Colon and Rectal Surgery, 2005, 16, 162-169.	0.2	2

#	Article	IF	Citations
169	Chemotherapy for Colorectal Cancer. Digestive Surgery, 2005, 22, 401-414.	0.6	53
170	Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Annals of Oncology, 2005, 16, 1311-1319.	0.6	560
171	Beyond 5-fluorouracil: new horizons in systemic therapy for advanced colorectal cancer. Expert Opinion on Investigational Drugs, 2005, 14, 607-628.	1.9	17
172	Cetuximab Therapy and Symptomatic Hypomagnesemia. Journal of the National Cancer Institute, 2005, 97, 1221-1224.	3.0	224
173	Treatment of Elderly Cancer Patients with Chemotherapy. Cancer Investigation, 2005, 23, 537-547.	0.6	10
174	Combined Analysis of Efficacy: The Addition of Bevacizumab to Fluorouracil/Leucovorin Improves Survival for Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2005, 23, 3706-3712.	0.8	644
175	Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Annals of Oncology, 2005, 16, 1305-1310.	0.6	136
176	Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer. European Journal of Cancer, 2005, 41, 2241-2249.	1.3	11
177	The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. European Journal of Surgical Oncology, 2005, 31, 325-330.	0.5	18
178	Gastrointestinal cancer: recent developments in medical oncology. European Journal of Surgical Oncology, 2005, 31, 453-460.	0.5	25
179	Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: A prospective study. European Journal of Surgical Oncology, 2005, 31, 1145-1151.	0.5	62
182	Benefit-Risk Assessment of Irinotecan in Advanced Colorectal Cancer. Drug Safety, 2005, 28, 417-433.	1.4	26
183	5-Fluorouracilâ€“Based Chemotherapy for Advanced Colorectal Cancer in Elderly Patients: A North Central Cancer Treatment Group Study. Clinical Colorectal Cancer, 2005, 4, 325-331.	1.0	39
184	Capecitabine Versus Continuous-Infusion 5-Fluorouracil for Colorectal Cancer: A Retrospective Efficacy and Safety Comparison. Clinical Colorectal Cancer, 2005, 5, 89-100.	1.0	22
185	Capecitabine/Oxaliplatin, a Safe and Active First-Line Regimen for Older Patients Metastatic Colorectal Cancer: Post Hoc Analysis of a Large Phase II Study. Clinical Colorectal Cancer, 2005, 5, 101-107.	1.0	55
186	Current Strategies Using Hepatic Arterial Infusion Chemotherapy for the Treatment of Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, 166-174.	1.0	36
187	Pemetrexed/Oxaliplatin for First-Line Treatment of Patients with Advanced Colorectal Cancer: A Phase II Trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program. Clinical Colorectal Cancer, 2005, 5, 181-187.	1.0	17
188	Safety and Efficacy of Irinotecan plus High-Dose Leucovorin and Intravenous Bolus 5-Fluorouracil for Metastatic Colorectal Cancer: Pooled Analysis of Two Consecutive Southern Italy Cooperative Oncology Group Trials. Clinical Colorectal Cancer, 2005, 5, 203-210.	1.0	5

#	Article	IF	Citations
189	Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, 257-262.	1.0	11
190	FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, 263-267.	1.0	30
191	Cancer and Leukemia Group B/Southwest Oncology Group Trial 80405: A Phase III Trial of Chemotherapy and Biologics for Patients with Untreated Advanced Colorectal Adenocarcinoma. Clinical Colorectal Cancer, 2005, 5, 292-294.	1.0	27
192	An Overview of Approaches to Adjuvant Therapy for Colorectal Cancer in the United States. Clinical Colorectal Cancer, 2005, 5, S11-S18.	1.0	14
193	Cetuximab in Previously Treated Colorectal Cancer. Clinical Colorectal Cancer, 2005, 5, S28-S33.	1.0	9
194	Recent Data with Antiâ€"Epidermal Growth Factor Receptor Antibodies and Irinotecan in Colon Cancer. Clinical Colorectal Cancer, 2005, 5, S81-S88.	1.0	7
195	The Future Development of Bevacizumab in Colorectal Cancer. Oncology, 2005, 69, 34-45.	0.9	10
196	Recent Advances in the Systemic Therapy of Metastatic Colorectal Cancer. American Journal of Cancer, 2005, 4, 15-34.	0.4	4
197	Cancer colorectal. , 2006, , 129-144.		0
198	Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious?. British Journal of Cancer, 2006, 94, 363-371.	2.9	95
199	Optimal treatment of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2006, 6, 801-812.	1.1	16
200	Phase II Trial Alternating FOLFOX-6 and FOLFIRI Regimens in Second-Line Therapy of Patients with Metastatic Colorectal Cancer (FIREFOX Study). Cancer Investigation, 2006, 24, 154-159.	0.6	25
201	Recent developments in colorectal cancer treatment by monoclonal antibodies. Expert Opinion on Biological Therapy, 2006, 6, 1175-1192.	1.4	18
202	The new era in the treatment of advanced colorectal cancer patients: the role of monoclonal antibodies. Expert Opinion on Emerging Drugs, 2006, 11, 665-683.	1.0	1
203	Panitumumab in colon cancer: a review and summary of ongoing trials. Expert Opinion on Biological Therapy, 2006, 6, 1229-1235.	1.4	29
204	Randomized Controlled Trial of Reduced-Dose Bolus Fluorouracil Plus Leucovorin and Irinotecan or Infused Fluorouracil Plus Leucovorin and Oxaliplatin in Patients With Previously Untreated Metastatic Colorectal Cancer: A North American Intergroup Trial. Journal of Clinical Oncology, 2006, 24, 3347-3353.	0.8	205
205	The safety of bevacizumab. Expert Opinion on Drug Safety, 2006, 5, 289-301.	1.0	30
206	XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. British Journal of Cancer, 2006, 94, 969-975.	2.9	114

#	Article	IF	Citations
207	Phase I Study of Single-Dose Oxaliplatin in Japanese Patients with Malignant Tumors. Japanese Journal of Clinical Oncology, 2006, 36, 295-300.	0.6	25
208	Optimum chemotherapy for metastatic colorectal cancer. Lancet, The, 2006, 368, 2039-2041.	6.3	8
209	Therapy for Metastatic Colorectal Cancer. Oncologist, 2006, 11, 981-987.	1.9	72
210	Update on Capecitabine in Colorectal Cancer. Oncologist, 2006, 11, 1003-1009.	1.9	34
211	Emerging therapies for metastatic carcinoma to the liver. Community Oncology, 2006, 3, 567-573.	0.2	2
212	Assessing the combination of FOLFOX or FOLFIRI with bevacizumab, cetuximab, or both in metastatic colorectal cancer. Community Oncology, 2006, 3, 593-598.	0.2	4
214	Advances in Chemotherapy for Colorectal Cancer. Clinical Gastroenterology and Hepatology, 2006, 4, 808-821.	2.4	22
215	Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century. Surgical Oncology Clinics of North America, 2006, 15, 159-173.	0.6	7
217	New Agents, Combinations, and Opportunities in the Treatment of Advanced and Early-Stage Colon Cancer. Surgical Clinics of North America, 2006, 86, 1023-1043.	0.5	8
218	Highlights From: The 2006 American Society of Clinical Oncology Gastrointestinal Cancers Symposium San Francisco, CA, January 2006. Clinical Colorectal Cancer, 2006, 5, 398-402.	1.0	4
219	Targeting the Epidermal Growth Factor Receptor in the Treatment of Colorectal Cancer. Drugs, 2006, 66, 1441-1463.	4.9	12
220	A Phase III Randomized, Open-Label, Controlled Trial of Chemotherapy and Bevacizumab with or Without Panitumumab in the First-Line Treatment of Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 5, 363-367.	1.0	28
221	Neoadjuvant Treatment of Unresectable Liver Metastases from Colorectal Cancer. Clinical Colorectal Cancer, 2006, 5, 405-412.	1.0	6
222	Multicenter Phase II Study of Fixed Sequences of Capecitabine Combined with Oxaliplatin or Irinotecan in Patients with Previously Untreated Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 5, 429-435.	1.0	4
223	Southwest Oncology Group 0408: Phase II Trial of Neoadjuvant Capecitabine/Oxaliplatin/Bevacizumab for Resectable Colorectal Metastases in the Liver. Clinical Colorectal Cancer, 2006, 5, 436-438.	1.0	5
224	Long-Term Treatment with Bevacizumab for Patients with Metastatic Colorectal Cancer: Case Report. Clinical Colorectal Cancer, 2006, 6, 66-69.	1.0	14
225	Phase I Study of Gefitinib plus FOLFIRI in Previously Untreated Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2006, 6, 208-213.	1.0	21
226	Prognostic Factors Predictive of Response and Survival to a Modified FOLFOX Regimen: Importance of an Increased Neutrophil Count. Clinical Colorectal Cancer, 2006, 6, 297-304.	1.0	29

#	Article	IF	Citations
227	A case of bone metastasis of colon cancer that markedly responded to S-1/CPT-11 combination chemotherapy and became curable by resection. World Journal of Surgical Oncology, 2006, 4, 3.	0.8	6
228	Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Annals of Surgical Oncology, 2006, 13, 887-898.	0.7	89
229	Recent trends and future perspectives in isolated hepatic perfusion in the treatment of liver tumors. Expert Review of Anticancer Therapy, 2006, 6, 553-565.	1.1	9
230	Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imagingâ€"Defined Poor-Risk Rectal Cancer. Journal of Clinical Oncology, 2006, 24, 668-674.	0.8	432
231	Bevacizumab: An angiogenesis inhibitor for the treatment of solid malignancies. Clinical Therapeutics, 2006, 28, 1779-1802.	1.1	473
232	Down-regulation of BCRP/ABCG2 in colorectal and cervical cancer. Biochemical and Biophysical Research Communications, 2006, 343, 571-577.	1.0	59
233	Treatment of hepatic metastases from colorectal cancer: Many doubts, some certainties. Cancer Treatment Reviews, 2006, 32, 214-228.	3.4	91
234	Irinotecan in the treatment of colorectal cancer. Cancer Treatment Reviews, 2006, 32, 491-503.	3.4	148
235	Metastatic colorectal cancer. Cancer Treatment Reviews, 2006, 32, 557-571.	3.4	11
236	A National Cancer Institute of Canada Clinical Trials Group Study â€" IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancer. European Journal of Cancer, 2006, 42, 193-199.	1.3	9
237	Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. European Journal of Cancer, 2006, 42, 2212-2221.	1.3	481
238	Methodological issues in the economic analysis of cancer treatments. European Journal of Cancer, 2006, 42, 2867-2875.	1.3	79
239	Surgical treatment of liver metastases of colorectal cancer: Strategies and controversies in 2006. European Journal of Surgical Oncology, 2006, 32, 473-483.	0.5	45
240	Cancers of the bowel and hepatobiliary tract. Update on Cancer Therapeutics, 2006, 1, 353-365.	0.9	1
241	Recent developments in the clinical activity of topoisomerase-1 inhibitors. Update on Cancer Therapeutics, 2006, 1, 117-145.	0.9	12
243	Folfox4 in Advanced Colorectal Cancer: A Monoinstitutional Experience. Tumori, 2006, 92, 193-196.	0.6	0
244	Urinary Neopterin in Patients with Liver Tumors. Tumori, 2006, 92, 318-322.	0.6	6
245	Resection of Colorectal Liver Metastases: Current Perspectives. Cancer Control, 2006, 13, 32-41.	0.7	75

#	Article	IF	Citations
246	Alternating hepatic arterial infusion and systemic chemotherapy for stage IV colorectal cancer with synchronous liver metastasis. Oncology Reports, 2006, 16, 865.	1.2	2
247	Oxaliplatin plus hydroxycamptothecine versus oxaliplatin plus 5-fluorouracil and leucovorin in treatment of advanced colorectal cancer. Chinese Medical Journal, 2006, 119, 1829-1833.	0.9	1
248	Chemotherapy with Mitomycin C and Capecitabine in Patients with Advanced Colorectal Cancer Pretreated with Irinotecan and Oxaliplatin. Tumori, 2006, 92, 285-289.	0.6	9
249	Urinary Neopterin in Patients with Advanced Colorectal Carcinoma. International Journal of Biological Markers, 2006, 21, 190-198.	0.7	39
252	Radiofrequency Ablation of Hepatic Metastases from Colorectal Cancer: Are Newer Generation Probes Better?. American Surgeon, 2006, 72, 875-879.	0.4	38
255	Pharmacogenomics of Colorectal Cancer. , 2006, , 287-316.		0
256	Drug Development for Advanced Colorectal Cancer in the United States. , 2006, , 317-335.		0
257	Monoclonal Antibodies Against Epidermal Growth Factor Receptor in Advanced Colorectal Carcinoma: Clinical Efficacy and Markers of Sensitivity&#. Reviews on Recent Clinical Trials, 2006, 1, 113-118.	0.4	3
258	Irinotecan, Oxaliplatin Plus Bolus 5-Fluorouracil and Low Dose Folinic Acid Every 2 Weeks. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 45-51.	0.6	7
259	Survival of Rectal Cancer Patients in Belgium 1997â€“98 and the Potential Benefit of a National Project. Acta Chirurgica Belgica, 2006, 106, 149-157.	0.2	22
260	Retrospective Study of Capecitabine and Celecoxib In Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 232-239.	0.6	32
261	Conformal Radiotherapy of the Dominant Liver Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 562-567.	0.6	35
262	The Combination of Capecitabine and Thalidomide in Previously Treated, Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2006, 29, 40-44.	0.6	13
263	FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). British Journal of Cancer, 2006, 94, 798-805.	2.9	345
264	Surgical resection of hepatic metastases from colorectal cancer: A systematic review of published studies. British Journal of Cancer, 2006, 94, 982-999.	2.9	759
265	A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. British Journal of Cancer, 2006, 94, 1281-1286.	2.9	15
266	A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. British Journal of Cancer, 2006, 94, 1287-1292.	2.9	40
267	Oxaliplatin-related neurotoxicity: How and why?. Critical Reviews in Oncology/Hematology, 2006, 59, 159-168.	2.0	226

#	Article	IF	Citations
268	Novel targets in gastric and esophageal cancer. Critical Reviews in Oncology/Hematology, 2006, 59, 128-138.	2.0	26
269	The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 3061-3068.	0.8	328
270	Unresectable Hepatic Colorectal Metastases: Need for New Surgical Strategies. Annals of Surgical Oncology, 2006, 13, 5-6.	0.7	22
271	Second Hepatectomy for Recurrent Colorectal Liver Metastasis: Analysis of Preoperative Prognostic Factors. Annals of Surgical Oncology, 2006, 13, 1579-1587.	0.7	52
272	Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement. Annals of Surgical Oncology, 2006, 13, 1284-1292.	0.7	37
273	Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study. Investigational New Drugs, 2006, 24, 335-341.	1.2	17
274	A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Investigational New Drugs, 2006, 24, 343-346.	1.2	13
275	SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Investigational New Drugs, 2006, 24, 347-351.	1.2	2
278	Current directions in chemotherapy for colorectal cancer. Journal of Gastroenterology, 2006, 41, 821-831.	2.3	5
279	Continued Survival of More Than Ten Years, Without Resection of Metastatic Disease, in Patients With Metastatic Colorectal Cancer Treated With Biomodulated Fluorouracil: Report of Two Cases. Diseases of the Colon and Rectum, 2006, 49, 407-410.	0.7	1
280	Outcome of Metastatic Colorectal Cancer: Analysis of a Consecutive Series of 229 Patients. The Impact of a Multidisciplinary Approach. Diseases of the Colon and Rectum, 2006, 49, 1596-1601.	0.7	24
281	Interdisciplinary management of colorectal cancer liver metastases. European Surgery - Acta Chirurgica Austriaca, 2006, 38, 107-111.	0.3	9
282	Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer. European Journal of Health Economics, 2006, 7, 107-113.	1.4	7
283	Biological imaging for selecting and monitoring cancer therapy; a pathway to individualised therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 1-5.	3.3	11
284	Colorectal carcinoma: from tumorigenesis to treatment. Cellular and Molecular Life Sciences, 2006, 63, 663-671.	2.4	35
286	Prevention of irinotecan associated diarrhea by intestinal alkalization. A pilot study in gastrointestinal cancer patients. Clinical and Translational Oncology, 2006, 8, 208-212.	1.2	12
287	Targeted therapies for patients with advanced colorectal cancer: focus on cetuximab. Targeted Oncology, 2006, 1, 2-12.	1.7	2
288	Metastatic colorectal cancer: Therapeutic options. Current Treatment Options in Oncology, 2006, 7, 389-398.	1.3	6

#	Article	IF	Citations
289	The role of pharmacogenetics in making treatment decisions in colorectal cancer. Current Colorectal Cancer Reports, 2006, 2, 109-115.	1.0	1
290	Oxaliplatin and irinotecan: From advanced to adjuvant therapy of colon cancer. Current Colorectal Cancer Reports, 2006, 2, 142-148.	1.0	0
291	Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. Gastroenterologie Clinique Et Biologique, 2006, 30, 1349-1353.	0.9	16
292	Metastatic colorectal cancer. Gastroenterologie Clinique Et Biologique, 2006, 30, 30-42.	0.9	7
294	Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery, 2006, 139, 263-273.	1.0	95
295	Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer. Cancer, 2006, 106, 2241-2246.	2.0	9
296	How much can current interventions reduce colorectal cancer mortality in the U.S.?. Cancer, 2006, 107, 1624-1633.	2.0	178
297	The trans-metastasis hepatectomy (through metastases previously ablated with radiofrequency): Results of a 13-case study of colorectal cancer. Journal of Surgical Oncology, 2006, 93, 8-12.	0.8	22
298	A Prospective Randomized Study of Irinotecan (CPT-11), Leucovorin (LV) and 5-Fluorouracil (5FU) versus Leucovorin and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma. Journal of Chemotherapy, 2006, 18, 538-544.	0.7	6
299	A Phase II Study of Irinotecan with 5-Fluorouracil and Leucovorin in Patients with Pretreated Gastroenteropancreatic Well-Differentiated Endocrine Carcinomas. Oncology, 2006, 70, 134-140.	0.9	26
300	Biological agents versus chemotherapy in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 1251-1271.	0.9	3
301	Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Annals of Oncology, 2006, 17, 1665-1672.	0.6	30
303	First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. Annals of Oncology, 2006, 17, 1249-1254.	0.6	22
306	Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan. Oncology, 2006, 70, 106-114.	0.9	21
307	Recent advances in the systemic management of colorectal cancer. Future Oncology, 2006, 2, 643-650.	1.1	7
308	Percutaneous laser ablation in patients with isolated unresectable liver metastases from colorectal cancer: Results of a phase II study. Acta OncolÃ³gica, 2006, 45, 77-83.	0.8	35
309	Target Practice: Figuring Out Which, When, and Why to Use Systemic Therapies for Metastatic Colon Cancer. Cancer Investigation, 2006, 24, 98-105.	0.6	9
310	Endoscopic Oncology. , 2006, , .		0

#	Article	IF	Citations
311	Challenges in the treatment of gastrointestinal tumours. Annals of Oncology, 2006, 17, v137-v141.	0.6	2
313	Should Continuous Infusion 5-Fluorouracil Become the Standard of Care in the USA as It Is in Europe?. Cancer Investigation, 2006, 24, 50-55.	0.6	22
314	Thymidine Phosphorylase and Capecitabine: A Predictive Marker for Therapy Selection?. Journal of Clinical Oncology, 2006, 24, 4051-4053.	0.8	7
315	Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Annals of Oncology, 2006, 17, 968-973.	0.6	60
316	Randomised Phase III study of biweekly 24-h infusion of high-dose 5FU with folinic acid and oxaliplatin versus monthly plus 5-FU/folinic acid in first-line treatment of advanced colorectal cancer. Annals of Oncology, 2006, 17, 443-449.	0.6	30
317	Guidelines for resection of colorectal cancer liver metastases. Gut, 2006, 55, iii1-iii8.	6.1	278
318	Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Annals of Oncology, 2006, 17, 450-456.	0.6	211
319	Chemotherapy-Induced Steatohepatitis in Colorectal Cancer Patients. Journal of Clinical Oncology, 2006, 24, 5467-5467.	0.8	23
320	Phase II Study of Capecitabine, Oxaliplatin, and Erlotinib in Previously Treated Patients With Metastastic Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 1892-1897.	0.8	94
322	Efficacy of a nitric oxideâ€“releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Molecular Cancer Therapeutics, 2006, 5, 919-926.	1.9	43
323	Thymidine Phosphorylase Expression Is Associated With Response to Capecitabine Plus Irinotecan in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2006, 24, 4069-4077.	0.8	98
324	Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. Annals of Oncology, 2006, 17, 252-258.	0.6	29
325	Chemotherapy Regimen Predicts Steatohepatitis and an Increase in 90-Day Mortality After Surgery for Hepatic Colorectal Metastases. Journal of Clinical Oncology, 2006, 24, 2065-2072.	0.8	1,198
326	Downstaging or Downsizing: Time for a New Staging System in Advanced Colorectal Cancer?. Journal of Clinical Oncology, 2006, 24, 2702-2706.	0.8	44
327	Turning Point for Colorectal Cancer Clinical Trials. Journal of Clinical Oncology, 2006, 24, 3322-3324.	0.8	6
328	Evolving role of antineoplastic agents in colorectal cancer. American Journal of Health-System Pharmacy, 2006, 63, S4-S11.	0.5	4
329	Chemotherapy-Induced Carcinoembryonic Antigen Surge in Patients with Metastatic Colorectal Cancer. Oncology, 2006, 70, 49-53.	0.9	29
330	Neoadjuvant Chemotherapy for Metastatic Colon Cancer: Too Much Caution and Still Too Much to Be Assessed. Journal of Clinical Oncology, 2006, 24, 2217-2218.	0.8	6

#	Article	IF	Citations
332	Alternative clinical end points in rectal cancerâ€"are we getting closer?. Annals of Oncology, 2006, 17, 1239-1248.	0.6	82
333	Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial. Journal of Clinical Oncology, 2006, 24, 4976-4982.	0.8	523
334	Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer. British Journal of Cancer, 2006, 95, 1195-1201.	2.9	28
335	Management of advanced colorectal cancer: state of the art. British Journal of Cancer, 2006, 95, 131-138.	2.9	92
336	The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients. British Journal of Cancer, 2006, 95, 13-20.	2.9	35
337	OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancerâ€"A GERCOR Study. Journal of Clinical Oncology, 2006, 24, 394-400.	0.8	750
338	Irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. Expert Opinion on Pharmacotherapy, 2006, 7, 687-703.	0.9	11
339	Chemotherapy for elderly patients with advanced colorectal carcinoma. Expert Review of Anticancer Therapy, 2006, 6, 795-800.	1.1	9
340	Effects of 5-fluorouracil adjuvant treatment of colon cancer. Expert Review of Anticancer Therapy, 2006, 6, 785-794.	1.1	13
341	Fractionated Administration of Irinotecan and Cisplatin in Japanese Patients With Extensive-Stageâ€"Disease Small-Cell Lung Cancer. Journal of Clinical Oncology, 2006, 24, 5175-5175.	0.8	1
342	Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver. Human Gene Therapy, 2006, 17, 1214-1224.	1.4	163
343	First- and second-line therapy of metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2006, 6, 921-930.	1.1	17
344	Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 5218-5224.	0.8	321
345	Chemotherapy for colorectal cancer in the metastatic and adjuvant setting: past, present and future. Expert Review of Anticancer Therapy, 2007, 7, 477-487.	1.1	23
346	A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Treatment of Patients with Metastatic Colorectal Carcinoma. Oncology Research and Treatment, 2007, 30, 169-174.	0.8	15
347	A Renewed Call for Equipoise. Journal of Clinical Oncology, 2007, 25, 3392-3394.	0.8	11
348	Targeted Therapy Trials: Approval Strategies, Target Validation, or Helping Patients?. Journal of Clinical Oncology, 2007, 25, 1639-1641.	0.8	14
349	Phase II Trial of Cetuximab in Combination With Fluorouracil, Leucovorin, and Oxaliplatin in the First-Line Treatment of Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 5225-5232.	0.8	306

#	Article	IF	Citations
350	Gene Expression Signature in Advanced Colorectal Cancer Patients Select Drugs and Response for the Use of Leucovorin, Fluorouracil, and Irinotecan. Journal of Clinical Oncology, 2007, 25, 773-780.	0.8	168
351	Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy. Journal of Clinical Oncology, 2007, 25, 4562-4568.	0.8	217
352	Schedule-dependent activity of 5-fluorouracil and irinotecan combination in the treatment of human colorectal cancer: in vitro evidence and a phase I dose-escalating clinical trial. British Journal of Cancer, 2007, 96, 21-28.	2.9	24
353	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. British Journal of Cancer, 2007, 97, 1469-1474.	2.9	77
354	Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer. Expert Review of Anticancer Therapy, 2007, 7, 503-518.	1.1	30
355	Neoadjuvant chemotherapy for patients with liver metastases from colorectal cancer. Expert Review of Anticancer Therapy, 2007, 7, 887-897.	1.1	9
356	The Continuum of Care: A Paradigm for the Management of Metastatic Colorectal Cancer. Oncologist, 2007, 12, 38-50.	1.9	218
357	Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. British Journal of Cancer, 2007, 97, 1035-1039.	2.9	119
358	Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. British Journal of Cancer, 2007, 96, 439-444.	2.9	34
359	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. Expert Review of Anticancer Therapy, 2007, 7, 1027-1041.	1.1	3
360	Prognostic and Predictive Markers in Colorectal Cancer â€“ The Role of New Genomic Technologies. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2007, 5, 255-261.	0.3	0
361	Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. Annals of Oncology, 2007, 18, 305-310.	0.6	59
362	XELOX Followed by XELIRI or the Reverse Sequence in Advanced Colorectal Cancer. Oncology, 2007, 73, 298-304.	0.9	7
363	Phase I/II Study of CPT-11 plus UFT in Patients with Advanced/Recurrent Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102. Japanese Journal of Clinical Oncology, 2007, 37, 521-527.	0.6	0
364	Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii25-ii26.	0.6	11
365	Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta OncolÃ³gica, 2007, 46, 982-988.	0.8	13
367	Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta OncolÃ³gica, 2007, 46, 697-701.	0.8	33
368	Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis. Annals of Oncology, 2007, 18, 1995-1999.	0.6	60

#	Article	IF	Citations
369	Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification. Annals of Oncology, 2007, 18, 1666-1672.	0.6	75
370	A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. Annals of Oncology, 2007, 18, 782-788.	0.6	47
371	Central Venous Access Port-related Complications in Outpatient Chemotherapy for Colorectal Cancer. Japanese Journal of Clinical Oncology, 2007, 37, 951-954.	0.6	23
372	A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer. Oncology, 2007, 73, 9-20.	0.9	18
373	Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis. British Journal of Radiology, 2007, 80, e170-e172.	1.0	1
374	Mitomycin C, 5-Fluorouracil, Leucovorin, and Oxaliplatin as a Salvage Therapy for Patients with Cisplatin-Resistant Advanced Gastric Cancer: A Phase I Dose Escalation Trial. Oncology Research and Treatment, 2007, 30, 29-34.	0.8	7
375	Phase I Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer. Oncology, 2007, 72, 58-63.	0.9	19
376	Assessment of Baseline Clinical Predictive Factors of Response to Cetuximab-Irinotecan in Patients with Irinotecan-Refractory Metastatic Colorectal Cancer. Oncology, 2007, 73, 185-191.	0.9	6
377	5-Fluorouracil, Leucovorin and Oxaliplatin plus Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer: A Single-Institute Study. Oncology, 2007, 72, 4-9.	0.9	15
378	Initiation of High Frequency Multi-Drug Resistance Following Kinase Targeting by siRNAs. Cell Cycle, 2007, 6, 2001-2004.	1.3	14
379	Panitumumab a novel drug in cancer treatment. Annals of Oncology, 2007, 18, vi16-vi21.	0.6	30
381	Impact of Complete Response to Chemotherapy on Overall Survival in Advanced Colorectal Cancer: Results From Intergroup N9741. Journal of Clinical Oncology, 2007, 25, 3469-3474.	0.8	68
382	Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest. Journal of Clinical Oncology, 2007, 25, 1670-1676.	0.8	1,083
383	Efficacy and Safety of an Irinotecan plus Bolus 5-Fluorouracil and L-Leucovorin Regimen for Metastatic Colorectal Cancer in Japanese Patients: Experience in a Single Institution in Japan. Japanese Journal of Clinical Oncology, 2007, 37, 686-691.	0.6	10
384	Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?. Clinical Cancer Research, 2007, 13, 6909s-6912s.	3.2	6
385	Hepatic Resection After Rescue Cetuximab Treatment for Colorectal Liver Metastases Previously Refractory to Conventional Systemic Therapy. Journal of Clinical Oncology, 2007, 25, 4593-4602.	0.8	183
386	Randomized, Controlled Trial of Irinotecan Plus Infusional, Bolus, or Oral Fluoropyrimidines in First-Line Treatment of Metastatic Colorectal Cancer: Results From the BICC-C Study. Journal of Clinical Oncology, 2007, 25, 4779-4786.	0.8	709
387	Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study. Annals of Oncology, 2007, 18, 77-81.	0.6	46

#	Article	IF	Citations
388	Phase II Study of Oxaliplatin in Japanese Patients with Metastatic Colorectal Cancer Refractory to Fluoropyrimidines. Japanese Journal of Clinical Oncology, 2007, 37, 440-445.	0.6	13
389	Managing Older Patients With Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 1891-1897.	0.8	83
390	A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan. Annals of Oncology, 2007, 18, 2025-2029.	0.6	43
391	Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis from Colorectal Cancer. , 2007, 134, 425-440.		34
392	Sequential Administration of 5-Fluorouracil (5FU)/Leucovorin (LV) Followed by Irinotecan (CPT-11) at Relapse versus CPT-11 Followed by 5-FU/LV in Advanced Colorectal Carcinoma. Chemotherapy, 2007, 53, 282-291.	0.8	14
393	Mitomycin C and Etoposide in Advanced Colorectal Carcinoma. Chemotherapy, 2007, 53, 218-225.	0.8	6
394	Presurgical Chemotherapy in Patients Being Considered for Liver Resection. Oncologist, 2007, 12, 825-839.	1.9	93
395	Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. Journal of Clinical Oncology, 2007, 25, 4217-4223.	0.8	258
396	Phase III Study Comparing a Semimonthly With a Monthly Regimen of Fluorouracil and Leucovorin As Adjuvant Treatment for Stage II and III Colon Cancer Patients: Final Results of GERCOR C96.1. Journal of Clinical Oncology, 2007, 25, 3732-3738.	0.8	135
401	Antiangiogenic Therapy for Colorectal Cancer. , 2007, , .		0
403	Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses. Oncology Reports, 0, , .	1.2	4
406	Effective Second-Line Treatment with Cetuximab and Bevacizumab in a Patient with Hepatic Metastases of Colorectal Cancer and Hyperbilirubinemia. Oncology Research and Treatment, 2007, 30, 509-512.	0.8	8
407	Targeted Strategies in the Treatment of Metastatic Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2007, 5, 983-990.	2.3	8
408	Evaluation of Adjuvant Chemotherapy Irinotecan + 5-Fluorouracil + Leucovorine in Advanced Colorectal Cancer. Acta Chirurgica Belgica, 2007, 107, 297-301.	0.2	2
409	Irinotecan With 5-FU/FA in Advanced Biliary Tract Adenocarcinomas. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 319-324.	0.6	41
410	Targeting the Epidermal Growth Factor Receptor in Colorectal Carcinoma. Cancer Nursing, 2007, 30, S1-S9.	0.7	5
411	A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. Anti-Cancer Drugs, 2007, 18, 1103-1107.	0.7	3
412	Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases. European Journal of Gastroenterology and Hepatology, 2007, 19, 988-994.	0.8	6

#	Article	IF	Citations
413	An Update on Treatment Advances for the First-Line Therapy of Metastatic Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 276-281.	1.0	42
414	The Impact of Margins on Outcome After Hepatic Resection for Colorectal Metastasis. Annals of Surgery, 2007, 246, 295-300.	2.1	207
415	Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis. Anti-Cancer Drugs, 2007, 18, 17-21.	0.7	3
417	Update in colorectal, hepatobiliary and pancreatic cancers. Update on Cancer Therapeutics, 2007, 2, 141-156.	0.9	0
418	The ABCs of Colorectal Cancer. Seminars in Oncology Nursing, 2007, 23, 1-8.	0.7	5
419	Metastatic Colorectal Cancer: The Treatment Continuum. Seminars in Oncology Nursing, 2007, 23, 9-21.	0.7	1
420	Case Studies in Metastatic Colorectal Cancer. Seminars in Oncology Nursing, 2007, 23, 36-43.	0.7	0
421	Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. European Journal of Cancer, 2007, 43, 55-63.	1.3	87
422	Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. European Journal of Cancer, 2007, 43, 2037-2045.	1.3	249
423	The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. European Journal of Cancer, 2007, 43, 2487-2494.	1.3	72
424	The pain with platinum: Oxaliplatin and neuropathy. European Journal of Cancer, 2007, 43, 2631-2633.	1.3	19
425	Hepatic artery infusion of high-dose melphalan at reduced flow during isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: A clinical and pharmacologic evaluation. European Journal of Surgical Oncology, 2007, 33, 874-881.	0.5	26
426	Treatment of advanced colorectal cancer in the elderly. European Journal of Surgical Oncology, 2007, 33, S84-S87.	0.5	4
427	Bringing unresectable liver disease to resection with curative intent. European Journal of Surgical Oncology, 2007, 33, S42-S51.	0.5	60
428	Increasing long-term survival in advanced colorectal cancer. European Journal of Surgical Oncology, 2007, 33, S1-S4.	0.5	27
429	Neoadjuvant treatment before resection of liver metastases. European Journal of Surgical Oncology, 2007, 33, S35-S41.	0.5	22
430	Extending the frontiers of resectability in advanced colorectal cancer. European Journal of Surgical Oncology, 2007, 33, S52-S58.	0.5	37
431	Cytotoxic chemotherapy for advanced, non-resectable colorectal cancer. European Journal of Surgical Oncology, 2007, 33, S17-S23.	0.5	0

#	Article	IF	Citations
432	Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan. Clinical Therapeutics, 2007, 29, 2256-2267.	1.1	39
433	Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet, The, 2007, 370, 135-142.	6.3	593
434	Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet, The, 2007, 370, 143-152.	6.3	520
435	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, The, 2007, 370, 2103-2111.	6.3	2,140
436	Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncology, The, 2007, 8, 898-911.	5.1	149
437	Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting. Supportive Cancer Therapy, 2007, 4, 233-240.	0.3	9
438	Biomarkers for therapeutic efficacy. European Journal of Cancer, Supplement, 2007, 5, 129-142.	2.2	4
439	Objectives of chemotherapy for unresectable liver metastases: Best response or resection?. European Journal of Cancer, Supplement, 2007, 5, 317-321.	2.2	1
440	A welcome addition to the therapeutic armamentarium against colorectal cancer. Community Oncology, 2007, 4, 123-125.	0.2	1
442	Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 3224-3229.	0.8	121
443	A Phase II Trial of Oxaliplatin, Folinic Acid, and 5-Fluorouracil (FOLFOX4) as First-Line Chemotherapy in Advanced Colorectal Cancer: A China Single-Center Experience. Cancer Investigation, 2007, 25, 599-605.	0.6	2
444	Cetuximab in the treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2007, 7, 243-256.	1.4	18
445	Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2007, 25, 1658-1664.	0.8	1,828
446	Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncology, 2007, 3, 141-148.	1.1	22
447	Current and emerging trends in the treatment of metastatic colorectal cancer. Hematology/Oncology Clinics of North America, 2007, 21, 8-17.	0.9	0
448	The Role of Chemotherapy in the Curative Treatment of Patients with Liver Metastases from Colorectal Cancer. Surgical Oncology Clinics of North America, 2007, 16, 537-556.	0.6	11
449	Colorectal Cancer. Mayo Clinic Proceedings, 2007, 82, 114-129.	1.4	55
450	Hepatic Yttrium-90 Radioembolotherapy in Metastatic Colorectal Cancer Treated with Cetuximab or Bevacizumab. Journal of Vascular and Interventional Radiology, 2007, 18, 1588-1591.	0.2	34

#	Article	IF	Citations
451	Balancing Risk and Benefit for First-Line Treatment of Metastatic Colorectal Cancer: A Graphic Communication Tool for Patients and Physicians. Supportive Cancer Therapy, 2007, 4, 101-109.	0.3	2
452	Effect of Combined Therapy With Low-Dose 5-Aza-2â€²-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15. Annals of Surgical Oncology, 2007, 14, 1752-1762.	0.7	42
453	Metastatic Colorectal Cancer. Drugs, 2007, 67, 1851-1867.	4.9	36
454	Toxicities and Survival Among Octogenarians and Nonagenarians with Colorectal Cancer Treated with Chemotherapy or Concurrent Chemoradiation Therapy. Clinical Colorectal Cancer, 2007, 6, 362-366.	1.0	13
455	Severe Diarrhea in Patients with Advanced- Stage Colorectal Cancer Receiving FOLFOX or FOLFIRI Chemotherapy: The Development of a Risk Prediction Tool. Clinical Colorectal Cancer, 2007, 6, 367-373.	1.0	20
456	Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 427-432.	1.0	95
457	Reversible Grade 4 Hyperbilirubinemia in a Patient with UGT1A1 7/7 Genotype Treated with Irinotecan and Cetuximab. Clinical Colorectal Cancer, 2007, 6, 447-449.	1.0	9
458	Current Treatment Strategies in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 508-515.	1.0	13
459	Phase II Trial of Oxaliplatin/Irinotecan/5-Fluorouracil/Leucovorin for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 516-521.	1.0	6
460	Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 522-528.	1.0	13
461	Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: A Phase III Trial of Chemotherapy and Biologic Agents for Patients with Untreated Advanced Colorectal Adenocarcinoma. Clinical Colorectal Cancer, 2007, 6, 536-538.	1.0	14
462	Modification of Leucovorin Dose Within a Simplified FOLFOX Regimen Improves Tolerability Without Compromising Efficacy. Clinical Colorectal Cancer, 2007, 6, 578-582.	1.0	3
463	Increased Frequency of Uridine Diphosphate Glucuronosyltransferase 1A1 7/7 in Patients Experiencing Severe Irinotecan-Induced Toxicities. Clinical Colorectal Cancer, 2007, 6, 583-587.	1.0	7
464	Oxaliplatin and Fixed-Rate Infusional Gemcitabine in the Second-Line Treatment of Patients with Metastatic Colon Cancer: Final Results of a Phase II Trial Prematurely Closed as a Result of Poor Accrual. Clinical Colorectal Cancer, 2007, 6, 641-645.	1.0	6
465	Phase II Trial of 5-Fluorouracil/Leucovorin/Gemcitabine/Cisplatin as Second-Line Treatment in Patients with Metastatic or Recurrent Colorectal Carcinoma: A Cancer Therapeutics Research Group Study. Clinical Colorectal Cancer, 2007, 6, 646-651.	1.0	6
466	Safety and Efficacy of First-Line Chemotherapy in Unresected Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 710-715.	1.0	8
467	A Retrospective on the Inhibition of Epidermal Growth Factor Receptor as a Therapeutic Strategy for Patients with Relapsed Metastatic Colorectal Cancer: Impact on Treatment of Today's Patients. Clinical Colorectal Cancer, 2007, 7, S8-S15.	1.0	2
468	Exploring Alternative Individualized Treatment Strategies in Colorectal Cancer. Clinical Colorectal Cancer, 2007, 7, S28-S36.	1.0	5

#	Article	IF	Citations
469	The Role of Aggressive Regional Therapy for Colorectal Liver Metastases. Cancer Investigation, 2007, 25, 458-463.	0.6	11
470	Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1â€“5, 2007. Clinical Colorectal Cancer, 2007, 6, 614-620.	1.0	0
471	The Clinical Efficacy of FOLFIRI and Bevacizumab in Combination as First-Line Therapy of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2007, 6, 621-624.	1.0	5
473	A phase II study of irinotecan, high-dose 24-h continuous intravenous infusion of floxuridine and leucovorin (IFLUX) for advanced, previously untreated colorectal cancer. Anti-Cancer Drugs, 2007, 18, 955-961.	0.7	0
474	An Oxaliplatin + 5-Fluorouracil Bolus + Folinic Acid (BFOL) Regimen as First-Line Treatment in Metastatic Colorectal Cancer Patients. Tumori, 2007, 93, 557-561.	0.6	0
475	Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. Core Evidence, 2007, .	4.7	0
476	Cetuximab in Colon Cancer. International Journal of Biological Markers, 2007, 22, 62-70.	0.7	5
477	Chemotherapy in Colorectal Cancer - Past, Present and Futuret. Journal of Bangladesh College of Physicians & Surgeons, 2007, 24, 69-74.	0.0	1
478	Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. British Journal of Surgery, 2007, 94, 274-286.	0.1	475
479	First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer, 2007, 110, 752-758.	2.0	38
480	The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 1089-1108.	1.0	36
481	Colorectal Cancer Therapeutics and the Challenges of Applied Pharmacogenomics. Current Problems in Cancer, 2007, 31, 315-366.	1.0	5
482	Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene, 2007, 26, 3661-3678.	2.6	46
483	Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. Cancer Gene Therapy, 2007, 14, 139-150.	2.2	34
484	Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment. British Journal of Cancer, 2007, 96, 206-212.	2.9	68
485	Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis. British Journal of Cancer, 2007, 96, 546-550.	2.9	8
486	Regression of intestinal adenomas by vaccination with heat shock protein 105â€pulsed bone marrowâ€derived dendritic cells in Apc^{Min/+} mice. Cancer Science, 2007, 98, 1930-1935.	1.7	17
487	Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases?. Liver International, 2007, 27, 938-943.	1.9	65

#	Article	IF	Citations
488	Adjuvant Treatment of Colorectal Cancer. Ca-A Cancer Journal for Clinicians, 2007, 57, 168-185.	157.7	227
489	Front-line Bevacizumab in combination with Oxaliplatin, Leucovorin and 5-Fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer, 2007, 7, 91.	1.1	94
490	Update for Surgeons: Recent and Noteworthy Changes in Therapeutic Regimens for Cancer of the Colon and Rectum. Journal of the American College of Surgeons, 2007, 205, 468-478e1.	0.2	4
492	Chemotherapy in metastatic colorectal cancer. Surgical Oncology, 2007, 16, 65-70.	0.8	40
493	Palliation of hepatic tumors. Surgical Oncology, 2007, 16, 277-291.	0.8	44
494	Developing Strategies for Liver Metastases From Colorectal Cancer. Seminars in Oncology, 2007, 34, S7-S11.	0.8	49
495	Cetuximab efficacy in patients treated routinely in university hospitals. Gastroenterologie Clinique Et Biologique, 2007, 31, 941-949.	0.9	3
497	Actual role of radiofrequency ablation of liver metastases. European Radiology, 2007, 17, 2062-2070.	2.3	97
498	Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study. Annals of Surgical Oncology, 2007, 14, 759-765.	0.7	161
499	Asymptomatic Colorectal Cancer with Un-Resectable Liver Metastases: Immediate Colorectal Resection or Up-Front Systemic Chemotherapy?. Annals of Surgical Oncology, 2007, 14, 766-770.	0.7	146
500	Targeting of Insulin-like Growth Factor-I Receptor with a Monoclonal Antibody Inhibits Growth of Hepatic Metastases from Human Colon Carcinoma in Mice. Annals of Surgical Oncology, 2007, 14, 2838-2846.	0.7	23
501	Site-Specific Gene Expression Profiles and Novel Molecular Prognostic Factors in Patients with Lower Gastrointestinal Adenocarcinoma Diffusely Metastatic to Liver or Peritoneum. Annals of Surgical Oncology, 2007, 14, 3460-3471.	0.7	61
505	Preoperative Chemotherapy and the Outcome of Liver Resection for Colorectal Metastases. World Journal of Surgery, 2007, 31, 353-364.	0.8	47
506	Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study. Cancer Chemotherapy and Pharmacology, 2007, 59, 613-620.	1.1	23
507	Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 60, 383-389.	1.1	18
508	Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 60, 351-356.	1.1	21
509	Phase I and pharmacokinetic trial of AP5346, a DACHâ€“platinumâ€“polymer conjugate, administered weekly for three out of every 4Âweeks to advanced solid tumor patients. Cancer Chemotherapy and Pharmacology, 2007, 60, 523-533.	1.1	108
510	The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 75-81.	1.1	10

#	Article	IF	Citations
511	Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction. Cancer Chemotherapy and Pharmacology, 2007, 61, 97-104.	1.1	6
512	A phase II study of irinotecan in combination with doxifluridine, an intermediate form of capecitabine, in patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 275-281.	1.1	3
513	Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 283-289.	1.1	18
514	Third-line therapy for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2007, 61, 1-13.	1.1	8
515	Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer, 2007, 10, 104-111.	2.7	29
516	Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience. International Journal of Clinical Oncology, 2007, 12, 218-223.	1.0	19
518	The short-time effects of chemotherapy with combinations of hydroxycamptothecine and oxaliplatin in treatment of advanced colorectal cancer. Chinese-German Journal of Clinical Oncology, 2007, 6, 40-43.	0.1	1
519	Surgical Resection of Colorectal Liver Metastases in Patients with Expanded Indications: A Single-Center Experience with 501 Patients. Diseases of the Colon and Rectum, 2007, 50, 478-488.	0.7	95
521	Combination therapy of S-1 and CDDP for patients with colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2007, 133, 841-846.	1.2	3
522	Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy. Journal of Cancer Research and Clinical Oncology, 2007, 133, 783-785.	1.2	2
523	The prognostic factors of stage IV colorectal cancer and assessment of proper treatment according to the patientâ€™s status. International Journal of Colorectal Disease, 2007, 22, 1301-1310.	1.0	69
524	Pulmonary metastasis from colorectal carcinoma with hepatic metastasis. General Thoracic and Cardiovascular Surgery, 2007, 55, 455-460.	0.4	11
525	Oxaliplatin, fluorouracil and leucovorin (FOLFOX) as first-line chemotherapy for metastatic or recurrent colorectal cancer patients. Chinese Journal of Clinical Oncology, 2007, 4, 397-400.	0.0	4
526	Targeted therapy for metastatic colorectal cancer: Current challenges and future directions. Current Colorectal Cancer Reports, 2007, 3, 109-115.	1.0	1
527	Chemotherapy intensification. Current Colorectal Cancer Reports, 2007, 3, 116-122.	1.0	0
529	Surgical Therapy for Colorectal Metastases to the Liver. Journal of Gastrointestinal Surgery, 2007, 11, 1057-1077.	0.9	206
530	Liver Resection for Primarily Unresectable Colorectal Metastases Downsized by Chemotherapy. Journal of Gastrointestinal Surgery, 2007, 11, 318-324.	0.9	55
531	Preoperative Chemotherapy for Colorectal Liver Metastases: Impact on Hepatic Histology and Postoperative Outcome. Journal of Gastrointestinal Surgery, 2007, 11, 860-868.	0.9	237

#	Article	IF	Citations
532	Chemotherapy-Induced Normalization of FDG Uptake by Colorectal Liver Metastases Does Not Usually Indicate Complete Pathologic Response. Journal of Gastrointestinal Surgery, 2007, 11, 1112-1119.	0.9	90
533	Targeted therapy for oesophageal cancer: an overview. Cancer and Metastasis Reviews, 2008, 27, 273-288.	2.7	23
534	Fibrosis, Portal Hypertension, and Hepatic Volume Changes Induced by Intra-arterial Radiotherapy with 90Yttrium Microspheres. Digestive Diseases and Sciences, 2008, 53, 2556-2563.	1.1	132
536	Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil,) Tj ETQq1 1 0.784314 rgBT /Over Immunotherapy, 2008, 57, 977-986.	2.0	81
537	Resection of Colorectal Liver Metastases: Is a Resection Margin of 3Âmm Enough?. World Journal of Surgery, 2008, 32, 2047-2056.	0.8	36
538	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 579-585.	1.1	17
539	Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemotherapy and Pharmacology, 2008, 62, 195-201.	1.1	146
540	Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemotherapy and Pharmacology, 2008, 62, 931-936.	1.1	30
544	What is the impact of biologicals in colorectal cancer?. Targeted Oncology, 2008, 3, 59-69.	1.7	0
545	Complete pathological response of colorectal liver metastases after chemotherapy and bevacizumab treatment: a case report. Targeted Oncology, 2008, 3, 253-258.	1.7	2
546	Selective Surgical Treatment of Patients with Rectal Carcinoma and Unresectable Synchronous Metastases Based on Response to Preoperative Chemotherapy. Journal of Gastrointestinal Surgery, 2008, 12, 1246-1250.	0.9	8
547	Interval Period Tumor Progression: Does Delayed Hepatectomy Detect Occult Metastases in Synchronous Colorectal Liver Metastases?. Journal of Gastrointestinal Surgery, 2008, 12, 1391-1398.	0.9	47
549	The Role of Targeted Therapy in the Treatment of Advanced Colorectal Cancer. Current Treatment Options in Oncology, 2008, 9, 357-374.	1.3	5
550	Hepatic artery infusion in the treatment of colorectal cancer metastases. Current Colorectal Cancer Reports, 2008, 4, 106-113.	1.0	0
551	Sequential chemotherapy for advanced colorectal cancer: Should we ever start with a single cytotoxic agent?. Current Colorectal Cancer Reports, 2008, 4, 130-138.	1.0	5
552	Irinotecan versus oxaliplatin for adjuvant colon cancer therapy: Why do the results differ?. Current Colorectal Cancer Reports, 2008, 4, 167-172.	1.0	0
553	Consensus on the medical treatment of colon cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 79-90.	0.3	10
554	Safety of irinotecan and infusional fluorouracil/leucovorin (FOLFIRI) in Japan: a retrospective review of 48 patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2008, 13, 144-149.	1.0	12

#	Article	IF	Citations
555	Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers. International Journal of Clinical Oncology, 2008, 13, 472-473.	1.0	0
557	Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. Journal of Gastroenterology, 2008, 43, 842-848.	2.3	2
558	Clinical identification of colorectal cancer patients benefiting from adjuvant uracilâ€“tegafur (UFT): a randomized controlled trial. Journal of Cancer Research and Clinical Oncology, 2008, 134, 1319-1323.	1.2	2
559	New look at the old management of unknown primary. Journal of Surgical Oncology, 2008, 98, 71-72.	0.8	1
560	Systemic therapy for metastatic colorectal cancer. Cancer, 2008, 112, 1879-1891.	2.0	26
561	Advanced bladder cancer: Status of firstâ€line chemotherapy and the search for active agents in the secondâ€line setting. Cancer, 2008, 113, 1284-1293.	2.0	62
562	Synergistic antitumor activity of the novel SNâ€38â€incorporating polymeric micelles, NK012, combined with 5â€fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5â€fluorouracil. International Journal of Cancer, 2008, 122, 2148-2153.	2.3	53
563	Management and Survival Trends in Advanced Colorectal Cancer. Clinical Oncology, 2008, 20, 626-630.	0.6	9
564	Phase I Study of Preoperative Radiation Therapy With Concurrent Infusional 5-Fluorouracil and Oxaliplatin Followed by Surgery and Postoperative 5-Fluorouracil Plus Leucovorin for T3/T4 Rectal Adenocarcinoma: ECOG E1297. International Journal of Radiation Oncology Biology Physics, 2008, 72, 108-113.	0.4	24
565	Positron Emission Tomography Detection of Distant Metastatic or Synchronous Disease in Patients with Locally Advanced Rectal Cancer Receiving Preoperative Chemoradiation. Annals of Surgical Oncology, 2008, 15, 704-711.	0.7	49
566	Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics, 2008, 9, 1079-1099.	0.6	30
567	Efficacy of a continuous venous infusion of fluorouracil and daily divided dose cisplatin as adjuvant therapy in resectable colorectal cancer: A prospective randomized trial. Surgery Today, 2008, 38, 623-632.	0.7	8
568	A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British Journal of Cancer, 2008, 98, 1614-1618.	2.9	49
569	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. British Journal of Cancer, 2008, 99, 577-583.	2.9	7
570	Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines. British Journal of Cancer, 2008, 99, 1607-1612.	2.9	79
571	Review article: current management of metastatic colorectal cancer â€“ the evolving impact of targeted drug therapies. Alimentary Pharmacology and Therapeutics, 2008, 27, 997-1005.	1.9	12
573	Colon Cancer in Older Adults. Seminars in Oncology, 2008, 35, 561-568.	0.8	17
574	Utility of Pretreatment Bilirubin Level and UGT1A1 Polymorphisms in Multivariate Predictive Models of Neutropenia Associated with Irinotecan Treatment in Previously Untreated Patients with Colorectal Cancer. Archives of Drug Information, 2008, 1, 97-106.	1.6	4

#	Article	IF	Citations
575	Role of hepatectomy in treating multiple bilobar colorectal cancer metastases. Surgery, 2008, 143, 259-270.	1.0	35
576	Locoregional Treatment of Malignant Hepatic Tumors with Biologic Response Modifiers. Surgical Oncology Clinics of North America, 2008, 17, 935-955.	0.6	2
577	Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial. Expert Review of Anticancer Therapy, 2008, 8, 1237-1245.	1.1	11
578	Bevacizumab. Drugs, 2008, 68, 487-506.	4.9	98
579	Triplet Combination of Fluoropyrimidines, Oxaliplatin, and Irinotecan in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 7-14.	1.0	15
580	Current Status of Chemotherapy for Advanced Colorectal Cancer in Japan. Clinical Colorectal Cancer, 2008, 7, 15-24.	1.0	3
581	Second-Line Management of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 25-32.	1.0	5
582	Oxaliplatin in Combination with 5-Fluorouracil/Leucovorin or Capecitabine in Elderly Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 60-64.	1.0	28
583	Cetuximab plus XELIRI or XELOX for First-Line Therapy of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 110-117.	1.0	12
584	Colon Cancer: Update on Adjuvant Therapy. Clinical Colorectal Cancer, 2008, 7, 178-183.	1.0	35
585	Is XELOX Equivalent to FOLFOX or Other Continuous-Infusion 5-Fluorouracil Chemotherapy in Metastatic Colorectal Cancer?. Clinical Colorectal Cancer, 2008, 7, 206-211.	1.0	8
586	Regional Chemotherapy for Liver-Limited Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 247-259.	1.0	24
587	A Phase II Study of Cetuximab/Irinotecan in Patients with Heavily Pretreated Metastatic Colorectal Cancer: Predictive Value of Early Specific Toxicities. Clinical Colorectal Cancer, 2008, 7, 273-279.	1.0	8
588	Update on Novel Strategies to Optimize Cetuximab Therapy in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 300-308.	1.0	7
589	Sequential Versus Combination Therapy in the Treatment of Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, 315-320.	1.0	4
590	Treatment of Recurrent Metastatic Colon Cancer in the Age of Modern Adjuvant Therapy. Clinical Colorectal Cancer, 2008, 7, 321-324.	1.0	6
591	First-Line Treatment of Patients with Metastatic Colorectal Cancer: An Overview of Recent Data on Chemotherapy plus Targeted Agents. Clinical Colorectal Cancer, 2008, 7, S47-S51.	1.0	6
592	Understanding the Predictive Role of K-ras for Epidermal Growth Factor Receptorâ€“Targeted Therapies in Colorectal Cancer. Clinical Colorectal Cancer, 2008, 7, S52-S57.	1.0	14

#	Article	IF	Citations
593	Hepatic Arterial Infusion of Oxaliplatin and Intravenous LV5FU2 in Unresectable Liver Metastases from Colorectal Cancer after Systemic Chemotherapy Failure. Annals of Surgical Oncology, 2008, 15, 219-226.	0.7	168
594	Late recurrence of large peri-stomal metastasis following abdomino-perineal resection of rectal cancer. World Journal of Surgical Oncology, 2008, 6, 96.	0.8	21
595	Is Hepatic Resection Justified After Chemotherapy in Patients With Colorectal Liver Metastases and Lymph Node Involvement?. Journal of Clinical Oncology, 2008, 26, 3672-3680.	0.8	172
596	Systemic Treatment of Colorectal Cancer. Gastroenterology, 2008, 134, 1296-1310.e1.	0.6	418
597	Exploring the roles of combination and sequential strategies in palliative CRC care. European Journal of Cancer, Supplement, 2008, 6, 1-4.	2.2	1
598	Assessing the role of combination therapy in mCRC. European Journal of Cancer, Supplement, 2008, 6, 5-11.	2.2	2
599	Staging of Advanced Colorectal Cancer. Surgical Oncology Clinics of North America, 2008, 17, 503-517.	0.6	7
600	Systemic Therapy for Colon Cancer. Gastroenterology Clinics of North America, 2008, 37, 287-295.	1.0	21
601	Costâ€“effectiveness ofUGT1A1genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer. Pharmacogenomics, 2008, 9, 539-549.	0.6	43
602	Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer. European Journal of Cancer, 2008, 44, 652-662.	1.3	4
603	The Oncosurge strategy for the management of colorectal liver metastases â€“ An external validation study. European Journal of Surgical Oncology, 2008, 34, 538-540.	0.5	8
604	Drug interactions between chemotherapeutic regimens and antiepileptics. Clinical Therapeutics, 2008, 30, 1385-1407.	1.1	141
605	A review on oxaliplatin-induced peripheral nerve damage. Cancer Treatment Reviews, 2008, 34, 368-377.	3.4	275
606	Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treatment Reviews, 2008, 34, 293-301.	3.4	26
607	Review article: panitumumab â€•a fully human antiâ€EGFR monoclonal antibody for treatment of metastatic colorectal cancer. Alimentary Pharmacology and Therapeutics, 2008, 28, 269-281.	1.9	44
608	Introduction: Advances in treatment of metastatic colorectal cancer. Cancer Treatment Reviews, 2008, 34, S1-S2.	3.4	3
609	First-line combination treatment of colorectal cancer with hepatic metastases: Choosing a targeted agent. Cancer Treatment Reviews, 2008, 34, S3-S7.	3.4	77
610	Sequential or combination chemotherapy for a patient with mCRC?. Cancer Treatment Reviews, 2008, 34, S12-S16.	3.4	0

#	Article	IF	Citations
611	A dilemma in geriatric oncology: Malignant bowel obstruction in an 81-year-old man. Cancer Treatment Reviews, 2008, 34, S17-S22.	3.4	0
612	Perioperative chemotherapy for resectable hepatic metastases. Lancet, The, 2008, 371, 963-965.	6.3	71
613	EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2311-2319.	0.8	884
614	Hepatic Yttrium-90 Radioembolization of Chemotherapy-refractory Colorectal Cancer Liver Metastases. Journal of Vascular and Interventional Radiology, 2008, 19, 1187-1195.	0.2	130
615	Adjuvant and Palliative Chemotherapy for Colon Cancer in the Elderly Patient. Seminars in Colon and Rectal Surgery, 2008, 19, 239-246.	0.2	2
616	Isolated Hepatic Perfusion for the Treatment of Liver Tumors: Sunset or Sunrise?. Surgical Oncology Clinics of North America, 2008, 17, 877-894.	0.6	1
617	Development of Isolated Hepatic Perfusion for Patients Who Have Unresectable Hepatic Malignancies. Surgical Oncology Clinics of North America, 2008, 17, 857-876.	0.6	12
618	Optimal approach to potentially resectable liver metastases from colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 1533-1539.	1.1	4
619	The Role of Molecular Markers in Predicting Response to Therapy in Patients with Colorectal Cancer. Molecular Diagnosis and Therapy, 2008, 12, 87-98.	1.6	22
620	Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 319-329.	1.1	11
621	Progress and challenges in the adjuvant treatment of stage II and III colon cancers. Expert Review of Anticancer Therapy, 2008, 8, 595-604.	1.1	20
622	Therapy for Unresectable Metastatic Colorectal Cancer. Seminars in Colon and Rectal Surgery, 2008, 19, 216-225.	0.2	0
623	Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Annals of Oncology, 2008, 19, 1720-1726.	0.6	163
624	Metastatic Rectal Cancer Responding to Third-line Therapy Employing Bevacizumab After Failure of Oxaliplatin and Irinotecan: Case Report. Japanese Journal of Clinical Oncology, 2008, 38, 493-496.	0.6	5
625	Impact of Baseline Sum of Longest Diameter in Target Lesions by RECIST on Survival of Patients with Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2008, 38, 689-694.	0.6	14
626	First-line single-agent cetuximab in patients with advanced colorectal cancer. Annals of Oncology, 2008, 19, 711-716.	0.6	40
627	A Phase II Study of Gefitinib, 5-Fluorouracil, Leucovorin, and Oxaliplatin in Previously Untreated Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2008, 14, 7074-7079.	3.2	46
628	Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines. Japanese Journal of Clinical Oncology, 2008, 38, 762-769.	0.6	33

#	Article	IF	Citations
629	Advances in Chemotherapy against Advanced or Metastatic Colorectal Cancer. Digestion, 2008, 77, 13-22.	1.2	34
630	Phase I/II Study of 24-Hour Infusion of Irinotecan Combined with Oral UFT for Metastatic Colorectal Cancer. Chemotherapy, 2008, 54, 140-146.	0.8	10
631	Linkage of Pluripotent Stem Cell- Associated Transcripts to Regulatory Gene Networks. Cells Tissues Organs, 2008, 188, 31-45.	1.3	9
632	A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer. Chemotherapy, 2008, 54, 228-235.	0.8	24
633	Chemotherapy prior to Hepatic Resection for Colorectal Liver Metastases: Helpful until Harmful?. Digestive Surgery, 2008, 25, 421-429.	0.6	47
634	Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials. Journal of Clinical Oncology, 2008, 26, 1443-1451.	0.8	216
635	Safety and Efficacy of Modified FOLFOX6 for Treatment of Metastatic or Locally Advanced Colorectal Cancer. Chemotherapy, 2008, 54, 395-403.	0.8	17
636	Bimonthly Chemotherapy with Oxaliplatin, Irinotecan, Infusional 5-Fluorouracil/Folinic Acid in Patients with Metastatic Colorectal Cancer Pretreated with Irinotecan- or Oxaliplatin-Based Chemotherapy. Journal of Chemotherapy, 2008, 20, 622-631.	0.7	9
637	Gefitinib in Combination with Oxaliplatin and 5-Fluorouracil in Irinotecan-Refractory Patients with Colorectal Cancer: A Phase I Study of the Arbeits gemeinschaft Internistische Onkologie (AIO). Onkologie, 2008, 31, 237-241.	1.1	9
638	High-Dose Irinotecan plus LV5FU2 or Simplified LV5FU (HD-FOLFIRI) for Patients with Untreated Metastatic Colorectal Cancer: A New Way to Allow Resection of Liver Metastases?. Oncology, 2008, 74, 17-24.	0.9	16
639	Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. Expert Review of Anticancer Therapy, 2008, 8, 183-189.	1.1	25
640	Systemic and targeted therapy for advanced colon cancer. Expert Review of Gastroenterology and Hepatology, 2008, 2, 135-149.	1.4	49
641	Oxaliplatin-based chemotherapy in the management of colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 1223-1236.	1.1	34
642	Capecitabine plus oxaliplatin for the treatment of colorectal cancer. Expert Review of Anticancer Therapy, 2008, 8, 161-174.	1.1	9
643	Urological Oncology. , 2008, , .		3
644	Chemotherapy for Colorectal Cancer Liver Metastases. Oncologist, 2008, 13, 1063-1073.	1.9	55
645	Urgent Need for a New Staging System in Advanced Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 4828-4833.	0.8	146
646	Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. Journal of Clinical Oncology, 2008, 26, 5910-5917.	0.8	149

#	Article	IF	Citations
647	A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. Annals of Oncology, 2008, 19, 909-914.	0.6	40
648	Management of early and advanced colorectal cancer: Therapeutic issues. American Journal of Health-System Pharmacy, 2008, 65, S8-S14.	0.5	9
649	Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study. Acta OncolÃ³gica, 2008, 47, 286-292.	0.8	12
650	Current and emerging therapies for metastatic colorectal cancer: Applying research findings to clinical practice. American Journal of Health-System Pharmacy, 2008, 65, S15-S21.	0.5	14
651	Disparities in the Use of Chemotherapy and Monoclonal Antibody Therapy for Elderly Advanced Colorectal Cancer Patients in the Community Oncology Setting. Oncologist, 2008, 13, 876-885.	1.9	62
652	Pathogenesis and Clinical Practice in Gastroenterology. , 2008, , .		0
653	Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery. Annals of Oncology, 2008, 19, 1659-1661.	0.6	67
654	Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2008, 26, 4544-4550.	0.8	55
655	Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii33-ii34.	0.6	28
656	Innovations in Chemotherapy for Metastatic Colorectal Cancer: An Update of Recent Clinical Trials. Oncologist, 2008, 13, 1074-1083.	1.9	63
657	Novel opportunities for thymidylate metabolism as a therapeutic target. Molecular Cancer Therapeutics, 2008, 7, 3029-3037.	1.9	51
658	Chemotherapy in Elderly Patients with Colorectal Cancer. Oncologist, 2008, 13, 390-402.	1.9	100
659	Colorectal Tumor Cells Treated with 5-FU, Oxaliplatin, Irinotecan, and Cetuximab Exhibit Changes in¹⁸F-FDG Incorporation Corresponding to Hexokinase Activity and Glucose Transport. Journal of Nuclear Medicine, 2008, 49, 1386-1394.	2.8	16
660	Challenges in treating older cancer patients: colon cancer. Annals of Oncology, 2008, 19, vii104-vii108.	0.6	2
661	Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group. Annals of Oncology, 2008, 19, 1442-1449.	0.6	45
662	Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Annals of Oncology, 2008, 19, 1141-1145.	0.6	92
663	Chemotherapy Treatments for Metastatic Colorectal Cancer: Is Evidence-Based Medicine in Practice?. Journal of Oncology Practice, 2008, 4, 271-276.	2.5	13
664	Sinusoidal Obstructive Syndrome Diagnosed With Superparamagnetic Iron Oxideâ€“Enhanced Magnetic Resonance Imaging in Patients With Chemotherapy-Treated Colorectal Liver Metastases. Journal of Clinical Oncology, 2008, 26, 4304-4310.	0.8	80

#	Article	IF	Citations
665	Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Annals of Oncology, 2008, 19, 1127-1134.	0.6	41
666	Expanding Criteria for Resectability of Colorectal Liver Metastases. Oncologist, 2008, 13, 51-64.	1.9	389
667	Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2008, 14, 215-223.	3.2	26
671	Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Annals of Oncology, 2008, 19, 920-926.	0.6	139
672	Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nature Clinical Practice Oncology, 2008, 5, 415-425.	4.3	19
673	Emerging drugs for ovarian cancer. Expert Opinion on Emerging Drugs, 2008, 13, 523-536.	1.0	9
674	Emerging drugs for colorectal cancer. Expert Opinion on Emerging Drugs, 2008, 13, 629-642.	1.0	10
675	Treatment of advanced or recurrent colorectal cancer with irinotecan in Japan and elsewhere. Expert Opinion on Pharmacotherapy, 2008, 9, 1223-1228.	0.9	1
676	The Impact of Chemotherapy on Overall Survival and Quality of Life of Patients with Metastatic Colorectal Cancer: A Review of Phase III Trials. Journal of Chemotherapy, 2008, 20, 14-27.	0.7	19
678	Phase I dose-escalating study of S-1 in combination with oxaliplatin for patients with advanced and/or metastatic colorectal cancer. Anti-Cancer Drugs, 2008, 19, 745-748.	0.7	2
679	Clinical Management of Patients with Colorectal Liver Metastasis Using Hepatic Arterial Infusion. , 2008, , 249-263.		0
680	Phase I/II study of combination therapy with S-1 and CPT-11 for metastatic colorectal cancer. Molecular Medicine Reports, 2008, 1, 925-30.	1.1	4
681	Pharmacologic Principles of Regional Therapy in the Treatment of Liver Metastases or Primary Liver Tumors. , 2008, , 38-52.		1
682	The clinical management of hepatic neoplasms. , 0, , 1-24.		2
683	Medical Management of Colorectal Liver Metastasis. , 2008, , 222-242.		1
684	R1 Resection by Necessity for Colorectal Liver Metastases. Annals of Surgery, 2008, 248, 626-637.	2.1	366
685	A Retrospective Study of Bifractionated CPT-11 With LF5FU Infusion (FOLFIRI-3) in Colorectal Cancer Patients Pretreated With Oxaliplatin and CPT-11 Containing Chemotherapies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 89-94.	0.6	7
686	First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. Current Opinion in Oncology, 2008, 20, 459-465.	1.1	11

#	Article	IF	Citations
687	Alternating XELFOX and XELFIRI in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 323-328.	0.6	5
688	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. OncoTargets and Therapy, 2008, , 17.	1.0	0
689	Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics: Targets and Therapy, 2008, 2, 53.	3.0	6
690	PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer. Cancer Imaging, 2008, 8, S46-S51.	1.2	19
691	Complete Remission of Unresectable Colon Cancer after Preoperative Chemotherapy Selected by Adenosine Triphosphate-Based Chemotherapy Response Assay. Journal of Korean Medical Science, 2008, 23, 916.	1.1	6
693	Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil. Journal of Medical Economics, 2008, 11, 311-325.	1.0	8
694	Clinical comparison of QOL and adverse events during postoperative adjuvant chemotherapy in outpatients with node-positive colorectal cancer or gastric cancer. Oncology Reports, 2009, 21, 1061-6.	1.2	9
695	Efficacy of 5-FU/LV plus CPT-11 as first-line adjuvant chemotherapy for stage IIIa colorectal cancer. Oncology Reports, 2009, 22, 621-9.	1.2	8
696	Heterogeneity of Adenosine Triphosphate-Based Chemotherapy Response Assay in Colorectal Cancer - Secondary Publication. Yonsei Medical Journal, 2009, 50, 697.	0.9	15
697	Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Management and Research, 2009, Volume 1, 79-88.	0.9	6
698	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, , 429.	3.0	2
699	Treatment of Colorectal Liver Metastases: A Review. Reviews on Recent Clinical Trials, 2009, 4, 56-62.	0.4	60
700	Phase II Study of Irinotecan, High-dose 5-fluorouracil, and Leucovorin Combination Chemotherapy in Taxane and Cisplatin-based Chemotherapy-refractory Metastatic Gastric Cancer. Chonnam Medical Journal, 2009, 45, 79.	0.1	0
701	Cancer du rectum avec mÃ©tastases synchrones non rÃ©sÃ©cables : les arguments du choix thÃ©rapeutique. CancÃ©ro Digest, 2009, 1, 126.	0.0	0
703	Vascular Endothelial Growth Factor Plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism?. Journal of Oncology, 2009, 2009, 1-9.	0.6	11
706	Role of oxaliplatin in the treatment of colorectal cancer. Therapeutics and Clinical Risk Management, 2009, 5, 229.	0.9	62
707	Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives. Expert Opinion on Pharmacotherapy, 2009, 10, 1095-1108.	0.9	10
708	Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. Annals of Oncology, 2009, 20, 892-896.	0.6	31

#	Article	IF	Citations
709	Review: Medical treatment of advanced colorectal cancer in 2009. Therapeutic Advances in Medical Oncology, 2009, 1, 55-68.	1.4	7
710	Commentary: Practice Patterns and Potential Impact on Quality Measures for a Practicing Physician. Journal of Oncology Practice, 2009, 5, 233-235.	2.5	2
711	FDA Review of a Panitumumab (Vectibixâ„¢) Clinical Trial for First-Line Treatment of Metastatic Colorectal Cancer. Oncologist, 2009, 14, 284-290.	1.9	53
712	Oxaliplatin or Irinotecan As Adjuvant Therapy for Colon Cancer: The Results Are In. Journal of Clinical Oncology, 2009, 27, 3082-3084.	0.8	33
713	Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2009, 27, 1948-1955.	0.8	160
714	Dual-Antibody Therapy in Advanced Colorectal Cancer: Gather Ye Rosebuds While Ye May. Journal of Clinical Oncology, 2009, 27, 655-658.	0.8	12
715	Longitudinal Patterns of Chemotherapy Use in Metastatic Colorectal Cancer. Journal of Oncology Practice, 2009, 5, 228-233.	2.5	24
716	Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. Annals of Oncology, 2009, 20, 1042-1047.	0.6	37
717	A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Annals of Oncology, 2009, 20, 1964-1970.	0.6	237
718	A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer. British Journal of Cancer, 2009, 101, 1658-1663.	2.9	149
719	Cost-effectiveness analysis of XELOX for metastatic colorectal cancer based on the NO16966 and NO16967 trials. British Journal of Cancer, 2009, 101, 12-18.	2.9	31
720	FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study. Annals of Oncology, 2009, 20, 1383-1386.	0.6	16
721	Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv61-iv63.	0.6	147
723	A Feasibility Study of UFT/LV and Irinotecan (TEGAFIRI) in Advanced or Metastatic Colorectal Cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304. Japanese Journal of Clinical Oncology, 2009, 39, 601-605.	0.6	5
724	A Pilot Human Evaluation of a Formulation of Irinotecan and Hyaluronic Acid in 5-Fluorouracil-Refractory Metastatic Colorectal Cancer Patients. Chemotherapy, 2009, 55, 49-59.	0.8	25
725	Phase III Noninferiority Trial Comparing Irinotecan With Oxaliplatin, Fluorouracil, and Leucovorin in Patients With Advanced Colorectal Carcinoma Previously Treated With Fluorouracil: N9841. Journal of Clinical Oncology, 2009, 27, 2848-2854.	0.8	59
726	Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer. Oncology, 2009, 76, 151-156.	0.9	13
727	Targeting the extracellular signature of metastatic colorectal cancers. Expert Opinion on Therapeutic Targets, 2009, 13, 363-379.	1.5	6

#	Article	IF	Citations
728	Resection of the Primary Colorectal Cancer Is Not Necessary in Nonobstructed Patients with Metastatic Disease. Oncologist, 2009, 14, 963-969.	1.9	48
729	Overview of Systemic Therapy for Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2009, 22, 251-256.	0.5	62
730	Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Annals of Oncology, 2009, 20, 5-16.	0.6	162
731	Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients. Cancer Biomarkers, 2009, 5, 167-175.	0.8	25
732	Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer. Oncology, 2009, 77, 192-196.	0.9	23
733	Bevacizumab plus Oxaliplatin-Based Regimens for the Treatment of Colorectal Cancer. Onkologie, 2009, 32, 431-439.	1.1	4
734	Thymidylate synthase gene variations: predictive and prognostic markers. Molecular Cancer Therapeutics, 2009, 8, 1000-1007.	1.9	61
735	Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Annals of Oncology, 2009, 20, 251-257.	0.6	13
737	Retrospective Analysis of S-1 Monotherapy in Patients with Metastatic Colorectal Cancer After Failure to Fluoropyrimidine and Irinotecan or to Fluoropyrimidine, Irinotecan and Oxaliplatin. Japanese Journal of Clinical Oncology, 2009, 39, 315-320.	0.6	12
738	Clinical Outcomes Associated with Bevacizumab-Containing Treatment of Metastatic Colorectal Cancer: The BRiTE Observational Cohort Study. Oncologist, 2009, 14, 862-870.	1.9	292
739	NCCTG Study N9741: Leveraging Learning from an NCI Cooperative Group Phase III Trial. Oncologist, 2009, 14, 970-978.	1.9	11
740	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. Journal of Clinical Oncology, 2009, 27, 3117-3125.	0.8	437
741	Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Annals of Oncology, 2009, 20, 244-250.	0.6	49
742	A Comprehensive Comparative Study on the Characteristics of Colorectal Cancer Chemotherapy. Japanese Journal of Clinical Oncology, 2009, 39, 367-375.	0.6	14
743	Radiofrequency ablation of colorectal liver metastases downstaged by chemotherapy. Acta Radiologica, 2009, 50, 716-721.	0.5	43
744	Making Circadian Cancer Therapy Practical. Integrative Cancer Therapies, 2009, 8, 371-386.	0.8	22
746	Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 7405-7411.	3.2	44
747	Reply to F. Montagnani et al. Journal of Clinical Oncology, 2009, 27, e134-e135.	0.8	0

#	Article	IF	Citations
748	Treatment of Fluorouracil-Refractory Patients With Liver Metastases From Colorectal Cancer by Using Yttrium-90 Resin Microspheres Plus Concomitant Systemic Irinotecan Chemotherapy. Journal of Clinical Oncology, 2009, 27, 4089-4095.	0.8	142
749	Safety, Pharmacokinetics, and Efficacy of CPX-1 Liposome Injection in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2009, 15, 692-700.	3.2	187
750	The role of floxuridine in metastatic liver disease. Molecular Cancer Therapeutics, 2009, 8, 1015-1025.	1.9	65
751	Phase I Study of Cediranib in Combination with Oxaliplatin and Infusional 5-Fluorouracil in Patients with Advanced Colorectal Cancer. Clinical Cancer Research, 2009, 15, 1481-1486.	3.2	36
752	Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. Journal of Controlled Release, 2009, 134, 18-25.	4.8	50
753	Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. Journal of Controlled Release, 2009, 137, 8-14.	4.8	101
754	Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study. BMC Cancer, 2009, 9, 112.	1.1	42
755	Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer, 2009, 9, 120.	1.1	63
756	A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer, 2009, 9, 156.	1.1	35
757	Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer, 2009, 9, 246.	1.1	31
758	Cost-minimization analysis of sequence changes between FOLFIRI and FOLFOX6 therapy for advanced colorectal cancer in Japan. Clinical Therapeutics, 2009, 31, 2433-2441.	1.1	4
760	Colorectal Cancer in Young Adults. Seminars in Oncology, 2009, 36, 439-450.	0.8	56
763	Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5â€fluorouracil in colorectal cancer. International Journal of Cancer, 2010, 126, 1691-1701.	2.3	19
764	Cost implications of new treatments for advanced colorectal cancer. Cancer, 2009, 115, 2081-2091.	2.0	54
765	Comparing safety and efficacy of firstâ€line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer. Cancer, 2009, 115, 2617-2629.	2.0	59
766	Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 before irinotecan administration for metastatic colorectal cancer. Cancer, 2009, 115, 3858-3867.	2.0	78
767	Rescue chemotherapy using multidrug chronomodulated hepatic arterial infusion for patients with heavily pretreated metastatic colorectal cancer. Cancer, 2009, 115, 4990-4999.	2.0	51
768	Evaluation of a peritoneal surface disease severity score in patients with colon cancer with peritoneal carcinomatosis. Journal of Surgical Oncology, 2009, 99, 9-15.	0.8	135

#	Article	IF	Citations
769	Evidenceâ€based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. Journal of Surgical Oncology, 2009, 100, 335-344.	0.8	33
770	Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Journal of Surgical Oncology, 2009, 100, 306-310.	0.8	27
771	Resected colorectal liver metastases: Does the survival differ according to postoperative chemotherapy regimen?. Journal of Surgical Oncology, 2009, 100, 713-718.	0.8	19
772	Long-term outcome in patients with adrenal metastases following resection of colorectal liver metastases. British Journal of Surgery, 2009, 96, 935-940.	0.1	15
773	Treatment for colorectal liver metastases: a review. Langenbeck's Archives of Surgery, 2009, 394, 973-983.	0.8	50
774	A phase I study of combination therapy with S-1 and irinotecan (CPT-11) in patients with advanced colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2009, 135, 365-370.	1.2	10
775	La recherche clinique en cancÃ©rologie digestive: de la cible Ã la vÃ©ritable personnalisation du traitement?. Oncologie, 2009, 11, 325-330.	0.2	0
776	Does maintenance of Bevacizumab after treatment failure have a role in metastatic colon cancer?. Chinese-German Journal of Clinical Oncology, 2009, 8, 24-32.	0.1	0
778	Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. Journal of Hepato-Biliary-Pancreatic Surgery, 2009, 16, 137-144.	2.0	124
779	Two-stage hepatectomy (R0) with portal vein ligationâ€"towards curing patients with extended bilobular colorectal liver metastases. International Journal of Colorectal Disease, 2009, 24, 409-418.	1.0	49
780	Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis. International Journal of Colorectal Disease, 2009, 24, 377-383.	1.0	2
781	Irinotecan as palliative chemotherapy for metastatic colorectal cancer: evolving tactics following initial treatment. International Journal of Colorectal Disease, 2009, 24, 605-612.	1.0	5
782	The role of salvage treatment in advanced colorectal cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 53-61.	2.0	13
783	The management of colorectal liver metastases: Expanding the role of hepatic resection in the age of multimodal therapy. Critical Reviews in Oncology/Hematology, 2009, 72, 65-75.	2.0	32
784	Health utility scores of colorectal cancer based on societal preference in Japan. Quality of Life Research, 2009, 18, 1095-1103.	1.5	24
785	A phase I study of an oral simulated FOLFOX with high dose capecitabine. Investigational New Drugs, 2009, 27, 461-468.	1.2	7
786	Clinical study of combining chemotherapy of oxaliplatin or 5-fluorouracil/leucovorin with hydroxycamptothecine for advanced colorectal cancer. Clinical Oncology and Cancer Research, 2009, 6, 117-123.	0.1	6
787	Evolving end points for clinical trials in advanced colorectal cancer. Current Colorectal Cancer Reports, 2009, 5, 135-139.	1.0	1

#	Article	IF	Citations
788	Curable metastatic colorectal cancer: Recommended paradigms. Current Oncology Reports, 2009, 11, 200-208.	1.8	48
789	Local Treatment for Recurrent Colorectal Hepatic Metastases after Partial Hepatectomy. Journal of Gastrointestinal Surgery, 2009, 13, 890-895.	0.9	34
790	Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer, 2009, 16, 275-280.	1.3	28
792	Hepatic Arterial Infusion Chemotherapy Using Fluorouracil Followed by Systemic Therapy Using Oxaliplatin Plus Fluorouracil and Leucovorin for Patients with Unresectable Liver Metastases from Colorectal Cancer. CardioVascular and Interventional Radiology, 2009, 32, 679-686.	0.9	8
793	Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemotherapy and Pharmacology, 2009, 63, 441-450.	1.1	10
794	Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients. Cancer Chemotherapy and Pharmacology, 2009, 63, 501-507.	1.1	5
795	Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: a multicenter phase II study. Cancer Chemotherapy and Pharmacology, 2009, 64, 657-663.	1.1	69
796	Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2009, 65, 97-105.	1.1	29
797	Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer, 2009, 100, 1704-1719.	2.9	89
798	Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. British Journal of Cancer, 2009, 101, 1039-1043.	2.9	24
799	Polymorphism of thymidylate synthase gene and chemosensitivity of 5â€fluorouracil regimen in metastatic gastrointestinal cancer. Journal of Digestive Diseases, 2009, 10, 118-123.	0.7	18
800	Rectal cancer. Critical Reviews in Oncology/Hematology, 2009, 70, 160-182.	2.0	14
801	Chemotherapy options and outcomes in older adult patients with colorectal cancer. Critical Reviews in Oncology/Hematology, 2009, 72, 155-169.	2.0	13
802	Colon cancer and the elderly: From screening to treatment in management of GI disease in the elderly. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2009, 23, 889-907.	1.0	47
803	Timing of Multimodality Therapy for Resectable Synchronous Colorectal Liver Metastases: A Retrospective Multi-Institutional Analysis. Annals of Surgical Oncology, 2009, 16, 1809-1819.	0.7	92
804	Synchronous Colorectal Liver Metastases: Is It Time to Reconsider Traditional Paradigms of Management?. Annals of Surgical Oncology, 2009, 16, 2395-2410.	0.7	64
805	Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. British Journal of Cancer, 2009, 101, 1033-1038.	2.9	154
806	Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer. Cancer Treatment Reviews, 2009, 35, 668-675.	3.4	28

#	Article	IF	Citations
807	Incidence and clinical implications of venous thromboembolism in advanced colorectal cancer patients: The â€˜GISCAD-alternating scheduleâ€™ study findings. European Journal of Cancer, 2009, 45, 65-73.	1.3	48
808	Neutropaenia as a prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. European Journal of Cancer, 2009, 45, 1757-1763.	1.3	73
809	Current perspective: Bevacizumab in colorectal cancer â€“ A time for reappraisal?. European Journal of Cancer, 2009, 45, 2452-2461.	1.3	34
810	Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. European Journal of Surgical Oncology, 2009, 35, 164-167.	0.5	60
811	Perioperative use of the LiMON method of indocyanine green elimination measurement for the prediction and early detection of post-hepatectomy liverÂfailure. European Journal of Surgical Oncology, 2009, 35, 957-962.	0.5	72
812	Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Metastatic Colorectal Cancer as a Novel Adoptive Cell Therapy Approach. The European Group for Blood and Marrow Transplantation Experience. Biology of Blood and Marrow Transplantation, 2009, 15, 326-335.	2.0	27
813	Colon, Rectal, and Anal Cancers. Seminars in Oncology Nursing, 2009, 25, 32-47.	0.7	19
814	Study into the use of cetuximab in metastatic colorectal cancer in a third level hospital. Farmacia Hospitalaria (English Edition), 2009, 33, 72-79.	0.0	0
815	Therapeutic use and profile of toxicity of the FOLFOX4 regimen. Farmacia Hospitalaria (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 42	0.0	0
816	The Multidisciplinary Management of Rectal Cancer. Surgical Clinics of North America, 2009, 89, 177-215.	0.5	34
817	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 1408-1417.	13.9	3,543
818	Is Levoleucovorin an Alternative to Racemic Leucovorin? A Literature Review. Clinical Colorectal Cancer, 2009, 8, 200-206.	1.0	14
819	Phase II Study of UFT with Leucovorin Plus Hepatic Arterial Infusion with Irinotecan, 5-Fluorouracil and Leucovorin for Non-Resectable Liver Metastases of Colorectal Cancer. Chemotherapy, 2009, 55, 76-82.	0.8	14
820	Mice with Cisplatin and Oxaliplatin-Induced Painful Neuropathy Develop Distinct Early Responses to Thermal Stimuli. Molecular Pain, 2009, 5, 1744-8069-5-9.	1.0	122
821	Multicenter safety study of mFOLFOX6 for unresectable advanced/recurrent colorectal cancer in elderly patients. Journal of Experimental and Clinical Cancer Research, 2009, 28, 109.	3.5	8
824	Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. Journal of Clinical Oncology, 2009, 27, 3379-3384.	0.8	370
825	Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. Journal of Clinical Oncology, 2009, 27, 5727-5733.	0.8	348
826	Treatment of patients with colorectal cancer: emphasis on liver metastases. Expert Opinion on Pharmacotherapy, 2009, 10, 109-124.	0.9	2

#	Article	IF	Citations
827	Cost-Effectiveness Analysis of Capecitabine Compared with Bolus 5-Fluorouracil/l-Leucovorin for the Adjuvant Treatment of Colon Cancer in Japan. Pharmacoeconomics, 2009, 27, 597-608.	1.7	21
828	Comparison of Oxaliplatin- and Cisplatin-Induced Painful Peripheral Neuropathy in the Rat. Journal of Pain, 2009, 10, 534-541.	0.7	112
829	Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 9-14.	1.0	5
830	Sequential Versus Combination Therapy in the Treatment of Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 17-22.	1.0	1
831	Chemotherapy, which drugs and when. European Journal of Cancer, 2009, 45, 50-56.	1.3	15
832	How to integrate biologicals in the continuum of care. European Journal of Cancer, 2009, 45, 57-69.	1.3	0
833	CÃ¡ncer colorrectal. Medicine, 2009, 10, 1730-1736.	0.0	0
834	Evolving Treatment of Advanced Colon Cancer. Annual Review of Medicine, 2009, 60, 207-219.	5.0	120
835	Salvage Therapy for Liver-dominant Colorectal Metastatic Adenocarcinoma: Comparison between Transcatheter Arterial Chemoembolization versus Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology, 2009, 20, 360-367.	0.2	72
836	Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anti-Cancer Drugs, 2009, 20, 105-108.	0.7	12
837	A phase II study of modified FOLFOX as first-line chemotherapy in elderly patients with advanced gastric cancer. Anti-Cancer Drugs, 2009, 20, 281-286.	0.7	28
838	UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?. Anti-Cancer Drugs, 2009, 20, 867-879.	0.7	37
839	A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 49-55.	0.6	28
840	Phase I and Pharmacokinetic Study of Tegafur-Uracil/Leucovorin Combined With 5-Fluorouracil/Leucovorin and Irinotecan in Patients With Advanced Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 56-60.	0.6	3
841	Advances in the Treatment of Metastatic Colorectal Cancer. American Journal of Therapeutics, 2009, 16, 412-420.	0.5	37
842	Long-Term Survival After Liver Resection for Colorectal Liver Metastases in Patients With Hepatic Pedicle Lymph Nodes Involvement in the Era of New Chemotherapy Regimens. Annals of Surgery, 2009, 249, 879-886.	2.1	61
843	Selective internal radiation therapy for liver metastases from colorectal cancer. The Cochrane Library, 2009, , CD007045.	1.5	19
844	Colon Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 778-831.	2.3	409

#	Article	IF	Citations
846	Advances in the treatment of metastatic colorectal carcinoma. Radiology and Oncology, 2009, 43, 1-8.	0.6	18
847	Capecitabine in colorectal cancer. Therapy: Open Access in Clinical Medicine, 2009, 6, 239-248.	0.2	0
848	Chemotherapy for the Elderly Patient With Colorectal Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 241-252.	1.0	18
849	The management of resectable and unresectable liver metastases from colorectal cancer. Current Opinion in Oncology, 2010, 22, 364-373.	1.1	79
850	Optimal Delivery of Cytotoxic Chemotherapy for Colon Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 214-219.	1.0	23
851	Chemotherapy-induced Liver Injury in Metastatic Colorectal Cancer: Semiquantitative Histologic Analysis of 334 Resected Liver Specimens Shows That Vascular Injury but not Steatohepatitis Is Associated With Preoperative Chemotherapy. American Journal of Surgical Pathology, 2010, 34, 784-791.	2.1	85
852	Effect of leucovorin on the antitumor efficacy of the 5-FU prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Oncology Letters, 2010, 1, 973-980.	0.8	12
853	Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test. Experimental and Therapeutic Medicine, 2010, 1, 325-329.	0.8	3
856	Primary colorectal signet-ring cell carcinoma: Clinicopathological features and postoperative survival. Surgery Today, 2010, 40, 234-238.	0.7	47
857	Survival benefit from ovarian metastatectomy in colorectal cancer patients with ovarian metastasis: a retrospective analysis. Cancer Chemotherapy and Pharmacology, 2010, 66, 229-235.	1.1	49
858	A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 829-835.	1.1	12
859	A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2010, 66, 987-992.	1.1	12
860	Pre-operative chemotherapy for colorectal cancer liver metastases: an update of recent clinical trials. Cancer Chemotherapy and Pharmacology, 2010, 66, 209-218.	1.1	23
862	Associations between glutathione S-transferase Ï€ Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiology, 2010, 34, 189-193.	0.8	28
863	Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases. International Journal of Colorectal Disease, 2010, 25, 1243-1249.	1.0	19
864	Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study. International Journal of Clinical Oncology, 2010, 15, 82-87.	1.0	56
865	Histological liver injury and surgical outcome after FOLFOX followed by a hepatectomy for colorectal liver metastases in Japanese patients. International Journal of Clinical Oncology, 2010, 15, 263-270.	1.0	24
866	Health-related quality of life in patients with advanced colorectal cancer: results from a phase II study of S-1 combined with irinotecan (CPT-11). International Journal of Clinical Oncology, 2010, 15, 280-286.	1.0	8

#	Article	IF	Citations
868	Palliative endoscopic and chemotherapeutic treatment. European Surgery - Acta Chirurgica Austriaca, 2010, 42, 287-298.	0.3	0
870	Psychological effects of cetuximab-induced cutaneous rash in advanced colorectal cancer patients. Supportive Care in Cancer, 2010, 18, 329-334.	1.0	31
871	Colorectal Liver Metastases; The Current Scenario. Indian Journal of Surgical Oncology, 2010, 1, 350-355.	0.3	2
873	Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clinical and Translational Oncology, 2010, 12, 533-542.	1.2	51
874	SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clinical and Translational Oncology, 2010, 12, 729-734.	1.2	9
875	Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges. Current Treatment Options in Oncology, 2010, 11, 1-13.	1.3	91
876	Evolving Treatment of Advanced Colorectal Cancer. Current Oncology Reports, 2010, 12, 153-159.	1.8	16
877	Node Yield and Node Involvement in Young Colon Cancer Patients: Is There a Difference in Cancer Survival Based on Age?. Journal of Gastrointestinal Surgery, 2010, 14, 1355-1361.	0.9	29
878	Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2010, 22, 181-185.	0.7	5
880	Regional Hepatic Chemotherapies in Treatment of Colorectal Cancer Metastases to the Liver. Seminars in Oncology, 2010, 37, 139-148.	0.8	25
881	Transient Receptor Potential Vanilloid 1 is Essential for Cisplatin-Induced Heat Hyperalgesia in Mice. Molecular Pain, 2010, 6, 1744-8069-6-15.	1.0	162
882	Annual report to the nation on the status of cancer, 1975â€2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer, 2010, 116, 544-573.	2.0	1,691
883	Liver resection of colorectal metastases in elderly patients. British Journal of Surgery, 2010, 97, 366-376.	0.1	220
884	Stereotactic body radiation therapy for colorectal liver metastases. British Journal of Surgery, 2010, 97, 377-382.	0.1	157
885	Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases. British Journal of Surgery, 2010, 97, 1279-1289.	0.1	128
886	Combined first-stage hepatectomy and colorectal resection in a two-stage hepatectomy strategy for bilobar synchronous liver metastases. British Journal of Surgery, 2010, 97, 1354-1362.	0.1	74
887	Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases (Br J Surg 2010; 97: 1279-1289). British Journal of Surgery, 2010, 97, 1290-1290.	0.1	0
888	Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases. Journal of Surgical Oncology, 2010, 102, 946-954.	0.8	4

#	Article	IF	Citations
889	Optimizing resection for â€œrespondingâ€•hepatic metastases after neoadjuvant chemotherapy. Journal of Surgical Oncology, 2010, 102, 1002-1008.	0.8	7
890	Evolution of neoadjuvant therapy for extended hepatic metastasesâ€”have we reached our (nonâ€•resectable) limit?. Journal of Surgical Oncology, 2010, 102, 922-931.	0.8	31
891	Role of intraâ€•arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. Journal of Surgical Oncology, 2010, 102, 988-995.	0.8	43
892	Biologic modulation of chemotherapy in patients with hepatic colorectal metastases: The role of antiâ€•VEGF and antiâ€•EGFR antibodies. Journal of Surgical Oncology, 2010, 102, 937-945.	0.8	8
893	Integration of panitumumab into the treatment of colorectal cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 16-26.	2.0	24
894	Improving disease control in advanced colorectal cancer: Panitumumab and cetuximab. Critical Reviews in Oncology/Hematology, 2010, 74, 193-202.	2.0	24
895	Optimizing the management of metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2010, 75, 15-26.	2.0	5
896	Colon cancer. Critical Reviews in Oncology/Hematology, 2010, 74, 106-133.	2.0	285
897	ACR AppropriatenessÂ® CriteriaÂ®: Rectal Cancerâ€”Metastatic Disease at Presentation. Current Problems in Cancer, 2010, 34, 201-210.	1.0	11
898	Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surgery, 2010, 10, 27.	0.6	81
899	Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. British Journal of Clinical Pharmacology, 2010, 69, 58-66.	1.1	88
900	Phase I study of irinotecan and doxifluridine for metastatic colorectal cancer focusing on the UGT1A1*28 polymorphism. Cancer Science, 2010, 101, 722-727.	1.7	30
901	Phase I/II study of a 3â€•week cycle of irinotecan and Sâ€•1 in patients with advanced colorectal cancer. Cancer Science, 2010, 101, 2591-2595.	1.7	7
902	The impact of new treatment options for advanced colorectal cancer on routine care: results of a retrospective analysis of 206 consecutive patients treated in a community-based oncology group practice in Germany. European Journal of Cancer Care, 2010, 19, 795-802.	0.7	2
903	KRAS mutational status assessment in patients with metastatic colorectal cancer: are the clinical implications so clear?. European Journal of Cancer Care, 2010, 19, 167-171.	0.7	2
904	Considerations when choosing oral chemotherapy: identifying and responding to patient need. European Journal of Cancer Care, 0, 19, 5-11.	0.7	24
905	Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status. British Journal of Cancer, 2010, 102, 255-261.	2.9	9
906	Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. British Journal of Cancer, 2010, 103, 159-164.	2.9	131

#	Article	IF	Citations
907	Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. British Journal of Cancer, 2010, 103, 315-323.	2.9	9
908	Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. British Journal of Cancer, 2010, 103, 1529-1535.	2.9	13
909	Guesstimates are not good enough for determining what is happening in routine care. British Journal of Cancer, 2010, 103, 1885-1886.	2.9	2
910	â€˜Stagedâ€™ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Disease, 2010, 12, e229-35.	0.7	35
911	Liver transplantation for colorectal liver metastases: revisiting the concept. Transplant International, 2010, 23, 679-685.	0.8	76
912	Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer. Journal of Oncology, 2010, 2010, 1-7.	0.6	4
915	Methylated BNIP3 gene in colorectal cancer prognosis. Oncology Letters, 2010, 1, 865-872.	0.8	21
916	Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.. Journal of Pharmacy and Pharmaceutical Sciences, 2010, 13, 615.	0.9	31
917	Treatment results including more than third-line chemotherapy for patients with advanced non-small cell lung cancer. Oncology Letters, 2010, 1, 51-55.	0.8	4
918	Irinotecan-based combination chemotherapy for metastatic small intestinal adenocarcinoma. Oncology Letters, 2010, 1, 423-426.	0.8	1
919	Chemotherapy for Colorectal Cancer. Journal of the Korean Medical Association, 2010, 53, 582.	0.1	4
920	Pharmacoeconomic Aspects of FOLFIRI or FOLFOX Regimens Administered with a Fully Ambulatory Pump Compared to the Day Hospital Setting. Tumori, 2010, 96, 438-442.	0.6	3
921	Colorectal cancer: a decade of progress. British Journal of Hospital Medicine (London, England:) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 26	0.2	2
922	Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice. Journal of Oncology Practice, 2010, 6, 301-307.	2.5	71
923	Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2010, 16, 2187-2197.	3.2	11
924	Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 866-871.	0.8	156
925	A Phase II Study of Irinotecan and Capecitabine for Patients with Unresectable Liver-only Metastases from Colorectal Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 10-16.	0.6	10
926	Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, 2010, 28, 453-459.	0.8	440

#	Article	IF	Citations
927	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. Journal of Clinical Oncology, 2010, 28, 3191-3198.	0.8	370
928	Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study. Annals of Oncology, 2010, 21, 781-786.	0.6	40
929	A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX30 and chronomodulated XELOX30 as first-line therapy in patients with advanced colorectal cancer. Annals of Oncology, 2010, 21, 87-91.	0.6	34
930	Mitochondrial Chaperone Trap1 and the Calcium Binding Protein Sorcin Interact and Protect Cells against Apoptosis Induced by Antiblastic Agents. Cancer Research, 2010, 70, 6577-6586.	0.4	120
931	Clinical and Economic Evaluation of First-line Therapy with FOLFIRI or Modified FOLFOX6 for Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2010, 40, 634-638.	0.6	9
932	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4706-4713.	0.8	909
933	Association Between Disease-Free Survival and Overall Survival When Survival Is Prolonged After Recurrence in Patients Receiving Cytotoxic Adjuvant Therapy for Colon Cancer: Simulations Based on the 20,800 Patient ACCENT Data Set. Journal of Clinical Oncology, 2010, 28, 460-465.	0.8	67
934	Palliative treatment of unresectable metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2010, 11, 63-77.	0.9	18
935	Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut, 2010, 59, 1383-1388.	6.1	294
936	Oxaliplatin-Free Interval as a Risk Factor for Hypersensitivity Reaction among Colorectal Cancer Patients Treated with FOLFOX. Oncology, 2010, 79, 136-143.	0.9	29
937	Drug Monitoring During FOLFOX6 Therapy in a Rectal Cancer Patient on Chronic Hemodialysis. Japanese Journal of Clinical Oncology, 2010, 40, 360-364.	0.6	15
939	Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Annals of Oncology, 2010, 21, 2324-2332.	0.6	106
940	Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Annals of Oncology, 2010, 21, 766-771.	0.6	21
941	Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancerâ€"an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009. Annals of Oncology, 2010, 21, 1579-1584.	0.6	58
942	Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Annals of Oncology, 2010, 21, v93-v97.	0.6	384
943	Chemotherapy: which drug and when?. Annals of Oncology, 2010, 21, vii130-vii133.	0.6	5
945	Influence of an independent review committee on assessment of response rate and progression-free survival in phase III clinical trials. Annals of Oncology, 2010, 21, 19-26.	0.6	42
947	Clinical features of interstitial lung disease induced by standard chemotherapy (FOLFOX or FOLFIRI) for colorectal cancer. Annals of Oncology, 2010, 21, 2005-2010.	0.6	33

#	Article	IF	Citations
948	An unusual cause of anaemia. Gut, 2010, 59, 1339-1339.	6.1	0
949	Long-Lasting Tumor Response in Patients with Panitumumab Monotherapy for Chemorefractory Metastatic Colorectal Carcinoma â€“ A Report of Two Cases. Case Reports in Oncology, 2010, 3, 154-159.	0.3	1
950	Dietary Methionine Restriction with FOLFOX Regimen as First Line Therapy of Metastatic Colorectal Cancer: A Feasibility Study. Oncology, 2010, 78, 205-209.	0.9	46
951	Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Onkologie, 2010, 33, 89-93.	1.1	7
952	Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer. Recent Patents on Anti-Cancer Drug Discovery, 2010, 5, 142-151.	0.8	3
953	Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer. Oncology, 2010, 79, 67-71.	0.9	12
954	Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dellâ€™Italia Meridionale Multicenter Phase II Study. Oncology, 2010, 79, 415-422.	0.9	16
955	S3 Guidelines for Colorectal Carcinoma. Zeitschrift Fur Gastroenterologie, 2010, 48, 65-136.	0.2	91
958	Survival Outcomes of a Salvage Patient Population after Radioembolization of Hepatic Metastases with Yttrium-90 Microspheres. Journal of Vascular and Interventional Radiology, 2010, 21, 1521-1526.	0.2	30
959	Ablation of Liver Metastases: Current Status. Journal of Vascular and Interventional Radiology, 2010, 21, S214-S222.	0.2	30
960	Targeted Therapeutic Agents for Colorectal Cancer. Gastroenterology Clinics of North America, 2010, 39, 601-613.	1.0	22
961	Treatment of Colorectal Cancer. Cancer Metastasis - Biology and Treatment, 2010, , 359-388.	0.1	0
962	Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer. Oncology, 2010, 79, 118-128.	0.9	21
963	Biomarkers and surrogate end pointsâ€”the challenge of statistical validation. Nature Reviews Clinical Oncology, 2010, 7, 309-317.	12.5	283
964	Clinical Genetics of Hereditary Colorectal Cancer. Hematology/Oncology Clinics of North America, 2010, 24, 837-859.	0.9	30
965	Metastatic Colorectal Cancer: From Improved Survival to Potential Cure. Oncology, 2010, 78, 237-248.	0.9	210
966	Modified-Irinotecan/Fluorouracil/Levoleucovorin Therapy as Ambulatory Treatment for Metastatic Colorectal Cancer. Clinical Drug Investigation, 2010, 30, 243-249.	1.1	5
967	Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 2010, 9, 8-14.	1.0	7

#	Article	IF	Citations
968	KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice. Clinical Colorectal Cancer, 2010, 9, 22-30.	1.0	22
969	A Phase II Study of Oxaliplatin, 5-Fluorouracil, Leucovorin, and High-Dose Capecitabine in Patients With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2010, 9, 157-161.	1.0	6
970	The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases. Clinical Colorectal Cancer, 2010, 9, 212-218.	1.0	40
971	Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions. Clinical Colorectal Cancer, 2010, 9, 269-273.	1.0	7
972	Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer, 2010, 9, 290-296.	1.0	8
973	Hepatic Arterial Infusion of 5-Fluorouracil for Patients With Liver Metastases From Colorectal Cancer Refractory to Standard Systemic Chemotherapy: A Multicenter, Retrospective Analysis. Clinical Colorectal Cancer, 2010, 9, 305-310.	1.0	24
974	Advances in the Treatment of Metastatic Colorectal Cancer. Disease-a-Month, 2010, 56, 187-203.	0.4	1
975	Oncogramme, a new individualized tumor response testing method: application to colon cancer. Cytotechnology, 2010, 62, 381-388.	0.7	6
976	Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. European Journal of Oncology Nursing, 2010, 14, 337-349.	0.9	34
977	Colorectal cancer. Lancet, The, 2010, 375, 1030-1047.	6.3	1,318
978	The role of anti-epidermal growth factor receptor monoclonal antibody monotherapy in the treatment of metastatic colorectal cancer. Cancer Treatment Reviews, 2010, 36, S1-S10.	3.4	23
979	Stage II and Stage III Colon Cancer. Cancer Journal (Sudbury, Mass), 2010, 16, 202-209.	1.0	39
980	Chemotherapy: Metastatic Disease. , 2010, , 189-222.		0
981	Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS) Tj ETQq1 1 0.784314 rgBT /Overlo		
984	An Update on Randomized Clinical Trials in Advanced and Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America, 2010, 19, 163-181.	0.6	7
985	Targeting NF-Î²B for colorectal cancer. Expert Opinion on Therapeutic Targets, 2010, 14, 593-601.	1.5	72
986	Baseline physical functioning status of metastatic colorectal cancer patients predicts the overall survival but not the activity of a front-line oxaliplatin-fluoropyrimidine doublet. Acta OncolÃ³gica, 2010, 49, 50-56.	0.8	9
987	Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers, 2010, 15, 243-248.	0.9	13

#	Article	IF	Citations
988	Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. Journal of Clinical Oncology, 2010, 28, 2556-2564.	0.8	146
989	Bevacizumab Plus Irinotecanâ€"Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens. Cancer Investigation, 2010, 28, 33-37.	0.6	16
990	Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer. Molecular Diagnosis and Therapy, 2010, 14, 375-384.	1.6	43
991	The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. Expert Opinion on Biological Therapy, 2011, 11, 405-413.	1.4	34
992	Impact of Young Age on Treatment Efficacy and Safety in Advanced Colorectal Cancer: A Pooled Analysis of Patients From Nine First-Line Phase III Chemotherapy Trials. Journal of Clinical Oncology, 2011, 29, 2781-2786.	0.8	61
993	Advances in regional chemotherapy of the liver. Expert Opinion on Drug Delivery, 2011, 8, 1057-1069.	2.4	15
994	Reviewing the safety of erlotinib in non-small cell lung cancer. Expert Opinion on Drug Safety, 2011, 10, 147-157.	1.0	22
995	In vitrodrug responses in primary and metastatic colorectal cancers. Scandinavian Journal of Gastroenterology, 2011, 46, 70-78.	0.6	12
996	Advances in the surgical treatment of colorectal liver metastases. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira (English Edition), 2011, 57, 215-222.	0.1	0
997	AvanÃ§os no tratamento cirÃºrgico das metÃ¡stases hepÃ¡ticas colorretais. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2011, 57, 220-227.	0.3	11
998	Treatment of Metastatic Colorectal Cancer. Seminars in Oncology, 2011, 38, 552-560.	0.8	69
999	The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis. Digestive and Liver Disease, 2011, 43, 194-198.	0.4	7
1000	Are we turning to more than a first line treatment of metastatic colorectal cancer with high dose irinotecan ?: A monocentric institution safety analysis of 46 patients. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 125-131.	0.7	6
1001	Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 48-54.	0.7	6
1002	Role of Drp1, a Key Mitochondrial Fission Protein, in Neuropathic Pain. Journal of Neuroscience, 2011, 31, 11404-11410.	1.7	79
1003	Optimal Management of Metastatic Colorectal Cancer. Drugs, 2011, 71, 869-884.	4.9	10
1004	Hepatic Intra-Arterial Injection of Drug-Eluting Bead, Irinotecan (DEBIRI) in Unresectable Colorectal Liver Metastases Refractory to Systemic Chemotherapy: Results of Multi-Institutional Study. Annals of Surgical Oncology, 2011, 18, 192-198.	0.7	176
1005	Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. BMC Cancer, 2011, 11, 247.	1.1	69

#	Article	IF	Citations
1006	Use of Bevacizumab in Metastatic Colorectal Cancer. Drugs in R and D, 2011, 11, 101-111.	1.1	8
1007	Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104â€"A Randomized Trial of the German AIO CRC Study Group. Journal of Clinical Oncology, 2011, 29, 1050-1058.	0.8	99
1008	Tumeurs digestives : cÃ1on â€" rectum. , 2011, , 359-386.		0
1009	Induction Chemotherapy. , 2011, , .		5
1010	Systemic Therapy for Colon Cancer. , 2011, , 167-183.		0
1011	Survival for Metastatic Colorectal Cancer in the Bevacizumab Era: A Population-based Analysis. Clinical Colorectal Cancer, 2011, 10, 97-101.	1.0	26
1012	A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab and Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 117-120.	1.0	2
1013	A Phase II Study of Oxaliplatin, Dose-intense Capecitabine, and High-dose Bevacizumab in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 210-216.	1.0	10
1014	Lactic Acidosis and Colon Cancer: Oncologic Emergency?. Clinical Colorectal Cancer, 2011, 10, 194-7.	1.0	10
1015	An Open-label, Single-arm, Phase 2 Trial of Panitumumab Plus FOLFIRI as Second-line Therapy in Patients with Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 171-177.	1.0	32
1016	Analysis for Prognostic Factors of 60-day Mortality: Evaluation of an Irinotecan-Based Phase III Trial Performed in the First-Line Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 317-324.	1.0	6
1017	Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 245-257.	1.0	20
1018	The Efficacy and Safety of Panitumumab Administered Concomitantly With FOLFIRI or Irinotecan in Second-Line Therapy for Metastatic Colorectal Cancer: The Secondary Analysis From STEPP (Skin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 333-339.	1.0	33
1019	A Decade of Advances in Cytotoxic Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2011, 10, 238-244.	1.0	49
1020	The Evolution of Adjuvant Therapy in the Treatment of Early-Stage Colon Cancer. Clinical Colorectal Cancer, 2011, 10, 218-226.	1.0	24
1021	Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. European Journal of Cancer, 2011, 47, 206-214.	1.3	43
1022	The development of a value based pricing index for new drugs in metastatic colorectal cancer. European Journal of Cancer, 2011, 47, 1299-1304.	1.3	7
1023	Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 2011, 47, 1826-1836.	1.3	17

#	Article	IF	Citations
1024	Modern insights into hepatic arterial infusion for liver metastases from colorectal cancer. European Journal of Cancer, 2011, 47, 2681-2690.	1.3	27
1025	In Vitro Schedule-Dependent Interaction Between Melphalan and Oxaliplatin in Human Colorectal Cancer Cell Lines. Journal of Surgical Research, 2011, 167, 273-278.	0.8	23
1026	Neoadjuvant chemotherapy for non-/resectable metastases. European Journal of Cancer, 2011, 47, S52-S60.	1.3	6
1027	Surgery of the primary in stage IV colorectal cancer with unresectable metastases. European Journal of Cancer, 2011, 47, S61-S66.	1.3	37
1028	Re-challenge and the concept of lines of therapy in metastatic colorectal cancer. European Journal of Cancer, 2011, 47, S76-S84.	1.3	9
1029	Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD) Tj ETQq1 1 0.784314 rgBT /Ov	5.1	128
1030	Use of a comprehensive panel of biomarkers to predict response to a fluorouracilâ€“oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics, 2011, 12, 433-442.	0.6	40
1031	Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet, The, 2011, 377, 1749-1759.	6.3	362
1032	Hepatic toxicity as a result of chemotherapy in the treatment of colorectal liver metastases. , 2011, , 49-55.		0
1033	Lymph Nodes Ratio Is Associated with the Survival of Colorectal Cancer Patients with Peritoneal Carcinomatosis. American Surgeon, 2011, 77, 602-607.	0.4	4
1034	Current treatment for colorectal liver metastases. World Journal of Gastroenterology, 2011, 17, 4067.	1.4	146
1035	Advances in Management of Metastatic Colorectal Cancer. , 0, , 356-368.		0
1036	Optimal chemotherapy treatment for patients with advanced colorectal cancer. Wspolczesna Onkologia, 2011, 1, 31-39.	0.7	1
1037	Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Current Oncology, 2011, 18, .	0.9	9
1038	Risk Factors for Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer. International Journal of Medical Sciences, 2011, 8, 210-215.	1.1	25
1039	Oxaliplatin: A Review in the Era of Molecularly Targeted Therapy. Current Oncology, 2011, 18, 18-25.	0.9	301
1040	Platinum Agent-Induced Hypersensitivity Reactions: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS. International Journal of Medical Sciences, 2011, 8, 332-338.	1.1	33
1041	Canadian Expert Group Consensus Recommendations: KRAS Testing in Colorectal Cancer. Current Oncology, 2011, 18, 180-184.	0.9	23

#	Article	IF	Citations
1042	Management of stage IV rectal cancer: Palliative options. World Journal of Gastroenterology, 2011, 17, 835.	1.4	53
1044	Phase I, pharmacokinetic, and bone marrow drug-level studies of trimonthly 48-h infusion of high-dose 5-fluorouracil and leucovorin in patients with metastatic colorectal cancers. Anti-Cancer Drugs, 2011, 22, 290-298.	0.7	4
1045	Concomitant Extrahepatic Disease in Patients With Colorectal Liver Metastases. Annals of Surgery, 2011, 253, 349-359.	2.1	130
1046	Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX. Anti-Cancer Drugs, 2011, 22, S1-S7.	0.7	0
1047	Molecular Predictors of Response to Chemotherapy in Colorectal Cancer. Cancer Journal (Sudbury,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.0	40
1048	Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer. Anti-Cancer Drugs, 2011, 22, 191-197.	0.7	21
1049	Results of Two Bi-Institutional Prospective Studies Using Intraperitoneal Oxaliplatin With or Without Irinotecan During HIPEC After Cytoreductive Surgery for Colorectal Carcinomatosis. Annals of Surgery, 2011, 254, 294-301.	2.1	150
1050	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. Current Drug Metabolism, 2011, 12, 918-931.	0.7	11
1051	Grade 3/4 neutropenia is a limiting factor in second-line FOLFIRI following FOLFOX4 failure in elderly patients with metastatic colorectal cancer. Oncology Letters, 2011, 2, 493-498.	0.8	9
1052	Pharmacological Advances in Metastatic Colorectal Cancer Management. , 2011, , .		0
1053	Fucoidan reduces the toxicities of chemotherapy for patients with unresectable advanced or recurrent colorectal cancer. Oncology Letters, 2011, 2, 319-322.	0.8	94
1056	Design and Endpoints of Clinical and Translational Trials in Advanced Colorectal Cancer. A Proposal from GROUP EspaÃ±ol Multidisciplinar en Cancer Digestivo (GEMCAD). Reviews on Recent Clinical Trials, 2011, 6, 158-170.	0.4	2
1057	Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncology Letters, 2011, 2, 309-313.	0.8	2
1059	A systematic review of FOLFOXIRI chemotherapy for the first-line treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Disease, 2011, 13, 846-852.	0.7	43
1060	Evolution of systemic therapy for metastatic colorectal cancerdoi. Colorectal Disease, 2011, 13, 852-854.	0.7	1
1061	Liver Resection for Colorectal Metastases in Older Adults: A Paired Matched Analysis. Journal of the American Geriatrics Society, 2011, 59, 2282-2290.	1.3	29
1062	Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 82-87.	0.7	6
1063	Clinical reports of pulmonary metastasectomy for colorectal cancer: a citation network analysis. British Journal of Cancer, 2011, 104, 1085-1097.	2.9	47

#	Article	IF	Citations
1064	FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer. British Journal of Cancer, 2011, 104, 1079-1084.	2.9	38
1065	Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surgical Oncology, 2011, 20, 57-72.	0.8	27
1066	Personalized Colon Cancer Care in 2010. Seminars in Oncology, 2011, 38, 284-308.	0.8	35
1067	From Chemotherapy to Targeted Therapy in Adjuvant Treatment for Stage III Colon Cancer. Seminars in Oncology, 2011, 38, 521-532.	0.8	40
1068	Liver-Directed Therapies in Colorectal Cancer. Seminars in Oncology, 2011, 38, 561-567.	0.8	6
1069	Cost-Effectiveness of Targeted Therapy With Cetuximab in Patients With K-ras Wild-Type Colorectal Cancer Presenting With Initially Unresectable Metastases Limited to the Liver in a German Setting. Clinical Therapeutics, 2011, 33, 482-497.	1.1	32
1071	A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: A Japanese experience. Surgery Today, 2011, 41, 84-90.	0.7	0
1072	Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients. Surgery Today, 2011, 41, 1067-1074.	0.7	18
1073	Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases. Surgery Today, 2011, 41, 526-532.	0.7	24
1074	Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surgery Today, 2011, 41, 1196-1199.	0.7	37
1075	A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: A Japanese experience. Surgery Today, 2011, 41, 1610-1616.	0.7	3
1076	Chemotherapy-Associated Liver Injury: Impact on Surgical Management of Colorectal Cancer Liver Metastases. Annals of Surgical Oncology, 2011, 18, 181-190.	0.7	54
1077	Association of C-reactive Protein Gene Polymorphisms and Colorectal Cancer. Annals of Surgical Oncology, 2011, 18, 1907-1915.	0.7	23
1078	Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer. Investigational New Drugs, 2011, 29, 1050-1056.	1.2	2
1079	Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1379-1396.	1.2	27
1080	Dietary glycine protects from chemotherapy-induced hepatotoxicity. Amino Acids, 2011, 40, 1139-1150.	1.2	27
1081	High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin. International Journal of Clinical Oncology, 2011, 16, 244-249.	1.0	33
1082	Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma. International Journal of Clinical Oncology, 2011, 16, 488-493.	1.0	5

#	Article	IF	Citations
1083	Liver resection for advanced or aggressive colorectal cancer metastases in the era of effective chemotherapy: a review. International Journal of Clinical Oncology, 2011, 16, 452-463.	1.0	10
1084	Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin. Cancer Chemotherapy and Pharmacology, 2011, 67, 147-152.	1.1	4
1085	Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases. Cancer Chemotherapy and Pharmacology, 2011, 67, 629-635.	1.1	6
1086	UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 279-284.	1.1	33
1087	Phase II study of FOLFOX4 with â€œwait and goâ€•strategy as first-line treatment for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2011, 68, 1215-1222.	1.1	5
1088	Metastatic Colorectal Cancer with Severe Liver Dysfunction Successfully Treated Using FOLFOX Therapy. Journal of Gastrointestinal Cancer, 2011, 42, 68-72.	0.6	7
1089	Feasibility of cetuximab given with a simplified schedule every 2Âweeks in advanced colorectal cancer: a multicenter, retrospective analysis. Medical Oncology, 2011, 28, 253-258.	1.2	16
1090	Treatment recommendations for metastatic colorectal cancer. Clinical and Translational Oncology, 2011, 13, 162-178.	1.2	24
1091	Multidisciplinary approach of colorectal liver metastases. Clinical and Translational Oncology, 2011, 13, 721-727.	1.2	16
1092	Recent developments and future perspectives in the systemic treatment of metastatic colorectal cancer. Memo - Magazine of European Medical Oncology, 2011, 4, 75-78.	0.3	1
1093	Therapeutic Efficacy of Combined Intraoperative Ablation and Resection for Colorectal Liver Metastases: An International, Multi-institutional Analysis. Journal of Gastrointestinal Surgery, 2011, 15, 336-344.	0.9	36
1094	The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?. Journal of Gastrointestinal Surgery, 2011, 15, 410-415.	0.9	11
1095	Treatment of colorectal liver metastases. World Journal of Surgical Oncology, 2011, 9, 154.	0.8	69
1096	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. BMC Medicine, 2011, 9, 10.	2.3	41
1097	Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer, 2011, 117, 343-352.	2.0	116
1098	Secondâ€line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of firstâ€line platinumâ€based chemotherapy. Cancer, 2011, 117, 1422-1428.	2.0	71
1099	Is resection of colorectal liver metastases after a secondâ€line chemotherapy regimen justified?. Cancer, 2011, 117, 4484-4492.	2.0	32
1100	Capecitabine plus oxaliplatin (XELOX) versus 5â€fluorouracil/leucovorin plus oxaliplatin (FOLFOXâ€6) as firstâ€line treatment for metastatic colorectal cancer. International Journal of Cancer, 2011, 128, 682-690.	2.3	131

#	Article	IF	Citations
1101	Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection. Critical Reviews in Oncology/Hematology, 2011, 79, 251-264.	2.0	41
1102	Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC)â€"results from NCIC CTG CO.17: a phase III trial of cetuximab versus best supportive care. Annals of Oncology, 2011, 22, 118-126.	0.6	41
1103	Anti-EGFR therapy in first-line colorectal cancer. Expert Review of Anticancer Therapy, 2011, 11, 1499-1503.	1.1	3
1104	Research Highlights: Revisiting the frontiers of pharmacogenomics of colon cancer. Pharmacogenomics, 2011, 12, 1243-1248.	0.6	0
1105	Liver metastases from colorectal cancer: how to best complement medical treatment with surgical approaches. Future Oncology, 2011, 7, 1299-1323.	1.1	14
1106	Multiagent Regimens for Metastatic Colorectal Cancer: If Some Is Good, More Must Be Better. Journal of the National Cancer Institute, 2011, 103, 4-5.	3.0	1
1107	Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategyâ€"An Aide et Recherche en CancÃ©rologie Digestive Group Study. Journal of Clinical Oncology, 2011, 29, 4199-4204.	0.8	51
1108	Randomized Trial of Two Induction Chemotherapy Regimens in Metastatic Colorectal Cancer: An Updated Analysis. Journal of the National Cancer Institute, 2011, 103, 21-30.	3.0	160
1109	A Multicenter Phase-II Study of 5-FU, Leucovorin and Oxaliplatin (FOLFOX6) in Patients with Pretreated Metastatic Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 63-68.	0.6	7
1110	Phase I/II Study of FOLFIRI in Japanese Patients with Advanced Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 204-209.	0.6	6
1111	Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial. Oncologist, 2011, 16, 1557-1564.	1.9	74
1112	Liver Metastasis: Biology and Clinical Management. Cancer Metastasis - Biology and Treatment, 2011, , .	0.1	6
1113	Response to Temozolomide in Patients With Metastatic Colorectal Cancer With Loss of MGMT Expression: A New Approach in the Era of Personalized Medicine?. Journal of Clinical Oncology, 2011, 29, e262-e265.	0.8	28
1114	Characterizing Medical Care by Disease Phase in Metastatic Colorectal Cancer. Journal of Oncology Practice, 2011, 7, 25s-30s.	2.5	22
1115	Interstitial Lung Disease During Chemotherapy Combined with Oxaliplatin and/or Bevacizumab in Advanced Colorectal Cancer Patients. Japanese Journal of Clinical Oncology, 2011, 41, 498-502.	0.6	17
1116	Colon Cancer Survival With Herbal Medicine and Vitamins Combined With Standard Therapy in a Whole-Systems Approach. Integrative Cancer Therapies, 2011, 10, 240-259.	0.8	38
1117	Balancing the efficacy and toxicity of chemotherapy in colorectal cancer. Therapeutic Advances in Medical Oncology, 2011, 3, 43-52.	1.4	90
1118	Hypothermic ante situm Resection in Tumors of the Hepatocaval Confluence. Digestive Surgery, 2011, 28, 100-108.	0.6	35

#	Article	IF	Citations
1119	Simplified Prognostic Model in Patients with Oxaliplatinâ€Based or Irinotecanâ€Based Firstâ€Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study. Oncologist, 2011, 16, 1228-1238.	1.9	73
1120	Improving patient access to cancer drugs in India: Using economic modeling to estimate a more affordable drug cost based on measures of societal value. International Journal of Technology Assessment in Health Care, 2011, 27, 23-30.	0.2	13
1121	Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. Annals of Oncology, 2011, 22, 369-375.	0.6	20
1122	Hepatic Resection vs Minimally Invasive Radiofrequency Ablation for the Treatment of Colorectal Liver Metastases. Archives of Surgery, 2011, 146, 1416.	2.3	33
1123	Multicentre Phase II Study of XELOX with Bevacizumab in Late-stage Elderly Patients with Unresectable Advanced/Recurrent Colorectal Cancer: An ASCA Study. Japanese Journal of Clinical Oncology, 2011, 41, 134-138.	0.6	1
1124	Response to Modified TEGAFIRI in a Patient with Synchronous Multiple Liver Metastases of Colon Cancer. Case Reports in Gastroenterology, 2011, 5, 95-99.	0.3	1
1125	Prolonged Survival of Patients with Metastatic Colorectal Cancer following First-Line Oxaliplatin-Based Chemotherapy with Molecular Targeting Agents and Curative Surgery. Oncology, 2011, 81, 167-174.	0.9	3
1126	Identification of a potent epigenetic biomarker for resistance to camptothecin and poor outcome to irinotecan-based chemotherapy in colon cancer. International Journal of Oncology, 2011, 40, 217-26.	1.4	11
1127	Progression-Free Survival Ratio As End Point for Phase II Trials in Advanced Solid Tumors. Journal of Clinical Oncology, 2011, 29, e451-e452.	0.8	34
1128	Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective. Therapeutic Advances in Medical Oncology, 2011, 3, 35-42.	1.4	23
1129	A genotype-directed phase Iâ€“IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer. British Journal of Cancer, 2011, 105, 53-57.	2.9	101
1130	A comparison of mortality and costs associated with FOLFOX versus FOLFIRI in stage IV colorectal cancer. Journal of Medical Economics, 2011, 14, 179-186.	1.0	8
1131	Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. British Journal of Cancer, 2011, 105, 1646-1653.	2.9	17
1132	Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised â€˜GISCADâ€™ trial. Annals of Oncology, 2011, 22, 1236-1242.	0.6	98
1133	Regimen Selection for First-line FOLFIRI and FOLFOX Based on UGT1A1 Genotype and Physical Background is Feasible in Japanese Patients with Advanced Colorectal Cancer. Japanese Journal of Clinical Oncology, 2011, 41, 617-623.	0.6	11
1134	Prospective Phase II Study of FOLFIRI for mCRC in Japan, Including the Analysis of UGT1A1*28/*6 Polymorphisms. Japanese Journal of Clinical Oncology, 2011, 41, 477-482.	0.6	47
1135	Phase II Study of Combined Treatment with Irinotecan and S-1 (IRIS) in Patients with Inoperable or Recurrent Advanced Colorectal Cancer (HGCSG0302). Oncology, 2011, 80, 70-75.	0.9	22
1136	Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: aÂrandomized EORTC Intergroup phase II study (EORTC 40004). Annals of Oncology, 2012, 23, 2619-2626.	0.6	370

#	Article	IF	Citations
1137	A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. Annals of Oncology, 2012, 23, 119-127.	0.6	23
1138	Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer. Scandinavian Journal of Gastroenterology, 2012, 47, 340-355.	0.6	24
1139	Management of Rectal Cancer and Liver Metastatic Disease: Which Comes First?. International Journal of Surgical Oncology, 2012, 2012, 1-5.	0.3	9
1140	Prognostic Ability of ¹⁸F-FDG PET/CT in the Assessment of Colorectal Liver Metastases. Journal of Nuclear Medicine, 2012, 53, 1345-1351.	2.8	33
1141	High-Cost Imaging in Elderly Patients with Stage IV Cancer. Journal of the National Cancer Institute, 2012, 104, 1165-1173.	3.0	36
1142	Management of Colorectal Carcinoma in Children and Young Adults. Journal of Pediatric Hematology/Oncology, 2012, 34, S76-S79.	0.3	28
1143	Current Trends in the Chemotherapy of Colorectal Cancer. Current Medicinal Chemistry, 2012, 19, 4414-4430.	1.2	2
1144	Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study. Annals of Oncology, 2012, 23, 2072-2077.	0.6	108
1145	Modified FOLFOX-6 Therapy for Heavily Pretreated Advanced Gastric Cancer Refractory to Fluorouracil, Irinotecan, Cisplatin and Taxanes: A Retrospective Study. Japanese Journal of Clinical Oncology, 2012, 42, 686-690.	0.6	12
1146	FOLFIRI Plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study). Japanese Journal of Clinical Oncology, 2012, 42, 134-138.	0.6	9
1147	Panitumumab: a summary of clinical development in colorectal cancer and future directions. Future Oncology, 2012, 8, 373-389.	1.1	16
1148	GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle, 2012, 11, 4203-4210.	1.3	20
1149	Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid,) Tj ETQq0 0 0 rgBT /Overlock 10 unresectable/metastatic colorectal cancer (mCRC). British Journal of Cancer, 2012, 106, 453-459.	2.9	49
1150	Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis. British Journal of Cancer, 2012, 106, 53-60.	2.9	15
1151	Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patients. British Journal of Cancer, 2012, 106, 799-804.	2.9	97
1152	Therapeutic strategy in unresectable metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2012, 4, 75-89.	1.4	73
1153	Curative Strategies for Liver Metastases from Colorectal Cancer: A Review. Oncologist, 2012, 17, 201-211.	1.9	19
1154	Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Annals of Oncology, 2012, 23, 2649-2655.	0.6	102

#	Article	IF	Citations
1155	Effect of coefficient of viscosity and ambient temperature on the flow rate of drug solutions in infusion pumps. Pharmaceutical Development and Technology, 2012, 17, 755-762.	1.1	5
1156	Characterization of an Oxaliplatin Sensitivity Predictor in a Preclinical Murine Model of Colorectal Cancer. Molecular Cancer Therapeutics, 2012, 11, 1500-1509.	1.9	36
1157	Uptake of Oxaliplatin and Bevacizumab for Treatment of Node-Positive and Metastatic Colon Cancer. Journal of Oncology Practice, 2012, 8, 156-163.	2.5	11
1158	Systemic chemotherapy and surgical cytoreduction for poorly differentiated and signet ring cell adenocarcinomas of the appendix. Annals of Oncology, 2012, 23, 652-658.	0.6	94
1159	Guidance for Life, Cell Death, and Colorectal Neoplasia by Netrin Dependence Receptors. Advances in Cancer Research, 2012, 114, 87-186.	1.9	5
1160	A Retrospective Study of S-1 Monotherapy as Second-line Treatment for Patients with Advanced Biliary Tract Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 800-806.	0.6	21
1161	Optimal Dose Period for Indisetron Tablets for Preventing Chemotherapy-Induced Nausea and Vomiting with Modified FOLFOX6: A Randomized Pilot Study. Chemotherapy, 2012, 58, 439-444.	0.8	1
1162	Serial FDGâ€“PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Annals of Oncology, 2012, 23, 1687-1693.	0.6	70
1163	Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: a phase II study. Journal of Chemotherapy, 2012, 24, 207-211.	0.7	5
1164	A Phase I Study of Infusional 5-Fluorouracil, Leucovorin, Oxaliplatin and Irinotecan in Japanese Patients with Advanced Colorectal Cancer Who Harbor <i>UGT1A1</i>*<i>1/</i>*<i>1/</i>*<i>1</i>,*<i>1/</i>*<i>6</i> or *<i>1/</i>*<i>28</i>. Oncology, 2012, 82, 242-248.	0.9	18
1165	Phase II Trial of Chemotherapy plus Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer That Progressed on Bevacizumab with Chemotherapy: The Gunma Clinical Oncology Group (GCOG) trial 001 SILK Study. Oncology, 2012, 83, 151-157.	0.9	10
1166	Independent Radiologic Review in Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis. Radiology, 2012, 263, 86-95.	3.6	4
1167	Acquired/intratumoral mutation of KRAS during metastatic progression of colorectal carcinogenesis. Oncology Letters, 2012, 3, 649-653.	0.8	7
1168	MUC2 protein expression status is useful in assessing the effects of hyperthermic intraperitoneal chemotherapy for peritoneal dissemination of colon cancer. International Journal of Oncology, 2012, 40, 960-4.	1.4	7
1169	100% Human Monoclonal Antibodies in Oncology: Hype or Breakthrough?. Current Topics in Medicinal Chemistry, 2012, 12, 1643-1648.	1.0	1
1170	Pathologic Complete Response After FOLFOX7 in a Locally Advanced Rectal Cancer. Journal of Clinical Gastroenterology, 2012, 46, 87-88.	1.1	1
1171	A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anti-Cancer Drugs, 2012, 23, 561-566.	0.7	91
1172	FOLFIRINOX for the treatment of colorectal cancer: latest evidence from clinical trials. Colorectal Cancer, 2012, 1, 181-184.	0.8	2

#	Article	IF	Citations
1173	Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer. Anti-Cancer Drugs, 2012, 23, 666-673.	0.7	14
1174	Factors Influencing Oncological Outcomes in Patients Who Develop Pulmonary Metastases After Curative Resection of Colorectal Cancer. Diseases of the Colon and Rectum, 2012, 55, 459-464.	0.7	33
1177	Optimizing Treatment Outcomes in Patients at Risk for Chemotherapy-Induced Nausea and Vomiting. Clinical Journal of Oncology Nursing, 2012, 16, 309-313.	0.3	9
1178	Combination therapies with oxaliplatin and oral capecitabine or intravenous 5-FU show similar toxicity profiles in gastrointestinal carcinoma patients if hand-food syndrome prophylaxis is performed continuously. Oncology Letters, 2012, 3, 1191-1194.	0.8	7
1179	Recent advances in treatment of metastatic colorectal cancer. Clinical Investigation, 2012, 2, 1109-1122.	0.0	0
1180	Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid. Pteridines, 2012, 23, 8-13.	0.5	1
1181	Individualized chemotherapy for colorectal cancer based on the collagen gel droplet-embedded drug sensitivity test. Oncology Letters, 2012, 4, 621-624.	0.8	8
1182	Optimizing first-line chemotherapy for metastatic colorectal cancer. Colorectal Cancer, 2012, 1, 241-253.	0.8	0
1183	Effects of the proapoptotic regulator Bcl-2/adenovirus EIB 19-kDa-interacting protein 3 on the chemosensitivity of human colon cancer cell lines. Oncology Letters, 2012, 4, 1195-1202.	0.8	3
1184	Levoleucovorin as Replacement for Leucovorin in Cancer Treatment. Annals of Pharmacotherapy, 2012, 46, 1349-1357.	0.9	11
1185	Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOXâ€“Bevacizumab or FOLFIRIâ€“Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study. Oncologist, 2012, 17, 1486-1495.	1.9	91
1186	FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancerâ€“subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Annals of Oncology, 2012, 23, 1693-1699.	0.6	88
1187	Chemotherapy for colorectal cancer â€“ Authors' reply. Lancet Oncology, The, 2012, 13, e4.	5.1	0
1188	Surgical Options for Initially Unresectable Colorectal Liver Metastases. HPB Surgery, 2012, 2012, 1-13.	2.2	27
1189	Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). Journal of Cancer Research and Clinical Oncology, 2012, 138, 1487-1492.	1.2	19
1190	Therapeutic strategies for hepatic metastasis of colorectal cancer: overview. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 523-527.	1.4	27
1191	Excess weight among colorectal cancer survivors: target for intervention. Journal of Gastroenterology, 2012, 47, 999-1005.	2.3	7
1192	Discrepancy between the NCI-CTCAE and DEB-NTC scales in the evaluation of oxaliplatin-related neurotoxicity in patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2012, 17, 341-347.	1.0	22

#	Article	IF	Citations
1193	Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. International Journal of Clinical Oncology, 2012, 17, 604-609.	1.0	25
1194	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology, 2012, 23, 2479-2516.	0.6	1,233
1195	Survival Differences in Patients With Metastatic Colorectal Cancer and With Single Site Metastatic Disease at Initial Presentation: Results From South Australian Clinical Registry for Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 247-254.	1.0	69
1196	Randomized Clinical Trials for Colorectal Cancer Peritoneal Surface Malignancy. Surgical Oncology Clinics of North America, 2012, 21, 665-688.	0.6	15
1197	Triplet Chemotherapy in Patients With Metastatic Colorectal Cancer: Toward the Best Way to Safely Administer a Highly Active Regimen in Clinical Practice. Clinical Colorectal Cancer, 2012, 11, 229-237.	1.0	18
1198	Cediranib Plus FOLFOX/CAPOX Versus Placebo Plus FOLFOX/CAPOX in Patients With Previously Untreated Metastatic Colorectal Cancer: A Randomized, Double-Blind, Phase III Study (HORIZON II). Journal of Clinical Oncology, 2012, 30, 3596-3603.	0.8	134
1199	Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe. Current Medical Research and Opinion, 2012, 28, 221-229.	0.9	28
1200	Oxaliplatin: a review of approved uses. Expert Opinion on Pharmacotherapy, 2012, 13, 125-137.	0.9	70
1201	Inflammation-Based Prognostic System Predicts Postoperative Survival of Colorectal Cancer Patients with a Normal Preoperative Serum Level of Carcinoembryonic Antigen. Annals of Surgical Oncology, 2012, 19, 3422-3431.	0.7	40
1202	A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe. Journal of Oncology Pharmacy Practice, 2012, 18, 57-67.	0.5	12
1203	Effectiveness of Bevacizumab With First-Line Combination Chemotherapy for Medicare Patients With Stage IV Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 608-615.	0.8	117
1204	Clinicallyâ€“relevant anticancer-antidepressant drug interactions. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 173-199.	1.5	13
1205	Detailed liver-specific imaging prior to pre-operative chemotherapy for colorectal liver metastases reduces intra-hepatic recurrence and the need for a repeat hepatectomy. Hpb, 2012, 14, 298-309.	0.1	30
1206	Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. Journal of Clinical Oncology, 2012, 30, 3499-3506.	0.8	1,214
1207	Quality of life following liver transplantation in patients with liver metastases from colorectal carcinoma. Scandinavian Journal of Caring Sciences, 2012, 26, 713-719.	1.0	13
1208	Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle, 2012, 11, 2518-2525.	1.3	22
1209	Dual-phase CT angiography through the port-catheter system for hepatic arterial infusion chemotherapy using multislice CT: assessment of system dysfunction and impact on predicting clinical problems. Acta Radiologica, 2012, 53, 1026-1034.	0.5	1
1211	Percutaneous radiofrequency ablation using internally cooled wet electrodes for treatment of colorectal liver metastases. Clinical Radiology, 2012, 67, 122-127.	0.5	11

#	Article	IF	Citations
1212	Biologic therapies in the metastatic colorectal cancer treatment continuum â€“ Applying current evidence to clinical practice. Cancer Treatment Reviews, 2012, 38, 397-406.	3.4	72
1213	Bevacizumab Combined With Chemotherapy in the Second-Line Treatment of Metastatic Colorectal Cancer: Results from the Phase II BEVACOLOR Study. Clinical Colorectal Cancer, 2012, 11, 38-44.	1.0	29
1214	Outcome of Second-Line Treatment After First-Line Chemotherapy With the GONO FOLFOXIRI Regimen. Clinical Colorectal Cancer, 2012, 11, 71-76.	1.0	17
1215	Literature Review and Practical Aspects on the Management of Oxaliplatin-Associated Toxicity. Clinical Colorectal Cancer, 2012, 11, 93-100.	1.0	64
1216	PTEN Gene Expression and Mutations in the PIK3CA Gene as Predictors of Clinical Benefit to Anti-Epidermal Growth Factor Receptor Antibody Therapy in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 143-150.	1.0	87
1217	Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 2012, 48, 1293-1298.	1.3	28
1218	Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. European Journal of Cancer, 2012, 48, 1969-1976.	1.3	18
1219	A phase II study of RO4929097 in metastatic colorectal cancer. European Journal of Cancer, 2012, 48, 997-1003.	1.3	124
1220	Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. European Journal of Cancer, 2012, 48, 1466-1475.	1.3	506
1221	Application of different methods to formulate PEG-liposomes of oxaliplatin: Evaluation in vitro and in vivo. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 273-280.	2.0	38
1222	Neoplasms of the Small and Large Intestine. , 2012, , 1278-1289.		1
1223	Hepatic Arterial Infusion with Irinotecan, Oxaliplatin, and Floxuridine plus Systemic Chemotherapy as First-Line Treatment of Unresectable Liver Metastases from Colorectal Cancer. Onkologie, 2012, 35, 4-4.	1.1	14
1224	Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews, 2012, 44, 148-172.	1.5	117
1225	Impact of the Specific Mutation in <i>KRAS</i> Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials. Oncology, 2012, 83, 241-247.	0.9	24
1226	Optimal use of current chemotherapy in multimodality therapy for advanced colorectal cancer. Oncology Letters, 2012, 3, 363-368.	0.8	5
1227	Yttrium-90 Radioembolization as Salvage Therapy for Colorectal Cancer With Liver Metastases. Clinical Colorectal Cancer, 2012, 11, 195-199.	1.0	26
1228	Topoisomerase I Inhibitors: Current Use and Prospects. Cancer Drug Discovery and Development, 2012, , 245-277.	0.2	2
1229	Treatment Decisions After Diagnosis of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 155-166.	1.0	84

#	Article	IF	Citations
1230	Upregulation of ERCC1 and DPD expressions after oxaliplatin-based first-line chemotherapy for metastatic colorectal cancer. British Journal of Cancer, 2012, 107, 1950-1955.	2.9	29
1231	Oncological Management of Unresectable Liver Metastases. Digestive Diseases, 2012, 30, 137-142.	0.8	11
1232	Integration of selective internal radiation therapy second-line: The InSIRT trial. European Journal of Cancer, Supplement, 2012, 10, 10-11.	2.2	0
1233	TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncology, The, 2012, 13, 993-1001.	5.1	267
1234	Management of colon cancer: resource-stratified guidelines from the Asian Oncology Summit 2012. Lancet Oncology, The, 2012, 13, e470-e481.	5.1	70
1235	Update on the optimal management of patients with colorectal liver metastases. Critical Reviews in Oncology/Hematology, 2012, 84, 59-70.	2.0	29
1236	Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients. Digestive and Liver Disease, 2012, 44, 74-79.	0.4	3
1237	A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. European Journal of Cancer, 2012, 48, 820-826.	1.3	16
1238	The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value in Health, 2012, 15, 22-31.	0.1	6
1239	TOP1gene copy numbers in colorectal cancer samples and cell lines and their association toin vitrodrug sensitivity. Scandinavian Journal of Gastroenterology, 2012, 47, 68-79.	0.6	26
1240	Clinical Update: Colon, Rectal, and Anal Cancers. Seminars in Oncology Nursing, 2012, 28, e1-e22.	0.7	16
1241	Role of the METâ€“HGF axis in colorectal cancer: precepts and prospects. Colorectal Cancer, 2012, 1, 329-341.	0.8	6
1242	Taxol, Camptothecin and Beyond for Cancer Therapy. Advances in Botanical Research, 2012, , 133-178.	0.5	5
1243	Treatment of colorectal cancer in older patients. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 716-725.	8.2	43
1244	Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. Current Colorectal Cancer Reports, 2012, 8, 153-160.	1.0	0
1245	Best Strategy in the Approach of Advanced Colorectal Cancer: Aggressive or Non-aggressive Chemotherapy?. Current Colorectal Cancer Reports, 2012, 8, 177-185.	1.0	0
1246	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 233-242.	1.0	0
1247	Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Medical Oncology, 2012, 29, 2842-2848.	1.2	15

#	Article	IF	Citations
1248	Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. British Journal of Cancer, 2012, 107, 1037-1043.	2.9	35
1249	Antiemetic Control with Palonosetron in Patients with Gastrointestinal Cancer Receiving a Fluoropyrimidine-Based Regimen in Addition to Either Irinotecan or Oxaliplatin: A Retrospective Study. Oncology, 2012, 83, 135-140.	0.9	1
1250	The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemotherapy and Pharmacology, 2012, 70, 575-581.	1.1	11
1251	Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis. International Journal of Colorectal Disease, 2012, 27, 997-1004.	1.0	54
1252	Second surgery or chemotherapy for relapse after radical resection of colorectal cancer metastases. Langenbeck's Archives of Surgery, 2012, 397, 1069-1077.	0.8	14
1253	Laparoscopic surgery for palliative resection of the primary tumor in incurable stage IV colorectal cancer. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 3201-3206.	1.3	9
1254	Implications of clinical risk score to predict outcomes of liver-confined metastasis of colorectal cancer. Surgical Oncology, 2012, 21, e125-e130.	0.8	8
1255	Treatment Regimen With Bevacizumab Decreases Mean Platelet Volume in Patients With Metastatic Colon Cancer. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 546-548.	0.7	23
1256	Bevacizumab for Metastatic Colorectal Cancer. Pharmacoeconomics, 2012, 30, 1119-1132.	1.7	35
1257	Metastatic colorectal cancer: Current treatment and future options for improved survivalMedical approach â€“ present status. Scandinavian Journal of Gastroenterology, 2012, 47, 296-314.	0.6	53
1258	Multidisciplinary Management of Rectal Cancer. , 2012, , .		5
1259	Irinotecan (CPT-11) Chemotherapy Alters Intestinal Microbiota in Tumour Bearing Rats. PLoS ONE, 2012, 7, e39764.	1.1	115
1260	KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells. PLoS ONE, 2012, 7, e50701.	1.1	44
1261	Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncology Reviews, 2012, 6, 6.	0.8	2
1262	Characterization of biological responses of colorectal cancer cells to anticancer regimens. [Chapchi] Journal Taehan Oekwa Hakhoe, 2012, 83, 21.	1.1	8
1263	Thymidylate synthase and thymidine phosphorylase mRNA expression in primary lesions using laser capture microdissection is useful for prediction of the efficacy of FOLFOX treatment in colorectal cancer patients with liver metastasis. Oncology Letters, 2012, 3, 983-989.	0.8	20
1264	The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemotherapy and Pharmacology, 2012, 69, 1591-1599.	1.1	22
1265	Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. Journal of Surgical Oncology, 2012, 106, 892-897.	0.8	32

#	Article	IF	Citations
1266	Hepatic artery infusional chemotherapy in patients with unresectable colorectal liver metastases and extrahepatic disease. Journal of Surgical Oncology, 2012, 106, 953-958.	0.8	13
1267	Bevacizumab: overview of the literature. Expert Review of Anticancer Therapy, 2012, 12, 567-580.	1.1	79
1268	Metastatic malignant liver tumors. , 2012, , 1290-1304.e4.		1
1269	Regional chemotherapy for liver tumors. , 2012, , 1417-1433.e3.		0
1270	Systemic chemotherapy for hepatic colorectal cancer. , 2012, , 1434-1443.e3.		0
1271	Multidisciplinary approach to a case of Lynch syndrome with colorectal, ovarian, and metastatic liver carcinomas. International Cancer Conference Journal, 2012, 1, 125-137.	0.2	0
1272	A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf treated with chemotherapy. Investigational New Drugs, 2012, 30, 1501-1510.	1.2	18
1273	Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. Investigational New Drugs, 2012, 30, 1690-1696.	1.2	22
1274	Does Radiofrequency Ablation Add to Chemotherapy for Unresectable Liver Metastases?. Current Colorectal Cancer Reports, 2012, 8, 130-137.	1.0	13
1275	Unresectable Colorectal Cancer Synchronous Metastases: How to Manage the Primary Tumor. Current Colorectal Cancer Reports, 2012, 8, 118-122.	1.0	0
1276	Expanding the Role of Surgical Therapy for Colorectal Liver Metastases. Current Colorectal Cancer Reports, 2012, 8, 138-142.	1.0	0
1277	Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients. Advances in Therapy, 2012, 29, 287-296.	1.3	0
1278	Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 141-150.	1.1	8
1279	Clinical and Cost Effectiveness of Bevacizumab + FOLFIRI Combination Versus FOLFIRI Alone as First-Line Treatment of Metastatic Colorectal Cancer in South Korea. Clinical Therapeutics, 2012, 34, 1408-1419.	1.1	14
1280	Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Critical Reviews in Oncology/Hematology, 2012, 83, 47-58.	2.0	17
1281	Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: Synergy or antagonism?. International Journal of Pharmaceutics, 2012, 426, 263-270.	2.6	7
1282	The application of pharmacoeconomic modelling to estimate a valueâ€based price for new cancer drugs. Journal of Evaluation in Clinical Practice, 2012, 18, 343-351.	0.9	8
1283	A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatinâ€based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels. Asia-Pacific Journal of Clinical Oncology, 2012, 8, 172-179.	0.7	2

#	Article	IF	Citations
1284	Improving the clinical risk score: An analysis of molecular biomarkers in the era of modern chemotherapy for resectable hepatic colorectal cancer metastases. Surgery, 2012, 151, 162-170.	1.0	30
1285	Firstâ€line sunitinib plus <scp>FOLFIRI</scp> in <scp>J</scp>apanese patients with unresectable/metastatic colorectal cancer: A phase <scp>II</scp> study. Cancer Science, 2012, 103, 1502-1507.	1.7	12
1286	A Systematic Review of Clinical Response and Survival Outcomes of Downsizing Systemic Chemotherapy and Rescue Liver Surgery in Patients with Initially Unresectable Colorectal Liver Metastases. Annals of Surgical Oncology, 2012, 19, 1292-1301.	0.7	153
1287	Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases. Clinical and Experimental Metastasis, 2012, 29, 91-99.	1.7	18
1288	Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. Investigational New Drugs, 2012, 30, 758-764.	1.2	19
1289	Antinociceptive Effect of Salvia Extract on Cisplatin-Induced Hyperalgesia in Mice. Neurophysiology, 2012, 43, 452-458.	0.2	7
1290	First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2012, 138, 65-72.	1.2	79
1291	A nomogram predicting diseaseâ€free survival in patients with colorectal liver metastases treated with hepatic resection: multicenter data collection as a Project Study for Hepatic Surgery of the Japanese Society of Hepatoâ€Biliaryâ€Pancreatic Surgery. Journal of Hepato-Biliary-Pancreatic Sciences, 2012, 19, 72-84.	1.4	162
1292	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2012, 17, 1-29.	1.0	658
1293	Modest advances in survival for patients with colorectalâ€associated peritoneal carcinomatosis in the era of modern chemotherapy. Journal of Surgical Oncology, 2013, 107, 307-311.	0.8	22
1294	Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma. Radiation Oncology, 2013, 8, 10.	1.2	14
1295	Use of monoclonal antibodies for metastatic colorectal cancer in the andalusian public health system. International Journal of Clinical Pharmacy, 2013, 35, 550-553.	1.0	5
1296	Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study. Chemotherapy, 2013, 59, 66-73.	0.8	12
1297	Regorafenib: from bench to bedside in colorectal cancer. Expert Review of Clinical Pharmacology, 2013, 6, 243-248.	1.3	4
1298	Conversion to Complete Resection and/or Ablation Using Hepatic Artery Infusional Chemotherapy in Patients with Unresectable Liver Metastases from Colorectal Cancer: A Decade of Experience at a Single Institution. Annals of Surgical Oncology, 2013, 20, 2901-2907.	0.7	49
1299	Resistance to Immunotherapeutic Antibodies in Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , .	0.1	2
1300	An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastinâ„¢) [ASCENT]. BMC Cancer, 2013, 13, 120.	1.1	18
1301	A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer, 2013, 13, 67.	1.1	41

#	Article	IF	Citations
1302	Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. Cancer, 2013, 119, 3429-3435.	2.0	26
1303	A Systematic Review of Repeat Hepatectomy for Recurrent Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2013, 17, 1312-1321.	0.9	52
1304	Classifying the Stage IV Colorectal Cancer: Prognostic Impact of Radical Resection for Colorectal liver Metastases and Proposal for a New Staging System. Cell Biochemistry and Biophysics, 2013, 67, 1445-1449.	0.9	2
1305	Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients. Medical Oncology, 2013, 30, 630.	1.2	16
1306	UGT1A1*6/*28 polymorphisms could predict irinotecan-induced severe neutropenia not diarrhea in Chinese colorectal cancer patients. Medical Oncology, 2013, 30, 604.	1.2	33
1307	SEOM Clinical guidelines for the treatment of advanced colorectal cancer 2013. Clinical and Translational Oncology, 2013, 15, 996-1003.	1.2	20
1308	The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 230-241.	1.0	2
1309	Role of Chemotherapy in Peritoneal Carcinomatosis in Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2013, 9, 242-249.	1.0	2
1310	Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. Current Colorectal Cancer Reports, 2013, 9, 213-222.	1.0	1
1311	A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2013, 31, 910-917.	1.2	26
1312	A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1657-1663.	1.1	3
1313	A phase II study of oxaliplatin in combination with leucovorin and fluorouracil as first-line chemotherapy in patients with metastatic squamous cell carcinoma of esophagus. Cancer Chemotherapy and Pharmacology, 2013, 71, 905-911.	1.1	22
1314	Surgical management of disappearing colorectal liver metastases. British Journal of Surgery, 2013, 100, 1414-1420.	0.1	71
1315	Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surgery Today, 2013, 43, 1088-1094.	0.7	11
1316	Axitinib and/or bevacizumab with modified FOLFOXâ€6 as firstâ€line therapy for metastatic colorectal cancer: A randomized phase 2 study. Cancer, 2013, 119, 2555-2563.	2.0	39
1317	Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology/Hematology, 2013, 85, 121-135.	2.0	19
1318	Drug-Induced Steatohepatitis. Clinics in Liver Disease, 2013, 17, 533-546.	1.0	81
1319	Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 72, 643-652.	1.1	22

#	Article	IF	Citations
1320	Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. BMC Cancer, 2013, 13, 611.	1.1	18
1321	Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. Medical Oncology, 2013, 30, 752.	1.2	13
1322	Colorectal Cancer in the Elderly. , 2013, , .		2
1323	Changing prognosis of metastatic colorectal adenocarcinoma: Differential improvement by age and tumor location. Cancer, 2013, 119, 3084-3091.	2.0	46
1324	Overexpression of Lgr5 correlates with resistance to 5-FU-based chemotherapy in colorectal cancer. International Journal of Colorectal Disease, 2013, 28, 1535-1546.	1.0	79
1325	Cancerâ€associated fibroblast and <scp>M</scp>2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Science, 2013, 104, 437-444.	1.7	235
1326	Underpinning the repurposing of anthracyclines towards colorectal cancer: assessment of topoisomerase II alpha gene copy number alterations in colorectal cancer. Scandinavian Journal of Gastroenterology, 2013, 48, 1436-1443.	0.6	8
1327	Colorectal Liver Metastases. Journal of Gastrointestinal Surgery, 2013, 17, 195-202.	0.9	81
1328	Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Investigational New Drugs, 2013, 31, 183-191.	1.2	11
1329	Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 29-37.	5.1	997
1330	Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. Hpb, 2013, 15, 106-115.	0.1	44
1331	Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study. Clinical Colorectal Cancer, 2013, 12, 239-247.	1.0	28
1332	Oxaliplatin-based Chemotherapy Might Provide Longer Progression-Free Survival in KRAS Mutant Metastatic Colorectal Cancer. Translational Oncology, 2013, 6, 363-369.	1.7	9
1333	Sequence of novel agents in multiple myeloma: An instrumental variable analysis. Leukemia Research, 2013, 37, 1077-1082.	0.4	1
1334	Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. Lancet Oncology, The, 2013, 14, 1278-1286.	5.1	227
1335	Patient experiences following liver transplantation due to liver metastases from colorectal cancer. European Journal of Oncology Nursing, 2013, 17, 269-274.	0.9	9
1336	Transcatheter Arterial Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres for Colorectal Liver Metastases after FOLFOX Failure: Results of a Phase I/II Study. Journal of Vascular and Interventional Radiology, 2013, 24, 56-65.	0.2	35
1337	How we treat metastatic colon cancer in older adults. Journal of Geriatric Oncology, 2013, 4, 295-301.	0.5	11

#	Article	IF	Citations
1338	Multiorgan Failure in a Patient Treated With the 5-Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Regimen. Clinical Colorectal Cancer, 2013, 12, 136-139.	1.0	1
1339	High expression of microRNAâ€625â€3p is associated with poor response to firstâ€line oxaliplatin based treatment of metastatic colorectal cancer. Molecular Oncology, 2013, 7, 637-646.	2.1	77
1340	Importance of Response to Neoadjuvant Therapy in Patients With Liver-Limited mCRC When the Intent Is Resection and/or Ablation. Clinical Colorectal Cancer, 2013, 12, 223-232.	1.0	6
1341	Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. European Journal of Cancer, 2013, 49, 1882-1888.	1.3	5
1342	Phase I â€“ II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report of the BE-1603 study. Pathologie Et Biologie, 2013, 61, e27-e31.	2.2	5
1343	Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases. Journal of Surgical Research, 2013, 182, 257-263.	0.8	12
1344	The expression of integrins is decreased in colon cancer cells treated with polysaccharide K. International Journal of Oncology, 2013, 42, 1175-1180.	1.4	4
1345	Segmental and lobar administration of drugâ€eluting beads delivering irinotecan leads to tumour destruction: a caseâ€“control series. Hpb, 2013, 15, 71-77.	0.1	23
1346	Management of advanced colorectal cancer, part 1. American Journal of Health-System Pharmacy, 2013, 70, 395-406.	0.5	28
1347	The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab. Angiogenesis, 2013, 16, 113-121.	3.7	9
1348	Phase II Trial of Alternating mFOLFOX6 and FOLFIRI Regimens in the First-Line Treatment for Unresectable or Metastatic Colorectal Cancer (KSCC0701). Oncology, 2013, 84, 233-239.	0.9	5
1349	Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1463-1472.	1.1	39
1350	Role of targeted agents in metastatic colorectal cancer. Targeted Oncology, 2013, 8, 83-96.	1.7	58
1351	Liver Resection for Colorectal Cancer Metastases. Current Oncology, 2013, 20, 255-265.	0.9	55
1352	Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 2013, 13, 597-611.	1.1	30
1353	A systematic review of twoâ€stage hepatectomy in patients with initially unresectable colorectal liver metastases. Hpb, 2013, 15, 483-491.	0.1	174
1354	New Developments in the Second-Line Treatment of Metastatic Colorectal Cancer: Potential Place in Therapy. Drugs, 2013, 73, 883-891.	4.9	22
1355	FOLFIRIÂ+Âbevacizumab as second-line therapy for metastatic colorectal cancer pretreated with oxaliplatin: a pooled analysis of published trials. Medical Oncology, 2013, 30, 486.	1.2	18

#	Article	IF	Citations
1356	Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. International Journal of Clinical Oncology, 2013, 18, 335-342.	1.0	19
1357	Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy. Clinical and Experimental Metastasis, 2013, 30, 447-455.	1.7	12
1358	Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC). Journal of Medical Economics, 2013, 16, 1387-1398.	1.0	30
1359	Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer. British Journal of Cancer, 2013, 108, 493-502.	2.9	43
1360	The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?. Critical Reviews in Oncology/Hematology, 2013, 85, 332-341.	2.0	8
1361	Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model. Value in Health, 2013, 16, 542-553.	0.1	20
1362	Endoscopic evaluation of primary tumor response in patients with metastatic colorectal cancer treated by systemic chemotherapy. International Journal of Clinical Oncology, 2013, 18, 864-868.	1.0	1
1363	An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer. Investigational New Drugs, 2013, 31, 1228-1235.	1.2	7
1364	A populationâ€based study of metastatic colorectal cancer in individuals aged â‰¥80 years. Cancer, 2013, 119, 722-728.	2.0	39
1365	Prognostic scoring system for stage IV colorectal cancer: is the AJCC sub-classification of stage IV colorectal cancer appropriate?. International Journal of Clinical Oncology, 2013, 18, 696-703.	1.0	32
1366	Chemotherapy and targeted agents for colorectal cancer in a realâ€life setting anticipate guidelines: the COLCHIC cohort study. Fundamental and Clinical Pharmacology, 2013, 27, 113-119.	1.0	4
1367	Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis. Molecular and Clinical Oncology, 2013, 1, 175-179.	0.4	12
1368	Correlation of progression-free and post-progression survival with overall survival in advanced colorectal cancer. Annals of Oncology, 2013, 24, 186-192.	0.6	62
1370	Adjuvant Systemic Chemotherapy with or without Bevacizumab in Patients with Resected Liver Metastases from Colorectal Cancer. Oncology, 2013, 84, 14-21.	0.9	22
1373	Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience. Colorectal Cancer, 2013, 2, 73-88.	0.8	9
1374	How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?. Future Oncology, 2013, 9, 825-829.	1.1	2
1375	Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action. Pharmaceuticals, 2013, 6, 988-1038.	1.7	16
1376	What is the optimal neo-adjuvant treatment for liver metastasis?. Therapeutic Advances in Medical Oncology, 2013, 5, 221-234.	1.4	12

#	Article	IF	Citations
1377	Comparison of Outcomes After Fluorouracil-Based Adjuvant Therapy for Stages II and III Colon Cancer Between 1978 to 1995 and 1996 to 2007: Evidence of Stage Migration From the ACCENT Database. Journal of Clinical Oncology, 2013, 31, 3656-3663.	0.8	65
1378	Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals of Oncology, 2013, 24, 1560-1567.	0.6	79
1379	Prognostic Significance of a Systemic Inflammatory Response in Patients Undergoing Multimodality Therapy for Advanced Colorectal Cancer. Oncology, 2013, 84, 100-107.	0.9	56
1380	Correlation between overall survival and growth modulation index in pre-treated sarcoma patients: a study from the French Sarcoma Group. Annals of Oncology, 2013, 24, 2681-2685.	0.6	19
1381	Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials. Clinical Cancer Research, 2013, 19, 969-976.	3.2	46
1382	Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 388-391.	0.6	5
1383	Randomized Phase II Study of Capecitabine With or Without Oxaliplatin as First-line Treatment for Elderly or Fragile Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 565-571.	0.6	12
1384	Pharmacogenetics of ABC and SLC transporters in metastatic colorectal cancer patients receiving first-line FOLFIRI treatment. Pharmacogenetics and Genomics, 2013, 23, 549-557.	0.7	49
1385	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. Anti-Cancer Drugs, 2013, 24, 980-985.	0.7	19
1386	Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III Trial. Journal of Clinical Oncology, 2013, 31, 1341-1347.	0.8	122
1387	Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer. Scandinavian Journal of Gastroenterology, 2013, 49, 84-91.	0.6	17
1388	Oxaliplatin for colorectal cancer: recent evidence from clinical trials. Colorectal Cancer, 2013, 2, 135-144.	0.8	1
1389	Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials. Clinical Cancer Research, 2013, 19, 225-235.	3.2	64
1390	Safety and Efficacy of Modified FOLFOX6 plus High-Dose Bevacizumab in Second-Line or Later Treatment of Patients with Metastatic Colorectal Cancer. Chemotherapy, 2013, 59, 79-84.	0.8	2
1391	Surgery for Colorectal Liver Metastases. Digestive Surgery, 2013, 30, 337-347.	0.6	31
1392	Multicenter Phase II Study of a New Effective S-1 and Irinotecan Combination Schedule in Patients with Unresectable Metastatic or Recurrent Colorectal Cancer. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S10769.	0.6	6
1393	Granulomatous Lung Disease Requiring Mechanical Ventilation Induced by a Single Application of Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Case Report. Case Reports in Oncological Medicine, 2013, 2013, 1-5.	0.2	7
1394	Secondâ€line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wildâ€type <scp>KRAS</scp>. Cancer Science, 2013, 104, 473-480.	1.7	6

#	Article	IF	Citations
1395	<scp>UGT1A1*6</scp>,<scp>1A7*3</scp>, and <scp>1A9*22</scp> genotypes predict severe neutropenia in <scp>FOLFIRI</scp>â€treated metastatic colorectal cancer in two prospective studies in Japan. Cancer Science, 2013, 104, 1662-1669.	1.7	29
1396	Pharmacokinetics of Irinotecan With and Without Panitumumab Coadministration in Patients With Metastatic Colorectal Cancer. Clinical Pharmacology in Drug Development, 2013, 2, 205-212.	0.8	3
1397	Liver resection for colorectal liver metastases with periâ€operative chemotherapy: oncological results of R1 resections. Hpb, 2013, 15, 359-364.	0.1	32
1398	Chromosome 20p11 gains are associated with liver-specific metastasis in patients with colorectal cancer. Gut, 2013, 62, 94-101.	6.1	16
1399	Ziv-aflibercept: A novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer. American Journal of Health-System Pharmacy, 2013, 70, 1887-1896.	0.5	31
1400	Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. British Journal of Cancer, 2013, 109, 1735-1743.	2.9	33
1401	Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. British Journal of Cancer, 2013, 108, 1931-1935.	2.9	43
1402	Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer. British Journal of Cancer, 2013, 109, 401-407.	2.9	148
1403	A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. British Journal of Cancer, 2013, 108, 503-511.	2.9	67
1404	Defining resectability of colorectal liver metastases: how and why?. Colorectal Cancer, 2013, 2, 61-72.	0.8	1
1405	Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therapeutic Advances in Gastroenterology, 2013, 6, 459-473.	1.4	27
1406	Autologous immune enhancement therapy: A case report of a stage IV colonic cancer. Oncology Letters, 2013, 5, 1611-1614.	0.8	9
1407	Intermittent therapy in the palliative treatment of metastatic colorectal cancer. Colorectal Cancer, 2013, 2, 219-232.	0.8	0
1408	Regorafenib: carving a niche in the crowded therapeutic landscape. Expert Review of Anticancer Therapy, 2013, 13, 385-393.	1.1	4
1409	Prolonging Survival Through a Personalized Approach in Metastatic Colorectal Cancer. The Journal of Oncopathology, 2013, 1, 31-41.	0.1	0
1410	Importance of Methanogenic Flora in Intestinal Toxicity During 5-Fluorouracil Therapy for Colon Cancer. Journal of Clinical Gastroenterology, 2013, 47, 9-11.	1.1	3
1412	Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. British Journal of Nutrition, 2013, 109, 1188-1195.	1.2	46
1413	Adjuvant therapy in patients with stage II and III colon cancer under 70 years of age. Colorectal Cancer, 2013, 2, 205-217.	0.8	0

#	Article	IF	Citations
1414	Polymorphisms of GSTP1, ERCC2 and TS-3â€²UTR are associated with the clinical outcome of mFOLFOX6 in colorectal cancer patients. Oncology Letters, 2013, 6, 648-654.	0.8	40
1415	Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncology Reports, 2013, 30, 2992-2998.	1.2	11
1416	Bevacizumab-containing regimens after cetuximab failure in Kras wild-type metastatic colorectal carcinoma. Oncology Letters, 2013, 5, 637-640.	0.8	10
1417	Prospective multicenter phase II clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases. [Chapchi] Journal Taehan Oekwa Hakhoe, 2013, 85, 154.	1.1	8
1418	Cutaneous metastasis of colon adenocarcinoma: case report and review of the literature. Anais Brasileiros De Dermatologia, 2013, 88, 56-58.	0.5	35
1419	Personalized treatment for advanced colorectal cancer: KRAS and beyond. Cancer Management and Research, 2013, 5, 387.	0.9	17
1420	Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Management and Research, 2013, 5, 377.	0.9	10
1421	Determining Timing of Hepatectomy for Colorectal Cancer with Distant Metastasis According to Imaging-Based Tumor Shrinkage Ratio. International Journal of Medical Sciences, 2013, 10, 1231-1241.	1.1	5
1422	Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. OncoTargets and Therapy, 2013, 6, 1761.	1.0	7
1423	First-Line Irinotecan Combined with 5-Fluorouracil and Leucovorin for High-Grade Metastatic Gastrointestinal Neuroendocrine Carcinoma. Tumori, 2013, 99, 57-60.	0.6	10
1425	Mechanisms of Topoisomerase I (TOP1) Gene Copy Number Increase in a Stage III Colorectal Cancer Patient Cohort. PLoS ONE, 2013, 8, e60613.	1.1	22
1426	SLCO1B1 and SLC19A1 Gene Variants and Irinotecan-Induced Rapid Response and Survival: A Prospective Multicenter Pharmacogenetics Study of Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e77223.	1.1	24
1427	The Assessment and Management of Chemotherapy Associated Liver Injury. , 2013, , .		1
1428	Should Noncurative Resection of the Primary Tumour Be Performed in Patients with Stage iv Colorectal Cancer? A Systematic Review and Meta-Analysis. Current Oncology, 2013, 20, 420-441.	0.9	42
1429	A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors?. Tumori, 2013, 99, e91-e95.	0.6	2
1430	Optimal Timing of Systemic Therapy in Resectable Colorectal Liver Metastases. American Surgeon, 2013, 79, 414-421.	0.4	4
1432	Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. International Journal of Oncology, 2014, 44, 17-26.	1.4	10
1433	Colorectal cancer in Chinese patients: current and emerging treatment options. OncoTargets and Therapy, 2014, 7, 1817.	1.0	29

#	Article	IF	Citations
1434	Effective inhibition of colon cancer cell growth with MgAl-layered double hydroxide (LDH) loaded 5-FU and PI3K/mTOR dual inhibitor BEZ-235 through apoptotic pathways. International Journal of Nanomedicine, 2014, 9, 3403.	3.3	26
1435	Serum Lactate Dehydrogenase Levels as a Predictive Marker of Oxaliplatin-Induced Hypersensitivity Reactions in Japanese Patients with Advanced Colorectal Cancer. International Journal of Medical Sciences, 2014, 11, 641-645.	1.1	10
1436	Current Approaches and Challenges for Monitoring Treatment Response in Colon and Rectal Cancer. Journal of Cancer, 2014, 5, 31-43.	1.2	64
1437	Cost-Effectiveness of First-Line Treatments for Patients with Kras Wild-Type Metastatic Colorectal Cancer. Current Oncology, 2014, 21, 541-550.	0.9	21
1438	FOLFIRI as Second-line Chemotherapy after Failure of FOLFOX4 in Advanced Colorectal Cancer: A Korean Single-center Experience. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2014, 63, 18.	0.2	1
1439	Cost Evaluation of Metastatic Colorectal Cancer Treatment in the Brazilian Public Healthcare System. Journal of Integrative Oncology, 2014, 04, .	0.3	0
1440	Management of locally advanced and metastatic colon cancer in elderly patients. World Journal of Gastroenterology, 2014, 20, 1910.	1.4	17
1441	The Complexity of Colorectal Cancer Biology â€" Putting Bricks on the Path to Personalized Medicine. , 0, , .		1
1442	Sequencing of treatment in metastatic colorectal cancer: Where to fit the target. World Journal of Gastroenterology, 2014, 20, 1993.	1.4	23
1444	Adjuvant Treatment in Colorectal Cancer. , 2014, , .		5
1446	Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report. Cancer Chemotherapy and Pharmacology, 2014, 74, 1321-1324.	1.1	2
1447	Evaluation of aflibercept in the treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2014, 14, 1493-1505.	1.4	9
1448	The CAIRO4 study: the role of surgery of the primary tumour with few or absent symptoms in patients with synchronous unresectable metastases of colorectal cancer â€" a randomized phase III study of the Dutch Colorectal Cancer Group (DCCG). BMC Cancer, 2014, 14, 741.	1.1	86
1449	S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial. BMC Cancer, 2014, 14, 883.	1.1	16
1450	Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer, 2014, 14, 897.	1.1	54
1451	Glyco-engineered anti-EGFR mAb elicits ADCC by NK cells from colorectal cancer patients irrespective of chemotherapy. British Journal of Cancer, 2014, 110, 1221-1227.	2.9	25
1452	Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?. Future Oncology, 2014, 10, 149-152.	1.1	0
1453	Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens. Cancers, 2014, 6, 1753-1768.	1.7	14

#	Article	IF	Citations
1454	Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature. Oncology Letters, 2014, 7, 1455-1458.	0.8	4
1456	Efficacy of Adding Bevacizumab in the First-Line Chemotherapy of Metastatic Colorectal Cancer: Evidence from Seven Randomized Clinical Trials. Gastroenterology Research and Practice, 2014, 2014, 1-8.	0.7	19
1457	Palliative self-expandable metal stents for acute malignant colorectal obstruction: clinical outcomes and risk factors for complications. Scandinavian Journal of Gastroenterology, 2014, 49, 967-973.	0.6	8
1458	A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer. Chemotherapy Research and Practice, 2014, 2014, 1-8.	1.6	1
1459	Impact of cetuximab in current treatment of metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2014, 14, 387-399.	1.4	7
1460	Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected pulmonary metastases from colorectal cancer. Thoracic Cancer, 2014, 5, 398-404.	0.8	6
1461	Does the type of firstâ€line regimens influence the receipt of secondâ€line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Medicine, 2014, 3, 124-133.	1.3	5
1462	Survival and tolerability of liver radioembolization: a comparison of elderly and younger patients with metastatic colorectal cancer. Hpb, 2014, 16, 1110-1116.	0.1	14
1463	Survival benefit from Sâ€1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: A metaâ€analysis. Cancer Science, 2014, 105, 1008-1014.	1.7	12
1464	FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer. Oncology, 2014, 87, 148-158.	0.9	15
1465	Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: Are we excluding patients who may benefit?. Journal of Surgical Oncology, 2014, 109, 104-109.	0.8	24
1466	Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 2014, 14, 1477-1493.	1.1	12
1467	Oxaliplatin-based versus irinotecan-based hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasis from appendiceal and colorectal cancer: a retrospective analysis. BMC Cancer, 2014, 14, 807.	1.1	29
1468	Phase II study of weekly irinotecan and capecitabine treatment in metastatic colorectal cancer patients. BMC Cancer, 2014, 14, 986.	1.1	5
1469	Predictors of recurrence after a first hepatectomy for colorectal cancer liver metastases: a retrospective analysis. World Journal of Surgical Oncology, 2014, 12, 391.	0.8	27
1470	Laparoscopic Surgery for Stage IV Colorectal Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2014, 24, 153-157.	0.4	3
1471	Outcome Analysis of a Decade-Long Experience of Isolated Hepatic Perfusion for Unresectable Liver Metastases at a Single Institution. Annals of Surgery, 2014, 259, 953-959.	2.1	11
1472	A Phase II Study of Bevacizumab, Oxaliplatin, and Capecitabine in Patients With Previously Untreated Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 19-23.	0.6	7

#	Article	IF	Citations
1473	State of the art: colorectal liver metastases. Future Oncology, 2014, 10, 29-32.	1.1	0
1474	Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer. Molecular Medicine Reports, 2014, 9, 669-676.	1.1	20
1475	Unintended Consequences of Expensive Cancer Therapeuticsâ€"The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity. JAMA Otolaryngology - Head and Neck Surgery, 2014, 140, 1225.	1.2	263
1476	Intestinal permeability in patients with metastatic colon cancer treated with patupilone. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1649-55.	1.4	9
1477	Predictive Value of Optimal Morphologic Response to First-Line Chemotherapy in Patients with Colorectal Liver Metastases. Digestion, 2014, 89, 43-48.	1.2	31
1478	Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer. Case Reports in Oncological Medicine, 2014, 2014, 1-6.	0.2	11
1479	Colorectal cancer and screening programs: not only analytical issues. Clinical Chemistry and Laboratory Medicine, 2014, 52, 1087-90.	1.4	0
1480	Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2014, 10, 322-329.	0.7	10
1481	Adverse Immunoregulatory Effects of 5FU and CPT11 Chemotherapy on Myeloid-Derived Suppressor Cells and Colorectal Cancer Outcomes. Cancer Research, 2014, 74, 6022-6035.	0.4	142
1482	Personalized treatment is better than one treatment fits all in the management of patients with mCRC: a consensus statement. Future Oncology, 2014, 10, 2643-2657.	1.1	6
1483	A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer. Anti-Cancer Drugs, 2014, 25, 1122-1128.	0.7	22
1484	MÃ©tastases hÃ©patiques, pulmonaires et pÃ©ritonÃ©ales des cancers colorectaux. Diagnostic and Interventional Imaging, 2014, 95, 514-524.	0.0	0
1485	FOLFOX4 With Cetuximab vs. UFOX With Cetuximab as First-Line Therapy in Metastatic Colorectal Cancer: The Randomized Phase II FUTURE Study. Clinical Colorectal Cancer, 2014, 13, 14-26.e1.	1.0	18
1486	What could Nintedanib (BIBF 1120), a triple inhibitor of VEGFR, PDGFR, and FGFR, add to the current treatment options for patients with metastatic colorectal cancer?. Critical Reviews in Oncology/Hematology, 2014, 92, 83-106.	2.0	30
1487	Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis. Journal of Gastroenterology, 2014, 49, 646-654.	2.3	41
1488	Cytoreductive surgery and intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis from colorectal origin. Clinical and Translational Oncology, 2014, 16, 128-140.	1.2	22
1489	A systematic review of a liverâ€first approach in patients with colorectal cancer and synchronous colorectal liver metastases. Hpb, 2014, 16, 101-108.	0.1	62
1490	Treatment of liver tumours with yttrium radioembolisation. Clinical and Translational Imaging, 2014, 2, 165-182.	1.1	2

#	Article	IF	Citations
1491	Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer. Medical Oncology, 2014, 31, 802.	1.2	33
1492	Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 473-480.	1.2	25
1493	Transarterial chemoembolization of unresectable systemic chemotherapyâ€refractory liver metastases from colorectal cancer: Longâ€term results over a 10â€year period. International Journal of Cancer, 2014, 134, 1225-1231.	2.3	65
1494	Strategies in the Multidisciplinary Management of Synchronous Colorectal Cancer and Resectable Liver Metastases. Current Colorectal Cancer Reports, 2014, 10, 227-238.	1.0	1
1495	Randomized Phase III Trial Exploring the Use of Long-Acting Release Octreotide in the Prevention of Chemotherapy-Induced Diarrhea in Patients With Colorectal Cancer: The LARCID Trial. Journal of Clinical Oncology, 2014, 32, 1006-1011.	0.8	36
1496	A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Investigational New Drugs, 2014, 32, 561-568.	1.2	2
1497	Chemotherapy and Targeted Therapy for Patients with Initially Unresectable Colorectal Liver Metastases, Focusing on Conversion Hepatectomy and Long-Term Survival. Annals of Surgical Oncology, 2014, 21, 405-413.	0.7	80
1498	Analysis of treatment that includes both hepatic and pulmonary resections for colorectal metastases. Surgery Today, 2014, 44, 702-711.	0.7	10
1499	Liver, lung and peritoneal metastases in colorectal cancers: Is the patient still curable? What should the radiologist know. Diagnostic and Interventional Imaging, 2014, 95, 513-523.	1.8	19
1500	Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surgical Oncology, 2014, 23, 53-60.	0.8	42
1501	Palliative Treatment of Metastatic Colorectal Cancer: What is the Optimal Approach?. Current Oncology Reports, 2014, 16, 363.	1.8	9
1502	Reconsideration of the Indications for Adjuvant Chemotherapy for Liver Metastases from Colorectal Cancer After Initial Hepatectomy. Annals of Surgical Oncology, 2014, 21, 139-146.	0.7	21
1503	Methods of overcoming treatment resistance in colorectal cancer. Critical Reviews in Oncology/Hematology, 2014, 89, 217-230.	2.0	58
1504	Effect of BRAF V600E mutation on tumor response of anti-EGFR monoclonal antibodies for first-line metastatic colorectal cancer treatment: a meta-analysis of randomized studies. Molecular Biology Reports, 2014, 41, 1291-1298.	1.0	27
1505	Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving firstâ€line oxaliplatinâ€based treatment. Molecular Oncology, 2014, 8, 59-67.	2.1	132
1506	Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opinion on Drug Safety, 2014, 13, 113-129.	1.0	30
1507	Colorectal Cancer with Potentially Resectable Hepatic Metastases: Optimizing Treatment. Current Oncology Reports, 2014, 16, 407.	1.8	25
1508	Cost Effectiveness Analysis of Pharmacokinetically-Guided 5-Fluorouracil in FOLFOX Chemotherapy for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 219-225.	1.0	35

#	Article	IF	Citations
1509	In Vivo Evaluation of Irinotecan-Loaded QuadraSphere Microspheres for Use in Chemoembolization of VX2 Liver Tumors. Journal of Vascular and Interventional Radiology, 2014, 25, 1727-1735.e1.	0.2	9
1510	Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2014, 25, iii1-iii9.	0.6	910
1511	Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. New England Journal of Medicine, 2014, 371, 1609-1618.	13.9	845
1512	Update on the Role of Imaging in Management of Metastatic Colorectal Cancer. Radiographics, 2014, 34, 1908-1928.	1.4	82
1513	Curable Patient With Metastatic Colorectal Cancer: Balancing Effective Therapies and Toxicities. Journal of Clinical Oncology, 2014, 32, 991-996.	0.8	10
1514	Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer. Journal of Surgical Oncology, 2014, 109, 250-254.	0.8	7
1515	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36
1516	Advances in the management of colorectal cancer: from biology to treatment. International Journal of Colorectal Disease, 2014, 29, 1031-1042.	1.0	75
1517	Adaptation of International Guidelines for Metastatic Colorectal Cancer: An Asian Consensus. Clinical Colorectal Cancer, 2014, 13, 145-155.	1.0	15
1518	New advances in local therapy for colorectal cancer metastases to the liver. Colorectal Cancer, 2014, 3, 183-193.	0.8	0
1519	The Challenge to Optimize Medical Therapy for Advanced Colorectal Cancer. Journal of the National Cancer Institute, 2014, 106, djt442-djt442.	3.0	1
1520	Stereotactic body radiation therapy for liver tumours. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2014, 18, 313-319.	0.6	15
1521	How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer?. Expert Opinion on Biological Therapy, 2014, 14, 743-748.	1.4	15
1522	Evaluation of the necessity of primary tumor resection for synchronous metastatic colorectal cancer. Surgery Today, 2014, 44, 2287-2292.	0.7	10
1523	Prognostic Impact of Primary Tumor Resection and Lymph Node Dissection in Stage IV Colorectal Cancer with Unresectable Metastasis: A Propensity Score Analysis in a Multicenter Retrospective Study. Annals of Surgical Oncology, 2014, 21, 2949-2955.	0.7	47
1524	Liver-Directed Treatments for Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2014, 15, 456-464.	1.3	8
1525	Management of Colon Cancer and Liver Metastases: Is There a Role for Molecularly Targeted Agents?. Current Colorectal Cancer Reports, 2014, 10, 133-139.	1.0	0
1526	Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Medical Oncology, 2014, 31, 976.	1.2	4

#	Article	IF	Citations
1527	Long-term survival of a patient with metachronous rectal metastasis from primary cecal cancer who underwent repetitive resection and chemotherapy: a case report. World Journal of Surgical Oncology, 2014, 12, 107.	0.8	4
1528	A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report. World Journal of Surgical Oncology, 2014, 12, 63.	0.8	1
1529	A phase Î™I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). Journal of Translational Medicine, 2014, 12, 108.	1.8	75
1530	Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. Biomedicine and Pharmacotherapy, 2014, 68, 409-412.	2.5	6
1531	Synthesis and biological evaluation of bile carboxamide derivatives with pro-apoptotic effect on human colon adenocarcinoma cell lines. European Journal of Medicinal Chemistry, 2014, 86, 279-290.	2.6	21
1532	Seeing the forest through the trees: A systematic review of the safety and efficacy of combination chemotherapies used in the treatment of metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2014, 91, 9-34.	2.0	27
1533	Sequencing of Antiangiogenic Agents in the Treatment of Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 135-144.	1.0	27
1534	Cancer economics, policy and politics: What informs the debate? Perspectives from the EU, Canada and US. Journal of Cancer Policy, 2014, 2, 1-11.	0.6	48
1535	Treatment of Colorectal Cancer with Unresectable Metastasis with Chemotherapy Without Primary Tumour Resection: Analysis of Tumour-related Complications. CirugÃa EspaÃ±ola (English Edition), 2014, 92, 30-37.	0.1	0
1537	Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. Medical Oncology, 2014, 31, 35.	1.2	15
1538	Current management of colorectal liver metastases. Colorectal Cancer, 2014, 3, 163-181.	0.8	1
1539	Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: A French population-based study. Digestive and Liver Disease, 2014, 46, 854-858.	0.4	46
1540	FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World Journal of Gastroenterology, 2014, 20, 10316.	1.4	61
1541	Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World Journal of Gastrointestinal Oncology, 2014, 6, 156.	0.8	48
1542	Management of colorectal cancer. F1000prime Reports, 2014, 6, 108.	5.9	86
1543	A novel system for predicting the toxicity of irinotecan based on statistical pattern recognition with UGT1A genotypes. International Journal of Oncology, 2014, 45, 1381-1390.	1.4	15
1544	Anal cancer. , 2014, , 337-348.		0
1545	KRAS and extended RAS molecular profiling in metastatic colorectal cancer. Colorectal Cancer, 2014, 3, 491-499.	0.8	0

#	Article	IF	Citations
1546	Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases. Hepatic Oncology, 2014, 1, 81-94.	4.2	9
1547	Retrospective analysis of efficacy and safety of third-line chemotherapy for metastatic colorectal cancer among elderly patients receiving targeted therapy in early lines. Journal of Clinical Gerontology and Geriatrics, 2015, 6, 95-99.	0.7	3
1548	TRIBE study: are all three cytotoxic drugs crucial? â€“ Authors' reply. Lancet Oncology, The, 2015, 16, e578-e579.	5.1	0
1549	DNA methylation status as a biomarker of antiâ€epidermal growth factor receptor treatment for metastatic colorectal cancer. Cancer Science, 2015, 106, 1722-1729.	1.7	25
1550	Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis. Molecular and Clinical Oncology, 2015, 3, 959-967.	0.4	9
1552	First report of a Japanese phase I study of triplet plus bevacizumab for chemotherapy-naive metastatic colorectal cancer (J1-TRIBE study). Cancer Treatment Communications, 2015, 4, 75-80.	0.4	3
1553	Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. BMC Cancer, 2015, 15, 626.	1.1	13
1556	Predictive factors for time to recurrence, treatment and post-recurrence survival in patients with initially resected colorectal liver metastases. World Journal of Surgical Oncology, 2015, 13, 328.	0.8	29
1557	Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on Kâ€ras status for unresectable colorectal liver metastasis (BECK study). Journal of Hepato-Biliary-Pancreatic Sciences, 2015, 22, 634-645.	1.4	21
1558	Clinicopathologic Features and Outcome of Young Adults With Stage IV Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 543-549.	0.6	20
1559	Secondâ€line chemotherapy for advanced biliary tract cancer after failure of the gemcitabineâ€platinum combination: A large multicenter study by the Association des Gastroâ€EntÃ©rologues Oncologues. Cancer, 2015, 121, 3290-3297.	2.0	95
1560	Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World Journal of Gastroenterology, 2015, 21, 12234.	1.4	226
1561	Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Design, Development and Therapy, 2015, 9, 3099.	2.0	45
1562	Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Wspolczesna Onkologia, 2015, 5, 385-390.	0.7	2
1563	A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Design, Development and Therapy, 2015, 9, 1653.	2.0	7
1564	Oxaliplatin-based first-line chemotherapy is associated with improved overall survival compared to first-line treatment with irinotecan-based chemotherapy in patients with metastatic colorectal cancer – Results from a prospective cohort study. Clinical Epidemiology, 2015, 7, 295.	1.5	16
1565	A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial. Drug Design, Development and Therapy, 2015, 9, 6067.	2.0	7
1566	Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0134732.	1.1	37

#	Article	IF	Citations
1567	Optimal Sequence of Irinotecan and Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer: A Population-Based Observational Study. PLoS ONE, 2015, 10, e0135673.	1.1	10
1568	von Willebrand Factor-Rich Platelet Thrombi in the Liver Cause Sinusoidal Obstruction Syndrome following Oxaliplatin-Based Chemotherapy. PLoS ONE, 2015, 10, e0143136.	1.1	16
1569	Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Research and Treatment, 2015, 47, 790-795.	1.3	10
1570	Neoadjuvant chemotherapy (NCT) plus targeted agents versus NCT alone in colorectal liver metastases patients: A systematic review and meta-analysis. Oncotarget, 2015, 6, 44005-44018.	0.8	13
1571	Colorectal cancer: Metastases to a single organ. World Journal of Gastroenterology, 2015, 21, 11767.	1.4	233
1572	Locoregional therapy and systemic cetuximab to treat colorectal liver metastases. World Journal of Gastrointestinal Oncology, 2015, 7, 47.	0.8	17
1573	Novel Strategy for Colorectal Liver Metastases -Estimated by the Concept for Hepatocyte Growth Factor. Archives in Cancer Research, 2015, 3, .	0.3	0
1574	Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Annals of Oncology, 2015, 26, 1201-1207.	0.6	134
1575	Postoperative irinotecan in resected stage IIâ€“III rectal cancer: final analysis of the French R98 Intergroup trial. Annals of Oncology, 2015, 26, 1208-1215.	0.6	10
1576	A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study. Investigational New Drugs, 2015, 33, 954-962.	1.2	2
1577	The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials. Acta OncolÃ³gica, 2015, 54, 1737-1746.	0.8	19
1578	EGFR signaling in colorectal cancer: a clinical perspective. Gastrointestinal Cancer: Targets and Therapy, 0, , 21.	5.5	10
1579	SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clinical and Translational Oncology, 2015, 17, 972-981.	1.2	26
1580	Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease. Current Colorectal Cancer Reports, 2015, 11, 369-377.	1.0	14
1581	Comet assay measures of <scp>DNA</scp> damage as biomarkers of irinotecan response in colorectal cancer inÂvitro and inÂvivo. Cancer Medicine, 2015, 4, 1309-1321.	1.3	20
1582	Bevacizumab Plus Chemotherapy Cost Effectiveness. Journal of Clinical Oncology, 2015, 33, 3840-3841.	0.8	3
1583	TRIBE study: are all three cytotoxic drugs crucial?. Lancet Oncology, The, 2015, 16, e577.	5.1	1
1584	Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy. Cancer Biology and Therapy, 2015, 16, 1710-1719.	1.5	15

#	Article	IF	Citations
1585	Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy. BMC Health Services Research, 2015, 16, 2.	0.9	15
1586	Circannual variation of efficacy outcomes in patients with newly diagnosed metastatic colorectal cancer and treated with first-line chemotherapy. Chronobiology International, 2015, 32, 1359-1366.	0.9	1
1587	A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer. Oncology, 2015, 88, 353-359.	0.9	6
1588	Successful Treatment with S-1 and Oxaliplatin Combination Therapy in an Elderly Patient with Metastatic Colorectal Cancer Initially Presenting with Membranous Nephropathy. Case Reports in Oncology, 2015, 8, 212-216.	0.3	0
1589	Vascular Endothelial Growth Factor A c.*237C>T polymorphism is associated with bevacizumab efficacy and related hypertension in metastatic colorectal cancer. Digestive and Liver Disease, 2015, 47, 331-337.	0.4	23
1590	The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. Clinical Colorectal Cancer, 2015, 14, 52-57.	1.0	33
1591	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	1.0	43
1592	Inclusion of targeted therapies in the standard of care for metastatic colorectal cancer patients in a German cancer center: the more the better?!. Journal of Cancer Research and Clinical Oncology, 2015, 141, 515-522.	1.2	10
1593	The potential role of immunotherapy to treat colorectal cancer. Expert Opinion on Investigational Drugs, 2015, 24, 329-344.	1.9	27
1594	Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Therapeutic Advances in Medical Oncology, 2015, 7, 153-169.	1.4	50
1595	A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. Journal of Cancer Research and Clinical Oncology, 2015, 141, 153-160.	1.2	26
1596	The Role of Neoadjuvant Therapy in Characterizing Indeterminate Lung Lesions in Patients with Resectable Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 2201-2208.	0.7	3
1597	Localization of sunitinib in in vivo animal and in vitro experimental models by MALDI mass spectrometry imaging. Analytical and Bioanalytical Chemistry, 2015, 407, 2245-2253.	1.9	15
1598	Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 17-23.	1.1	25
1599	First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United Statesâ€“Based Cost-Effectiveness Analysis. Journal of Clinical Oncology, 2015, 33, 1112-1118.	0.8	144
1600	Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study. European Journal of Cancer, 2015, 51, 473-481.	1.3	17
1601	A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Medical Oncology, 2015, 32, 325.	1.2	47
1602	Time course of safety and efficacy of aflibercept in combination with FOLFIRI in patients with metastatic colorectal cancer who progressed on previous oxaliplatin-based therapy. European Journal of Cancer, 2015, 51, 18-26.	1.3	21

#	Article	IF	Citations
1603	Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. Annals of Surgical Oncology, 2015, 22, 855-862.	0.7	9
1604	First-line chemotherapy for mCRCâ€"a review and evidence-based algorithm. Nature Reviews Clinical Oncology, 2015, 12, 607-619.	12.5	138
1605	Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer. Investigational New Drugs, 2015, 33, 977-984.	1.2	37
1606	A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI. Oncology, 2015, 88, 164-172.	0.9	19
1607	Transarterial chemoembolization (TACE) for colorectal liver metastasesâ€"current status and critical review. Langenbeck's Archives of Surgery, 2015, 400, 641-659.	0.8	55
1608	Systemic Therapy for Patients with Colorectal Cancer: State of the Art. , 2015, , 109-132.		1
1609	OPTIMAL TIMING FOR SURGICAL TREATMENT OF COLORECTAL LIVER METASTASES. Acta Medica Medianae, 2015, 54, 87-96.	0.0	0
1610	Benefit of primary tumor resection in stage IV colorectal cancer with unresectable metastasis: a multicenter retrospective study using a propensity score analysis. International Journal of Colorectal Disease, 2015, 30, 807-812.	1.0	21
1611	Should FOLFOXIRI Plus Bevacizumab Be the Standard Firstâ€Line Therapy in Metastatic Colorectal Cancer?. Oncologist, 2015, 20, 236-238.	1.9	5
1612	Approach to chemotherapy-associated thrombosis. Vascular Medicine, 2015, 20, 153-161.	0.8	54
1613	Impact of the spheroid model complexity on drug response. Journal of Biotechnology, 2015, 205, 14-23.	1.9	109
1614	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. Molecular Oncology, 2015, 9, 1169-1185.	2.1	91
1615	Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. European Journal of Cancer, 2015, 51, 942-949.	1.3	47
1616	Inhibition of Transient Receptor Potential Channel 5 Reverses 5-Fluorouracil Resistance in Human Colorectal Cancer Cells. Journal of Biological Chemistry, 2015, 290, 448-456.	1.6	78
1617	Trans-Arterial Chemoembolization with Irinotecan-Loaded Drug-Eluting Beads (DEBIRI) and Capecitabine in Refractory Liver Prevalent Colorectal Metastases: A Phase II Single-Center Study. CardioVascular and Interventional Radiology, 2015, 38, 1523-1531.	0.9	41
1618	Endostar in combination with modified FOLFOX6 as an initial therapy in advanced colorectal cancer patients: a phase I clinical trial. Cancer Chemotherapy and Pharmacology, 2015, 75, 547-557.	1.1	16
1619	A randomized phase II study of combination therapy with S-1, oral leucovorin, and oxaliplatin (SOL) and mFOLFOX6 in patients with previously untreated metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 75, 569-577.	1.1	16
1620	Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study. International Journal of Clinical Oncology, 2015, 20, 767-775.	1.0	78

#	Article	IF	Citations
1621	First-Line Therapy in Metastatic Colorectal Cancer Patients Not Candidates for Curative Surgery. Current Colorectal Cancer Reports, 2015, 11, 54-69.	1.0	0
1622	Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterology, 2015, 15, 37.	0.8	17
1623	GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer, 2015, 15, 47.	1.1	29
1624	Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). BMC Cancer, 2015, 15, 176.	1.1	2
1625	HGUE-C-1 is an atypical and novel colon carcinoma cell line. BMC Cancer, 2015, 15, 240.	1.1	6
1626	Unresolved issues and controversies surrounding the management of colorectal cancer liver metastasis. World Journal of Surgical Oncology, 2015, 13, 61.	0.8	16
1627	Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Letters, 2015, 364, 135-141.	3.2	147
1628	Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis. Annals of Oncology, 2015, 26, 477-485.	0.6	48
1629	DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan. British Journal of Clinical Pharmacology, 2015, 80, 581-588.	1.1	52
1630	Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo EspaÃ±ol Multidisciplinar en Cancer Digestivo (GEMCAD). Colorectal Cancer, 2015, 4, 97-112.	0.8	0
1631	Early Prediction by 18F-FDG PET/CT for Progression-Free Survival and Overall Survival in Patients With Metastatic Colorectal Cancer Receiving Third-Line Cetuximab-Based Therapy. Clinical Nuclear Medicine, 2015, 40, 200-205.	0.7	25
1632	Systematic Review With Network Meta-Analysis. Medicine (United States), 2015, 94, e379.	0.4	9
1633	Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. International Journal of Clinical Oncology, 2015, 20, 207-239.	1.0	548
1634	Comparison of Complete Pathologic Response and Hepatic Injuries Between Hepatic Arterial Infusion and Systemic Administration of Oxaliplatin in Patients with Colorectal Liver Metastases. Annals of Surgical Oncology, 2015, 22, 1925-1932.	0.7	35
1635	Determination of chemotherapeutic drugs in human urine by capillary electrophoresis with UV and fluorimetric detection using solid-supported liquid-liquid extraction for sample clean-up. Journal of Separation Science, 2015, 38, 1990-1997.	1.3	4
1636	Incorporating Anti-VEGF Pathway Therapy as a Continuum of Care in Metastatic Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 18.	1.3	11
1637	Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis. International Journal of Colorectal Disease, 2015, 30, 1305-1310.	1.0	30
1638	Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies. Investigational New Drugs, 2015, 33, 1093-1099.	1.2	6

#	Article	IF	Citations
1639	Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 925-932.	1.1	40
1640	A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. Investigational New Drugs, 2015, 33, 1225-1231.	1.2	46
1641	STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer, 2015, 15, 496.	1.1	20
1642	Treatment of advanced oesophagogastric cancer with FOLFOX-4 regimen followed by leucovorin/bolus and continuous infusion 5-FU as maintenance chemotherapy in patients aged â‰¥75years with impaired performance status. Journal of Geriatric Oncology, 2015, 6, 380-386.	0.5	7
1643	Cost Considerations in the Evaluation and Treatment of Colorectal Cancer. Current Treatment Options in Oncology, 2015, 16, 41.	1.3	8
1644	Survival of patients with KRAS wild-type metastatic colorectal cancer is identical after sequential treatment with cetuximab and bevacizumab regardless of the sequence â€“ A retrospective single-center study. Gastroenterology Report, 2015, 3, gov051.	0.6	5
1645	Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios. Future Oncology, 2015, 11, 2625-2628.	1.1	4
1647	Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project. Oncology, 2015, 88, 103-121.	0.9	9
1648	Hepatic Resection for Disappearing Liver Metastasis: a Cost-Utility Analysis. Journal of Gastrointestinal Surgery, 2015, 19, 1668-1675.	0.9	8
1649	The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator. European Journal of Surgical Oncology, 2015, 41, 859-867.	0.5	67
1650	Aflibercept for metastatic colorectal cancer: safety data from the Spanish named patient program. Expert Opinion on Drug Safety, 2015, 14, 1171-1179.	1.0	8
1651	The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. Future Oncology, 2015, 11, 1471-1478.	1.1	6
1652	Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance. Drug Resistance Updates, 2015, 23, 20-54.	6.5	57
1653	Trying to Understand Differing Results of FIRE-3 and 80405: Does the First Treatment Matter More Than Others?. Journal of Clinical Oncology, 2015, 33, 3686-3688.	0.8	16
1654	Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial â€“ the PRODIGE 22 - ECKINOXE trial. BMC Cancer, 2015, 15, 511.	1.1	43
1655	The pharmacological costs of complete liver resections in unselected advanced colorectal cancer patients: a review of published Phase II and III trials. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 101-110.	0.7	0
1656	Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites. Cancer Biology and Therapy, 2015, 16, 1726-1737.	1.5	75
1657	A Multicenter Phase II Trial of mFOLFOX6 Plus Bevacizumab to Treat Liver-Only Metastases of Colorectal Cancer that are Unsuitable for Upfront Resection (TRICC0808). Annals of Surgical Oncology, 2015, 22, 908-915.	0.7	34

#	Article	IF	Citations
1658	Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. British Journal of Cancer, 2015, 112, 313-318.	2.9	22
1659	Is More Not Better?. Hematology/Oncology Clinics of North America, 2015, 29, 85-116.	0.9	3
1660	Predictive and Prognostic Markers in the Treatment of Metastatic Colorectal Cancer (mCRC). Hematology/Oncology Clinics of North America, 2015, 29, 43-60.	0.9	24
1661	Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 370-376.	3.3	52
1662	Recent Therapeutic Advances in the Treatment of Colorectal Cancer. Annual Review of Medicine, 2015, 66, 83-95.	5.0	162
1663	Integrating Systemic and Surgical Approaches to Treating Metastatic Colorectal Cancer. Surgical Oncology Clinics of North America, 2015, 24, 199-214.	0.6	7
1664	Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database. Journal of Clinical Oncology, 2015, 33, 22-28.	0.8	87
1665	A Review of the Evolution of Systemic Chemotherapy in the Management of Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 1-10.	1.0	391
1666	BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2016, 29, 173-179.	0.5	7
1667	Observational cohort study focused on treatment continuity of patients administered XELOX plus bevacizumab for previously untreated metastatic colorectal cancer. OncoTargets and Therapy, 2016, Volume 9, 4113-4120.	1.0	3
1668	Patterns of Practice with Third-Line Anti-EGFR Antibody for Metastatic Colorectal Cancer. Current Oncology, 2016, 23, 329-333.	0.9	6
1669	Role of targeted therapy in metastatic colorectal cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 642.	0.8	80
1670	Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis. OncoTargets and Therapy, 2016, Volume 9, 4833-4842.	1.0	15
1671	Is early response by 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography a predictor of long-term outcome in patients with metastatic colorectal cancer?. Journal of Gastrointestinal Oncology, 2016, 7, 365-372.	0.6	2
1672	Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget, 2016, 7, 34811-34823.	0.8	43
1673	Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases. Oncology Letters, 2016, 12, 3127-3134.	0.8	2
1674	Successful Resection of Isolated Para-Aortic Lymph Node Recurrence from Advanced Sigmoid Colon Cancer following 156 Courses of FOLFIRI Regimen. Case Reports in Surgery, 2016, 2016, 1-5.	0.2	4
1676	Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells. Immune Network, 2016, 16, 99.	1.6	20

#	Article	IF	Citations
1677	Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab. Case Reports in Oncology, 2016, 9, 249-254.	0.3	12
1678	A Novel Computational Tool for Mining Real-Life Data: Application in the Metastatic Colorectal Cancer Care Setting. PLoS ONE, 2016, 11, e0154689.	1.1	0
1679	Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option. Case Reports in Oncology, 2016, 9, 379-386.	0.3	1
1680	Target hepatic artery regional chemotherapy and bevacizumab perfusion in liver metastatic colorectal cancer after failure of first-line or second-line systemic chemotherapy. Anti-Cancer Drugs, 2016, 27, 118-126.	0.7	6
1681	Targeting cancer cells in the tumor microenvironment: opportunities and challenges in combinatorial nanomedicine. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2016, 8, 208-222.	3.3	39
1682	Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial. Journal of Clinical Oncology, 2016, 34, 1564-1564.	0.8	5
1683	Chemotherapeutic outcomes for metastatic colorectal cancer in elderly patients aged â‰¥75 years: A single-institutional retrospective analysis. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 151-158.	0.7	1
1684	A tribute to biologics in advanced colorectal cancer treatment. Annals of Oncology, 2016, 27, 1372-1374.	0.6	4
1685	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 2016, 27, 1386-1422.	0.6	2,545
1686	Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ove	0.4	7
1687	Delivery of Adjuvant Oxaliplatin for Colon Cancer: Insights From Routine Clinical Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1548-1554.	2.3	7
1688	Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study. Oncology, 2016, 91, 127-134.	0.9	1
1690	The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer. SpringerPlus, 2016, 5, 1798.	1.2	19
1691	Is monitoring of plasma 5-fluorouracil levels in metastatic / advanced colorectal cancer clinically effective? A systematic review. BMC Cancer, 2016, 16, 523.	1.1	10
1693	Intermittent versus continuous systemic therapy as treatment for unresectable metastatic colorectal cancer. The Cochrane Library, 0, , .	1.5	0
1694	Colorectal Cancer: Management of Local Recurrence. , 2016, , 571-588.		0
1695	Colorectal Cancer: Management of Stage IV Disease. , 2016, , 589-616.		1
1696	PKM1 is involved in resistance to anti-cancer drugs. Biochemical and Biophysical Research Communications, 2016, 473, 174-180.	1.0	29

#	Article	IF	Citations
1697	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of Experimental and Clinical Cancer Research, 2016, 35, 56.	3.5	23
1698	Precision Medicine in Gastrointestinal Pathology. Archives of Pathology and Laboratory Medicine, 2016, 140, 449-460.	1.2	3
1699	Bevacizumab Efficacy Is Influenced by Primary Tumor Resection in First-Line Treatment of Metastatic Colorectal Cancer in a Retrospective Multicenter Study. Clinical Colorectal Cancer, 2016, 15, e165-e174.	1.0	9
1700	Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Annals of Oncology, 2016, 27, 1539-1546.	0.6	189
1701	Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy. Clinical Therapeutics, 2016, 38, 1376-1391.	1.1	11
1702	Adjuvant chemotherapy for colon cancer: the difference between Japanese and western strategies. Expert Opinion on Pharmacotherapy, 2016, 17, 783-790.	0.9	6
1703	Autologous Cytokine-Induced Killer Cells Improves Overall Survival of Metastatic Colorectal Cancer Patients: Results From a Phase II Clinical Trial. Clinical Colorectal Cancer, 2016, 15, 228-235.	1.0	38
1704	Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Therapeutic Advances in Medical Oncology, 2016, 8, 230-242.	1.4	58
1705	Cost-Effectiveness of Surgery, Stereotactic Body Radiation Therapy, and Systemic Therapy for Pulmonary Oligometastases. International Journal of Radiation Oncology Biology Physics, 2016, 95, 663-672.	0.4	29
1706	The 100 most influential manuscripts in colorectal cancer: A bibliometric analysis. Journal of the Royal College of Surgeons of Edinburgh, 2016, 14, 327-336.	0.8	27
1707	Oral drugs in the treatment of metastatic colorectal cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1351-1361.	0.9	21
1708	A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. BMC Cancer, 2016, 16, 91.	1.1	26
1709	A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1621-1628.	1.2	5
1710	A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. European Journal of Cancer, 2016, 67, 11-20.	1.3	58
1711	Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. European Journal of Radiology, 2016, 85, 1867-1874.	1.2	99
1712	Efficacy and safety of oxaliplatin, bevacizumab and oral S-1 for advanced recurrent colorectal cancer. Molecular and Clinical Oncology, 2016, 5, 391-394.	0.4	3
1713	Pathological complete response after neoadjuvant chemotherapy for rectal cancer with synchronous multiple liver metastases: a report of an unusual case. Surgical Case Reports, 2016, 2, 106.	0.2	4
1714	Phase II Study of Olaparib (AZDâ€2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer. Oncologist, 2016, 21, 172-177.	1.9	58

#	Article	IF	Citations
1715	CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. International Journal of Clinical Oncology, 2016, 21, 1091-1101.	1.0	20
1716	Expression of DNA double-strand break repair proteins predicts the response and prognosis of colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Oncology Reports, 2016, 35, 1349-1355.	1.2	23
1717	<scp>PEPCOL</scp>: a <scp>GERCOR</scp> randomized phase <scp>II</scp> study of nanoliposomal irinotecan <scp>PEP</scp>02 (<scp>MM</scp>â€398) or irinotecan with leucovorin/5â€fluorouracil as secondâ€line therapy in metastatic colorectal cancer. Cancer Medicine, 2016, 5, 676-683.	1.3	44
1718	The rapidly escalating cost of treating colorectal cancer in <scp>A</scp>ustralia. Asia-Pacific Journal of Clinical Oncology, 2016, 12, 33-40.	0.7	24
1719	Testing ERBB2 p.L755S kinase domain mutation as a druggable target in a patient with advanced colorectal cancer. Journal of Physical Education and Sports Management, 2016, 2, a001016.	0.5	5
1720	Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. Visceral Medicine, 2016, 32, 178-183.	0.5	32
1721	Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opinion on Emerging Drugs, 2016, 21, 267-282.	1.0	7
1722	The Pharmacological Costs of First-Line Therapies in Unselected Patients With Advanced Colorectal Cancer: A Review of Published Phase III Trials. Clinical Colorectal Cancer, 2016, 15, 277-284.	1.0	16
1724	Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer, 2016, 122, 3191-3198.	2.0	14
1725	Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer. Acta OncolÃ³gica, 2016, 55, 1443-1449.	0.8	6
1726	Cost-Effectiveness Analysis of Different Sequences of the Use of Epidermal Growth Factor Receptor Inhibitors for Wild-Type KRAS Unresectable Metastatic Colorectal Cancer. Journal of Oncology Practice, 2016, 12, e710-e723.	2.5	20
1727	Decision-making in geriatric oncology: systemic treatment considerations for older adults with colon cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1321-1340.	1.4	17
1728	Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncology, The, 2016, 17, 1709-1719.	5.1	442
1729	Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. The Cochrane Library, 0, , .	1.5	0
1730	Management of patients with colorectal liver metastasis in eleven questions and answers. Expert Review of Anticancer Therapy, 2016, 16, 1277-1290.	1.1	3
1731	Role of pelvic radiotherapy for locally advanced rectal cancer and synchronous unresectable distant metastases. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 805-810.	0.6	9
1732	Systemic Therapy for Metastatic Colorectal Cancer. , 2016, , 275-338.		0
1733	The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer. Medicine (United States), 2016, 95, e5284.	0.4	4

#	Article	IF	Citations
1734	Rechallenge with 5-fluorouracil in a patient who developed encephalopathy caused by 5-fluorouracil for colon cancer. International Cancer Conference Journal, 2016, 5, 131-135.	0.2	2
1735	Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice. Clinical Colorectal Cancer, 2016, 15, 381-388.	1.0	48
1736	IGF1R and c-met as therapeutic targets for colorectal cancer. Biomedicine and Pharmacotherapy, 2016, 82, 528-536.	2.5	33
1737	Diffusion-Related MRI Parameters for Assessing Early Treatment Response of Liver Metastases to Cytotoxic Therapy in Colorectal Cancer. American Journal of Roentgenology, 2016, 207, W26-W32.	1.0	36
1739	Metastatic Colorectal Cancer in Hispanics: Treatment Outcomes in a Treated Population. Clinical Colorectal Cancer, 2016, 15, e221-e227.	1.0	9
1740	Multidisciplinary management of stage IV colon cancer. Seminars in Colon and Rectal Surgery, 2016, 27, 213-218.	0.2	2
1741	Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations. European Journal of Surgical Oncology, 2016, 42, 1378-1384.	0.5	10
1742	Current targeted therapies in the treatment of advanced colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 276-293.	1.4	72
1743	Chinese Herbal Medicine and Fluorouracil-Based Chemotherapy for Colorectal Cancer. Integrative Cancer Therapies, 2016, 15, 285-307.	0.8	13
1744	Phase II study of oxaliplatin combined with S-1 and leucovorin (SOL) for Chinese patients with metastatic colorectal cancer. Chinese Journal of Cancer, 2016, 35, 8.	4.9	2
1745	Prognostic significance of the pre-chemotherapy lymphocyte-to-monocyte ratio in patients with previously untreated metastatic colorectal cancer receiving FOLFOX chemotherapy. Chinese Journal of Cancer, 2016, 35, 5.	4.9	21
1746	Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5â€fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer. International Journal of Cancer, 2016, 139, 946-954.	2.3	8
1747	Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 2016, 78, 397-403.	1.1	9
1748	Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. The Cochrane Library, 2016, 2, CD008593.	1.5	16
1749	From Molecular Biology to Clinical Trials: Toward Personalized Colorectal Cancer Therapy. Clinical Colorectal Cancer, 2016, 15, 104-115.	1.0	20
1750	Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701). International Journal of Clinical Oncology, 2016, 21, 557-565.	1.0	11
1751	Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-Î±-dependent necroptosis driven by RIP1 kinase and NF-ÎºB. Oncogene, 2016, 35, 3399-3409.	2.6	92
1752	Current and advancing treatments for metastatic colorectal cancer. Expert Opinion on Biological Therapy, 2016, 16, 93-110.	1.4	31

#	Article	IF	Citations
1753	Regorafenib in the treatment of colorectal cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 137-145.	0.9	10
1754	TAS-102: a novel antimetabolite for the 21st century. Future Oncology, 2016, 12, 153-163.	1.1	17
1755	MGMT in colorectal cancer: a promising component of personalized treatment. Tumor Biology, 2016, 37, 11443-11456.	0.8	11
1756	Transarterial Therapy for Colorectal Liver Metastases. Surgical Clinics of North America, 2016, 96, 369-391.	0.5	11
1757	Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 2016, 16, 557-571.	1.1	7
1758	Development and validation of an UPLCâ€“MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: Application to a pharmacokinetic study of irinotecan in rats. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1015-1016, 34-41.	1.2	28
1759	DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer. Clinical Cancer Research, 2016, 22, 1621-1631.	3.2	13
1760	Life and treatment goals of patients with advanced, incurable cancer. Supportive Care in Cancer, 2016, 24, 2953-62.	1.0	29
1761	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2016, 34, 1723-1731.	0.8	289
1762	Understanding the FOLFOXIRI-regimen to optimize treatment for metastatic colorectal cancer. Critical Reviews in Oncology/Hematology, 2016, 100, 117-126.	2.0	1
1763	UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer. International Journal of Clinical Oncology, 2016, 21, 696-703.	1.0	13
1765	Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial. European Journal of Cancer, 2016, 53, 155-162.	1.3	123
1766	Pharmacologic resistance in colorectal cancer: a review. Therapeutic Advances in Medical Oncology, 2016, 8, 57-84.	1.4	385
1767	MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncology, 2016, 12, 453-464.	1.1	33
1768	AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin. Pharmacogenomics Journal, 2016, 16, 272-279.	0.9	16
1769	Clinical Practice Patterns in Chemotherapeutic Treatment Regimens for Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2016, 15, 135-140.	1.0	28
1770	Safety and efficacy of palliative systemic chemotherapy combined with colorectal self-expandable metallic stents in advanced colorectal cancer: A multicenter study. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 230-238.	0.7	20
1771	The efficacy and safety of capecitabine plus bevacizumab combination as first-line treatment in elderly metastatic colorectal cancer patients. Clinical and Translational Oncology, 2016, 18, 617-624.	1.2	3

#	Article	IF	Citations
1772	Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort. Targeted Oncology, 2016, 11, 83-92.	1.7	3
1773	Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). International Journal of Clinical Oncology, 2016, 21, 110-117.	1.0	3
1774	Phase <scp>II</scp> study of cetuximab with irinotecan for <scp>KRAS</scp> wildâ€type colorectal cancer in <scp>J</scp>apanese patients. Asia-Pacific Journal of Clinical Oncology, 2017, 13, e132-e137.	0.7	4
1775	Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma. Clinical Colorectal Cancer, 2017, 16, 78-83.	1.0	21
1776	Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in patients with resectable colon or metastatic colorectal cancer. Journal of Oncology Pharmacy Practice, 2017, 23, 163-172.	0.5	6
1777	The significance of extended lymphadenectomy for colorectal cancer with isolated synchronous extraregional lymph node metastasis. Asian Journal of Surgery, 2017, 40, 254-261.	0.2	31
1778	Efficacy and safety of neoadjuvant chemotherapy with oxaliplatin, 5-fluorouracil, and levofolinate for T3 or T4 stage II/III rectal cancer: the FACT trial. Cancer Chemotherapy and Pharmacology, 2017, 79, 519-525.	1.1	31
1779	Chemotherapy in Patients with Initially Unresectable Liver Metastasis of Colorectal Cancer. , 2017, , 213-223.		0
1780	Second-line systemic therapy for metastatic colorectal cancer. The Cochrane Library, 2017, 1, CD006875.	1.5	26
1781	New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targets. Autophagy, 2017, 13, 781-819.	4.3	117
1782	Phase II study of bevacizumab and irinotecan as second-line therapy for patients with metastatic colorectal cancer previously treated with fluoropyrimidines, oxaliplatin, and bevacizumab. Cancer Chemotherapy and Pharmacology, 2017, 79, 579-585.	1.1	13
1783	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2017, 23, 4146-4154.	3.2	50
1784	Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. European Journal of Cancer, 2017, 76, 68-75.	1.3	65
1785	Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab. Journal of Medical Genetics, 2017, 54, 567-571.	1.5	4
1786	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. Oncologist, 2017, 22, 293-303.	1.9	5
1787	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. BMC Cancer, 2017, 17, 48.	1.1	17
1788	Third-line treatment of colorectal liver metastases using DEBIRI chemoembolization. Medical Oncology, 2017, 34, 37.	1.2	15
1789	Annexin A1 is involved in resistance to 5-FU in colon cancer cells. Oncology Reports, 2017, 37, 235-240.	1.2	38

#	Article	IF	Citations
1790	Treatment Options in Colorectal Liver Metastases: Hepatic Arterial Infusion. Visceral Medicine, 2017, 33, 47-53.	0.5	22
1791	Population-based study on resection rates and survival in patients with colorectal liver metastasis in Norway. British Journal of Surgery, 2017, 104, 580-589.	0.1	40
1792	Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody. Oncology, 2017, 92, 205-212.	0.9	7
1793	Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Scientific Reports, 2017, 7, 682.	1.6	24
1794	Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. Expert Opinion on Pharmacotherapy, 2017, 18, 753-758.	0.9	12
1795	FOLFOX and intensified split-course chemoradiation as initial treatment for rectal cancer with synchronous metastases. Acta OncolÃ³gica, 2017, 56, 646-652.	0.8	8
1796	Resection of colorectal liver metastases after second-line chemotherapy: is it worthwhile? A LiverMetSurvey analysis of 6415 patients. European Journal of Cancer, 2017, 78, 7-15.	1.3	42
1797	A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation. British Journal of Cancer, 2017, 116, 1279-1286.	2.9	37
1798	How health-related quality of life assessment should be used in advanced colorectal cancer clinical trials. Annals of Oncology, 2017, 28, 2077-2085.	0.6	30
1799	Treatment of Patients With Metastatic Colorectal Cancer in a Real-World Scenario: Probability of Receiving Second and Further Lines of Therapy and Description of Clinical Benefit. Clinical Colorectal Cancer, 2017, 16, 372-376.	1.0	19
1800	Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer. Cancer Science, 2017, 108, 455-460.	1.7	48
1801	Impact of chemotherapy on gastrointestinal functions and the enteric nervous system. Maturitas, 2017, 105, 23-29.	1.0	43
1802	Current status and future perspectives on treatment of liver metastasis in colorectal cancer. Oncology Reports, 2017, 37, 2553-2564.	1.2	98
1803	Clinical Features and Outcomes of Patients with Colorectal Cancers Harboring NRAS Mutations. Clinical Cancer Research, 2017, 23, 4753-4760.	3.2	56
1804	Resection of the Primary Tumor in Stage IV Colorectal Cancer. Surgical Clinics of North America, 2017, 97, 657-669.	0.5	42
1805	Hepatotoxicity following systemic therapy for colorectal liver metastases and the impact of chemotherapy-associated liver injury on outcomes after curative liver resection. European Journal of Surgical Oncology, 2017, 43, 1668-1681.	0.5	45
1806	Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2376.	3.8	3
1807	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer. JAMA - Journal of the American Medical Association, 2017, 317, 2392.	3.8	670

#	Article	IF	Citations
1808	Resistance Mechanisms to Colorectal Cancer Therapeutics and the Clinical Implications. Current Colorectal Cancer Reports, 2017, 13, 334-340.	1.0	1
1809	Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 81-90.	1.1	6
1810	UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis. Cancer Chemotherapy and Pharmacology, 2017, 80, 135-149.	1.1	34
1811	Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. Cancer Science, 2017, 108, 1504-1509.	1.7	6
1812	The combination of systemic chemotherapy and local treatment may improve the survival of patients with unresectable metastatic colorectal cancer. Molecular and Clinical Oncology, 2017, 6, 856-860.	0.4	7
1813	Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data. Seminars in Interventional Radiology, 2017, 34, 145-166.	0.3	18
1814	Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. Journal of Infection and Chemotherapy, 2017, 23, 493-497.	0.8	5
1815	Hepatic metastasis from colorectal cancer. , 2017, , 1339-1354.e4.		1
1816	FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. Clinical Colorectal Cancer, 2017, 16, 405-409.e2.	1.0	11
1817	Recent improvement of survival prognosis after pulmonary metastasectomy and advanced chemotherapy for patients with colorectal cancer. European Journal of Cardio-thoracic Surgery, 2017, 51, 869-873.	0.6	21
1818	Volumetric Versus Unidimensional Measures of Metastatic Colorectal Cancer in Assessing Disease Response. Clinical Colorectal Cancer, 2017, 16, 324-333.e1.	1.0	8
1819	Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases. Oncology, 2017, 92, 135-141.	0.9	5
1820	Pregnane X receptor is associated with unfavorable survival and induces chemotherapeutic resistance by transcriptional activating multidrug resistance-related protein 3 in colorectal cancer. Molecular Cancer, 2017, 16, 71.	7.9	23
1822	Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, 286-292.	1.0	6
1823	Intraarterial Therapy Using Micellar Nanoparticles Incorporating SN-38 in a Rabbit Liver Tumor Model. Journal of Vascular and Interventional Radiology, 2017, 28, 457-464.	0.2	2
1824	Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles. Therapeutic Delivery, 2017, 8, 29-47.	1.2	15
1827	Human microbiome signatures of differential colorectal cancer drug metabolism. Npj Biofilms and Microbiomes, 2017, 3, 27.	2.9	103
1828	Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients. Cancer Genetics, 2017, 218-219, 51-57.	0.2	14

#	Article	IF	Citations
1829	Evaluating Personalized Medicine in Multi-marker Multi-treatment Clinical Trials: Accounting for Heterogeneity. , 2017, , 125-149.		0
1831	Risk of Febrile Neutropenia Associated With Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1122-1130.	2.3	10
1832	The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. European Journal of Surgical Oncology, 2017, 43, 2001-2011.	0.5	18
1833	Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2017, 118, 54-62.	2.0	54
1834	Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Scientific Reports, 2017, 7, 10426.	1.6	8
1835	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients. European Journal of Cancer, 2017, 83, 106-115.	1.3	25
1836	Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatinâ€based chemotherapy in patients with metastatic colorectal cancer. Cancer, 2017, 123, 4506-4514.	2.0	8
1838	Using MRI to non-invasively and accurately quantify preoperative hepatic steatosis. Hpb, 2017, 19, 706-712.	0.1	4
1839	Exposureâ€“response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. Cancer Chemotherapy and Pharmacology, 2017, 80, 599-608.	1.1	18
1840	Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open, 2017, 2, e000147.	2.0	36
1841	European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open, 2017, 2, e000190.	2.0	13
1842	S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study. ESMO Open, 2017, 2, e000135.	2.0	17
1843	Recent developments in the treatment of metastatic colorectal cancer. Therapeutic Advances in Medical Oncology, 2017, 9, 551-564.	1.4	82
1844	Conversion and Neoadjuvant Therapies. , 2017, , 79-118.		0
1845	An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surgical Oncology Clinics of North America, 2017, 26, 667-687.	0.6	24
1846	Treatment of metastatic refractory colorectal cancer following regorafenib failure. Molecular and Clinical Oncology, 2017, 7, 308-312.	0.4	6
1847	Evidence-Based Review of Nonsurgical Management of Colorectal Cancer Liver Metastasis and Evolving Role of Interventional Radiology. Digestive Disease Interventions, 2017, 01, 184-194.	0.3	0
1848	ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Scientific Reports, 2017, 7, 14470.	1.6	44

#	Article	IF	Citations
1849	The potential role of nintedanib in treating colorectal cancer. Expert Opinion on Pharmacotherapy, 2017, 18, 1153-1162.	0.9	15
1850	Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen. Chemotherapy, 2017, 62, 215-224.	0.8	5
1851	Liposomal prednisolone phosphate potentiates the antitumor activity of liposomal 5-fluorouracil in C26 murine colon carcinomain vivo. Cancer Biology and Therapy, 2017, 18, 616-626.	1.5	11
1852	Sequential administration of XELOX and XELIRI is effective, feasible and well tolerated by patients with metastatic colorectal cancer. Oncology Letters, 2017, 13, 4947-4952.	0.8	4
1853	Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Annals of Medicine and Surgery, 2017, 20, 19-25.	0.5	13
1854	Antibody targeting of claudin-1 as a potential colorectal cancer therapy. Journal of Experimental and Clinical Cancer Research, 2017, 36, 89.	3.5	48
1855	Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis. Oncologist, 2017, 22, 694-699.	1.9	27
1856	Heterogeneity of Tumor Sizes in Multiple Pulmonary Metastases of Colorectal Cancer as a Prognostic Factor. Annals of Thoracic Surgery, 2017, 103, 254-260.	0.7	5
1857	A Comparison of Survival by Site of Metastatic Resection in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2017, 16, e23-e28.	1.0	4
1858	ABBV-399, a c-Met Antibodyâ€“Drug Conjugate that Targets Both METâ€“Amplified and c-Metâ€“Overexpressing Tumors, Irrespective of MET Pathway Dependence. Clinical Cancer Research, 2017, 23, 992-1000.	3.2	87
1859	Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison. Clinical Colorectal Cancer, 2017, 16, e15-e22.	1.0	64
1860	Effectiveness and safety of aflibercept for metastatic colorectal cancer: retrospective review within an early access program in Spain. Clinical and Translational Oncology, 2017, 19, 498-507.	1.2	15
1861	Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. Annals of Surgery, 2017, 265, 158-165.	2.1	115
1862	Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Therapeutic Advances in Medical Oncology, 2017, 9, 106-126.	1.4	36
1863	The impact of bevacizumab in metastatic colorectal cancer with an intact primary tumor: Results from a large prospective cohort study. Asia-Pacific Journal of Clinical Oncology, 2017, 13, 314-321.	0.7	7
1864	Emergency use of uridine triacetate for the prevention and treatment of lifeâ€threatening 5â€fluorouracil and capecitabine toxicity. Cancer, 2017, 123, 345-356.	2.0	91
1865	Hedyotis diffusa willd extract suppresses colorectal cancer growth through multiple cellular pathways. Oncology Letters, 2017, 14, 8197-8205.	0.8	21
1866	Efficacy and safety of FOLFIRI and biotherapy versus FOLFIRI alone for metastatic colorectal cancer patients. Medicine (United States), 2017, 96, e8767.	0.4	3

#	Article	IF	Citations
1867	Continuum of care strategy in metastatic colorectal cancer: a review. Colorectal Cancer, 2017, 6, 95-103.	0.8	0
1868	Upregulated HOXA9 expression is associated with lymph node metastasis in colorectal cancer. Oncology Letters, 2018, 15, 2756-2762.	0.8	17
1869	Conversion Therapy for Initially Borderline/Unresectable Metastases in Colon Cancer: What Is the Best Neoadjuvant Chemotherapy?. Current Colorectal Cancer Reports, 2017, 13, 419-428.	1.0	1
1870	Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. Journal of the National Cancer Institute, 2017, 109, .	3.0	466
1871	Impact of the individualization of the firstâ€line chemotherapy for advanced colorectal cancer based on collagen gel dropletâ€embedded drug sensitivity test. Oncology Letters, 2017, 14, 6045-6052.	0.8	6
1873	<i>TBX19</i> is overexpressed in colorectal cancer and associated with lymph node metastasis. Fukushima Journal of Medical Sciences, 2017, 63, 141-151.	0.1	11
1874	Spinal bone metastases in colorectal cancer: a retrospective analysis of stability, prognostic factors and survival after palliative radiotherapy. Radiation Oncology, 2017, 12, 115.	1.2	17
1875	Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board. JCO Precision Oncology, 2017, 1, 1-10.	1.5	18
1876	Anticancer effects of phytocannabinoids used with chemotherapy in leukaemia cells can be improved by altering the sequence of their administration. International Journal of Oncology, 2017, 51, 369-377.	1.4	56
1877	Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school. BMC Cancer, 2017, 17, 691.	1.1	7
1878	Impact of nutritional status in the era of FOLFOX/FIRI-based chemotherapy. World Journal of Surgical Oncology, 2017, 15, 162.	0.8	11
1879	Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy and Practice, 2017, 2, 238146831772965.	0.5	3
1880	Chemotherapies and future directions in metastatic colorectal cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 141-145.	0.3	0
1881	Enhanced expression of KIF4A in colorectal cancer is associated with lymph node metastasis. Oncology Letters, 2017, 15, 2188-2194.	0.8	17
1882	Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis. Oncology Letters, 2017, 15, 2065-2072.	0.8	6
1883	Herbal prescription, Danggui-Sayuk-Ga-Osuyu-Senggang-Tang, inhibits TNF-Î±-induced epithelial-mesenchymal transition in HCT116 colorectal cancer cells. International Journal of Molecular Medicine, 2017, 41, 373-380.	1.8	7
1884	Potential predictive factors for pathologic complete response after the neoadjuvant treatment of rectal adenocarcinoma: a single center experience. Cancer Biology and Medicine, 2017, 14, 327.	1.4	6
1885	Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Medicine and Pharmacy Reports, 2017, 90, 377-384.	0.2	3

#	Article	IF	Citations
1886	Thymidine phosphorylase expression and prognosis in colorectal cancer treated with 5â€‘fluorouracilâ€‘based chemotherapy: A metaâ€‘analysis. Molecular and Clinical Oncology, 2017, 7, 943-952.	0.4	19
1887	Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecanâ€‘induced toxicity in patients with cancer. Oncology Letters, 2017, 14, 5743-5752.	0.8	9
1888	Emerging combination therapies for metastatic colorectal cancer – impact of trifluridine/tipiracil. Cancer Management and Research, 2017, Volume 9, 461-469.	0.9	8
1889	Resistance mechanisms to drug therapy in breast cancer and other solid tumors: An opinion. F1000Research, 2017, 6, 288.	0.8	25
1890	Network meta-analysis of the efficacy of first-line chemotherapy regimens in patients with advanced colorectal cancer. Oncotarget, 2017, 8, 100668-100677.	0.8	8
1891	Systemic Therapy for Metastatic Colorectal Cancer: From Current Standards to Future Molecular Targeted Approaches. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 246-256.	1.8	20
1892	HedyotisÃ¯Â¿Â½diffusa Willd inhibits proliferation and induces apoptosis of 5â€FU resistant colorectal cancer cells by regulating the PI3K/AKT signaling pathway. Molecular Medicine Reports, 2017, 17, 358-365.	1.1	19
1893	Biologics in bowel cancer. Journal of Gastrointestinal Oncology, 2017, 8, 449-456.	0.6	4
1894	Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 65-72.	0.6	23
1895	Surgical Treatment following Chemo-Targeted Therapy with Bevacizumab for Lung Metastasis from Colorectal Carcinoma: Analysis of Safety and Histological Therapeutic Effects in Patients Treated at a Single Institution. Case Reports in Oncology, 2018, 11, 98-108.	0.3	3
1896	Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. Pharmacoeconomics, 2018, 36, 837-851.	1.7	18
1897	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. Journal of Immunotherapy, 2018, 41, 284-291.	1.2	11
1898	Recent advances in treatment for colorectal liver metastasis. Annals of Gastroenterological Surgery, 2018, 2, 167-175.	1.2	36
1899	Multivariate joint frailty model for the analysis of nonlinear tumor kinetics and dynamic predictions of death. Statistics in Medicine, 2018, 37, 2148-2161.	0.8	7
1900	Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San JosÃ©, Costa Rica, August 2016. ESMO Open, 2018, 3, e000315.	2.0	10
1901	A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study. Cancer Chemotherapy and Pharmacology, 2018, 81, 1035-1041.	1.1	3
1902	The best strategy for RAS wild-type metastatic colorectal cancer patients in first-line treatment: A classic and Bayesian meta-analysis. Critical Reviews in Oncology/Hematology, 2018, 125, 69-77.	2.0	17
1904	Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance. Stem Cell Research, 2018, 27, 109-120.	0.3	60

#	Article	IF	Citations
1905	Long-term survival in a patient with Virchowâ€™s lymph node metastasis of cecal cancer. International Cancer Conference Journal, 2018, 7, 1-5.	0.2	0
1906	A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, e257-e268.	1.0	6
1907	UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2018, 82, 87-98.	1.1	12
1909	Preoperative Chemotherapy May Not Influence the Remnant Liver Regenerations and Outcomes After Hepatectomy for Colorectal Liver Metastasis. World Journal of Surgery, 2018, 42, 3316-3330.	0.8	13
1910	Radiologic and pathologic response to neoadjuvant chemotherapy predicts survival in patients undergoing the liver-first approach for synchronous colorectal liver metastases. European Journal of Surgical Oncology, 2018, 44, 1069-1077.	0.5	16
1911	Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 5 colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology, The, 2018, 19, 660-671.	5.1	107
1912	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
1913	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2018, 23, 1-34.	1.0	1,187
1914	A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist, 2018, 23, 25-34.	1.9	63
1915	Some chemotherapeutics-treated colon cancer cells display a specific phenotype being a combination of stem-like and senescent cell features. Cancer Biology and Therapy, 2018, 19, 63-75.	1.5	56
1916	Conversion to Resection in Patients Receiving Systemic Chemotherapy for Unresectable and/or Metastatic Colorectal Cancerâ€”Predictive Factors and Prognosis. Clinical Colorectal Cancer, 2018, 17, e91-e97.	1.0	18
1917	Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, openâ€label, singleâ€arm, noncomparative trial. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 61-68.	0.7	8
1918	Combination of Irinotecan, Oxaliplatin and 5-Fluorouracil as a Rechallenge Regimen for Heavily Pretreated Metastatic Colorectal Cancer Patients. Journal of Gastrointestinal Cancer, 2018, 49, 470-475.	0.6	12
1919	Fabrication and Use of Poly(d,l-lactide-co-glycolide)-Based Formulations Designed for Modified Release of 5-Fluorouracil. Journal of Pharmaceutical Sciences, 2018, 107, 513-528.	1.6	30
1920	Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study. Oncology, 2018, 94, 19-24.	0.9	25
1921	Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer. Case Reports in Oncology, 2018, 10, 1029-1034.	0.3	6
1922	Determination of irinotecan and its metabolite SN-38 in dried blood spots using high-performance liquid-chromatography with fluorescence detection. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 51-58.	1.4	21
1923	Phase 2 study of treatment selection based on tumor thymidylate synthase expression in previously untreated patients with metastatic colorectal cancer: A trial of the ECOGâ€ACRIN Cancer Research Group (E4203). Cancer, 2018, 124, 688-697.	2.0	6

#	Article	IF	Citations
1924	External Beam Re-irradiation in Rectal Cancer. Clinical Oncology, 2018, 30, 116-123.	0.6	17
1925	Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma. Clinical Colorectal Cancer, 2018, 17, e189-e199.	1.0	24
1926	Systemic Therapy for Colon Cancer. Surgical Oncology Clinics of North America, 2018, 27, 235-242.	0.6	113
1927	Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study. Clinical Colorectal Cancer, 2018, 17, e99-e107.	1.0	2
1928	Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx^{Â®}): a placebo-controlled randomised phase II study (PLIANT). Acta OncolÃ³gica, 2018, 57, 393-402.	0.8	69
1929	Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review. Cancer Treatment Reviews, 2018, 62, 61-73.	3.4	47
1930	Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. In Vivo, 2018, 32, 151-158.	0.6	48
1931	Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. Oncotarget, 2018, 9, 18698-18711.	0.8	127
1932	Beyond the Knife: The Evolving Nonsurgical Management of Oligometastatic Colorectal Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 209-219.	1.8	7
1933	Treatment Strategies in Colorectal Cancer. , 2018, , .		1
1934	Impact of primary tumor location as a predictive factor in patients suffering from colorectal cancer treated with cytotoxic anticancer agents based on the collagen gel dropletâ€‘embedded drug sensitivity test. Oncology Letters, 2019, 17, 1842-1850.	0.8	6
1935	Therapeutic efficacy of systemic therapy for colorectal peritoneal carcinomatosis: surgeonâ€™s perspective. Pleura and Peritoneum, 2018, 3, 20180102.	0.5	20
1936	Local Treatment Options for Unresectable Liver Metastases in Colorectal Cancer. , 0, , .		0
1937	Role of Bacterial Translocation in the Progressive and Delayed Irinotecan Induced Diarrhea.. , 2018, 08, .		0
1938	Survival differences with immediate versus delayed chemotherapy for asymptomatic incurable metastatic colorectal cancer. The Cochrane Library, 2018, 2018, CD012326.	1.5	5
1939	Analysis of Mutational Spectra in Metastatic Colorectal Carcinoma: KRAS as an Indicator of Oxaliplatin-Based Chemotherapy. International Surgery, 2018, 103, 27-35.	0.0	2
1940	Radiofrequency ablation with systemic chemotherapy in the treatment of colorectal cancer liver metastasis: a 10-year single-center study. Cancer Management and Research, 2018, Volume 10, 5227-5237.	0.9	13
1942	Pathological complete response to mFOLFOX6 plus cetuximab therapy for unresectable colon cancer with multiple paraaortic lymph node metastases. Molecular and Clinical Oncology, 2018, 9, 587-591.	0.4	3

#	Article	IF	Citations
1943	Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations. ESMO Open, 2018, 3, e000399.	2.0	6
1944	Wnt Signalling-Targeted Therapy in the CMS2 Tumour Subtype: A New Paradigm in CRC Treatment?. Advances in Experimental Medicine and Biology, 2018, 1110, 75-100.	0.8	7
1945	Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-11.	0.8	33
1946	Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines. Scientific Reports, 2018, 8, 17744.	1.6	19
1947	17 Management of Liver Metastases. , 2018, , .		0
1949	FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial. European Journal of Cancer, 2018, 104, 108-116.	1.3	17
1950	Impact of Delayed Addition of Anti-EGFR Monoclonal Antibodies on the Outcome of First-Line Therapy in Metastatic Colorectal Cancer Patients: a Retrospective Registry-Based Analysis. Targeted Oncology, 2018, 13, 735-743.	1.7	6
1951	Treatment of patients with metastatic colorectal cancer and poor performance status: current evidence and challenges. Clinics, 2018, 73, e542s.	0.6	9
1952	miR-329 regulates the sensitivity of 5-FU in chemotherapy of colorectal cancer by targeting E2F1. Oncology Letters, 2018, 16, 3587-3592.	0.8	15
1953	First-line therapies in metastatic colorectal cancer: integrating clinical benefit with the costs of drugs. International Journal of Colorectal Disease, 2018, 33, 1505-1516.	1.0	7
1954	Network Meta-Analysis of Adjuvant Chemotherapy following Resection of Colorectal Liver Metastases. Gastrointestinal Tumors, 2018, 5, 21-31.	0.3	2
1955	Clinical significance of the globulinâ€toâ€albumin ratio for prediction of postoperative survival in patients with colorectal cancer. Annals of Gastroenterological Surgery, 2018, 2, 434-441.	1.2	14
1956	Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. ESMO Open, 2018, 3, e000411.	2.0	13
1957	Does the assessment of the quality of life in metastatic colon cancer in clinical practice make sense? Voice for discussion. Psychoonkologia, 2018, 22, 63-67.	0.1	0
1958	A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 1193-1198.	0.6	21
1959	Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. Clinical Colorectal Cancer, 2018, 17, 280-284.	1.0	33
1960	Use of Jianpi Jiedu Herbs in Patients with Advanced Colorectal Cancer: A Systematic Review and Meta-Analysis. Evidence-based Complementary and Alternative Medicine, 2018, 2018, 1-13.	0.5	19
1961	Practical fluorimetric assay for the detection of anticancer drug SN-38 in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2018, 159, 73-81.	1.4	7

#	Article	IF	Citations
1962	Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. Pharmacogenomics Journal, 2018, 18, 623-632.	0.9	8
1963	New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. International Journal of Medical Sciences, 2018, 15, 659-665.	1.1	59
1964	Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in Pharmacology, 2018, 9, 367.	1.6	24
1965	Chrysin Attenuates Cell Viability of Human Colorectal Cancer Cells through Autophagy Induction Unlike 5-Fluorouracil/Oxaliplatin. International Journal of Molecular Sciences, 2018, 19, 1763.	1.8	28
1966	Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2018, 18, 991-1006.	1.1	44
1967	Human Thymidylate Synthase Inhibitors Halting Ovarian Cancer Growth. Vitamins and Hormones, 2018, 107, 473-513.	0.7	12
1968	Impact of Primary Tumor Location on First-line Bevacizumab or Cetuximab in Metastatic Colorectal Cancer. Reviews on Recent Clinical Trials, 2018, 13, 139-149.	0.4	23
1969	Peritoneal Metastases in Colorectal Cancer. Annals of Surgical Oncology, 2018, 25, 2145-2151.	0.7	23
1970	Phase IB/II Study of Second-Line Therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS Wild-Type Metastatic Colorectal Cancer. Clinical Cancer Research, 2018, 24, 3838-3844.	3.2	7
1971	A correlation study of fluorouracil pharmacodynamics with clinical efficacy and toxicity. Tumori, 2018, 104, 157-164.	0.6	8
1972	The prognostic value of the systemic inflammatory score in patients with unresectable metastatic colorectal cancer. Oncology Letters, 2018, 16, 666-672.	0.8	9
1973	Expression of ILT3 predicts poor prognosis and is inversely associated with infiltration of CD45RO+ T cells in patients with colorectal cancer. Pathology Research and Practice, 2018, 214, 1621-1625.	1.0	9
1974	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Annals of Oncology, 2018, 29, 1800-1806.	0.6	32
1975	Improving Selection for Resection of Synchronous Para-Aortic Lymph Node Metastases in Colorectal Cancer. Digestive Surgery, 2019, 36, 369-375.	0.6	25
1976	MR texture analysis: potential imaging biomarker for predicting the chemotherapeutic response of patients with colorectal liver metastases. Abdominal Radiology, 2019, 44, 65-71.	1.0	49
1977	Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracilâ€based adjuvant chemotherapy benefit. FASEB Journal, 2019, 33, 151-162.	0.2	29
1978	Successful desensitization of a patient with cetuximab hypersensitivity: A case report. Journal of Oncology Pharmacy Practice, 2019, 25, 1726-1730.	0.5	5
1979	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. Cancer and Metastasis Reviews, 2019, 38, 307-313.	2.7	38

#	Article	IF	Citations
1980	Induced miRâ€31 by 5â€fluorouracil exposure contributes to the resistance in colorectal tumors. Cancer Science, 2019, 110, 2540-2548.	1.7	14
1981	Evaluation of the 5â€‘fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy. Molecular and Clinical Oncology, 2019, 11, 289-295.	0.4	3
1982	Selective TACE with irinotecan-loaded 40 Î¼m microspheres and FOLFIRI for colorectal liver metastases: phase I dose escalation pharmacokinetic study. BMC Cancer, 2019, 19, 758.	1.1	11
1983	Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer, 2019, 125, 4139-4147.	2.0	299
1984	Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treatment and Research, 2019, 179, 87-101.	0.2	45
1985	Current Trends in Systemic Therapies in Elderly Patients With Metastatic Colorectal Cancer. Current Colorectal Cancer Reports, 2019, 15, 105-111.	1.0	1
1987	Circulating Noncoding RNAs Have a Promising Future Acting as Novel Biomarkers for Colorectal Cancer. Disease Markers, 2019, 2019, 1-13.	0.6	9
1988	Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 320.	3.5	81
1989	Liver-Directed and Systemic Therapies for Colorectal Cancer Liver Metastases. CardioVascular and Interventional Radiology, 2019, 42, 1240-1254.	0.9	7
1990	Colorectal cancer in adolescents and young adults: Defining a growing threat. Pediatric Blood and Cancer, 2019, 66, e27941.	0.8	29
1992	Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?. CardioVascular and Interventional Radiology, 2019, 42, 1213-1220.	0.9	10
1994	Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients. Science Translational Medicine, 2019, 11, .	5.8	451
1995	Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion. Journal of Gastrointestinal Oncology, 2019, 10, 1010-1014.	0.6	7
1996	Prognostic factors of radiofrequency ablation therapy for liver metastases from colorectal cancer. Advances in Digestive Medicine, 2019, 6, 101-108.	0.1	1
1997	Use of perioperative chemotherapy in colorectal cancer metastatic to the liver. Gastroenterology Report, 2019, 7, 301-311.	0.6	16
1998	CA19-9 Concentration After First-line Chemotherapy Is Prognostic Predictor of Metastatic Colon Cancer. In Vivo, 2019, 33, 2087-2093.	0.6	3
1999	Quality of Life for Patients With Incurable Stage IV Colorectal Cancer: Randomized Controlled Trial Comparing Resection Versus Endoscopic Stenting. In Vivo, 2019, 33, 2065-2070.	0.6	15
2000	Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (<i>UGT1A1</i>). Biological and Pharmaceutical Bulletin, 2019, 42, 1839-1845.	0.6	6

#	Article	IF	Citations
2001	Evaluation and Clinical Significance of Jagged-1-activated Notch Signaling by APEX1 in Colorectal Cancer. Anticancer Research, 2019, 39, 6097-6105.	0.5	12
2002	KRAS codon 12 and 13 mutations may guide the selection of irinotecan or oxaliplatin in first-line treatment of metastatic colorectal cancer. Expert Review of Molecular Diagnostics, 2019, 19, 1131-1140.	1.5	9
2003	Cost-Effectiveness Analysis of Selective First-Line Use of Biologics for Unresectable RAS Wild-Type Left-Sided Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 597-609.	0.9	3
2004	miRâ€210â€3p mediates metabolic adaptation and sustains DNA damage repair of resistant colon cancer cells to treatment with 5â€fluorouracil. Molecular Carcinogenesis, 2019, 58, 2181-2192.	1.3	11
2005	KOOLSâ€“IFU: Kyoto Okayama Optical Low-dispersion Spectrograph with optical-fiber Integral Field Unit. Publication of the Astronomical Society of Japan, 2019, 71, .	1.0	36
2006	Efficacy and safety of antiâ€EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wildâ€type metastatic colorectal cancer: A metaâ€analysis. Journal of Evidence-Based Medicine, 2019, 12, 300-312.	0.7	10
2007	Comparative Efficacy of Preoperative, Postoperative, and Perioperative Treatments for Resectable Colorectal Liver Metastases: A Network Meta-Analysis. Frontiers in Pharmacology, 2019, 10, 1052.	1.6	3
2008	How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 1189.	1.7	4
2009	Combination chemotherapy with TASâ€102 plus bevacizumab in salvageâ€line treatment of metastatic colorectal cancer: A singleâ€center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvageâ€line therapy of metastatic colorectal cancer. Molecular and Clinical Oncology, 2019, 11, 390-396.	0.4	5
2010	Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. Journal of Global Oncology, 2019, 5, 1-6.	0.5	1
2011	Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer . Cancer Management and Research, 2019, Volume 11, 7787-7803.	0.9	33
2012	Evaluation of Continuous Tumor-Sizeâ€“Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2019, 2, e1911750.	2.8	6
2013	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	1.7	15
2014	Outcome of chemotherapy with or without targeted agents in metastatic colorectal cancer patients with deficient DNA mismatch repair: A single center, cohort study. Asia-Pacific Journal of Clinical Oncology, 2019, 15, 128-135.	0.7	4
2015	Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1110-1117.	0.7	7
2016	Treatment sequencing in metastatic colorectal cancer. European Journal of Cancer, 2019, 109, 70-83.	1.3	215
2017	Impact of pelvic bone marrow irradiation on the hematological toxicity of subsequent chemotherapy in rectal cancer. Neoplasma, 2019, 66, 276-280.	0.7	1
2018	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release, 2019, 307, 108-138.	4.8	49

#	Article	IF	Citations
2019	Natural products for treating colorectal cancer: A mechanistic review. Biomedicine and Pharmacotherapy, 2019, 117, 109142.	2.5	116
2020	Identification of a 13â€‘geneâ€‘based classifier as a potential biomarker to predict the effects of fluorouracilâ€‘based chemotherapy in colorectal cancer. Oncology Letters, 2019, 17, 5057-5063.	0.8	4
2021	Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study). International Journal of Clinical Oncology, 2019, 24, 1223-1230.	1.0	9
2022	High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy. Medical Oncology, 2019, 36, 63.	1.2	3
2023	Role of Hepatic Artery Infusion Chemotherapy in Treatment of Initially Unresectable Colorectal Liver Metastases. JAMA Surgery, 2019, 154, 768.	2.2	84
2024	Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2019, 10, 412-420.	0.6	6
2025	CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Molecular Cancer, 2019, 18, 91.	7.9	449
2026	Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wildâ€type KRAS exon 2 metastatic colorectal cancer. Cancer Medicine, 2019, 8, 3437-3446.	1.3	12
2027	Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4	1.2	
2028	Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2019, 1871, 434-454.	3.3	131
2029	Explaining the unexplainable: discrepancies in results from the CALGB/SWOG 80405 and FIRE-3 studies. Lancet Oncology, The, 2019, 20, e274-e283.	5.1	42
2030	Selecting treatment options in refractory metastatic colorectal cancer . OncoTargets and Therapy, 2019, Volume 12, 2271-2278.	1.0	20
2031	Induction of CD3+ and FoxP3+ T Cells in Left-sided Colorectal Tumors After UFT/LV Chemotherapy. Anticancer Research, 2019, 39, 1997-2005.	0.5	2
2032	Efficacy of combination therapy with zoledronic acid and cetuximab for unresectable rectal cancer with bone metastases: A case report. Molecular and Clinical Oncology, 2019, 10, 571-574.	0.4	3
2033	Adjuvant chemotherapy improves prognosis of resectable stage IV colorectal cancer: a comparative study using inverse probability of treatment weighting. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983896.	1.4	6
2034	FOLFOXIRI plus biologics in advanced colorectal cancer. Expert Opinion on Biological Therapy, 2019, 19, 411-422.	1.4	4
2035	The prognostic significance of the advanced lung cancer inflammation index in patients with unresectable metastatic colorectal cancer: a retrospective study. BMC Cancer, 2019, 19, 241.	1.1	34
2036	Uridine triacetate - an antidote in the treatment of 5-fluorouracil or capecitabine poisoning. Expert Opinion on Orphan Drugs, 2019, 7, 95-103.	0.5	2

#	Article	IF	Citations
2037	FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer, 2019, 18, 133-140.	1.0	44
2038	Phase <scp>II</scp> trial of aflibercept with <scp>FOLFIRI</scp> as a secondâ€line treatment for Japanese patients with metastatic colorectal cancer. Cancer Science, 2019, 110, 1032-1043.	1.7	30
2039	Development and validation of a novel prognostic score to predict survival in patients with metastatic colorectal cancer: the metastatic colorectal cancer score (mCCS). Colorectal Disease, 2019, 21, 816-826.	0.7	3
2040	Primary Tumor Resection in Patients with Incurable Localized or Metastatic Colorectal Cancer: A Systematic Review and Metaâ€analysis. World Journal of Surgery, 2019, 43, 1829-1840.	0.8	33
2041	Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer. Anticancer Research, 2019, 39, 1347-1353.	0.5	7
2042	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. Journal of Surgical Oncology, 2019, 119, 642-652.	0.8	28
2043	Impact of laterality and mucinous histology on relapse-free and overall survival in a registry-based colon cancer series. Scientific Reports, 2019, 9, 3668.	1.6	7
2044	Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies . Cancer Management and Research, 2019, Volume 11, 1705-1716.	0.9	22
2045	Efficacy of Second-Line Chemotherapy after a First-Line Triplet in Patients with Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 4217.	0.9	4
2046	A Review on the Scope of Photothermal Therapyâ€“Based Nanomedicines in Preclinical Models of Colorectal Cancer. Clinical Colorectal Cancer, 2019, 18, e200-e209.	1.0	61
2047	Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety. International Journal of Clinical Oncology, 2019, 24, 836-841.	1.0	3
2048	Systemic treatment for metastatic colorectal cancer in the era of precision medicine. Journal of Surgical Oncology, 2019, 119, 564-582.	0.8	55
2049	The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer. Disease Markers, 2019, 2019, 1-8.	0.6	16
2050	Historical perspective: Two decades of progress in treating metastatic colorectal cancer. Journal of Surgical Oncology, 2019, 119, 549-563.	0.8	45
2051	How we treat metastatic colorectal cancer. ESMO Open, 2019, 4, e000813.	2.0	49
2052	Palliative chemotherapy for patients with synchronous metastases of smallâ€bowel adenocarcinoma: A reflection of daily practice. United European Gastroenterology Journal, 2019, 7, 1380-1388.	1.6	2
2053	Health and Economic Impact of Intensive Surveillance for Distant Recurrence After Curative Treatment of Colon Cancer: A Mathematical Modeling Study. Diseases of the Colon and Rectum, 2019, 62, 872-881.	0.7	4
2054	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. Frontiers in Oncology, 2019, 9, 1312.	1.3	14

#	Article	IF	Citations
2055	Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma. Anticancer Research, 2019, 39, 6781-6786.	0.5	5
2056	The efficacy and safety of irinotecanâ€ŠÂ±â€Šbevacizumab compared with oxaliplatinâ€ŠÂ±â€Šbevacizumab for metastatic colorectal cancer. Medicine (United States), 2019, 98, e17384.	0.4	6
2057	Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease. Current Oncology, 2019, 26, 24-32.	0.9	11
2058	Current and Emerging Biomarkers in Metastatic Colorectal Cancer. Current Oncology, 2019, 26, 7-15.	0.9	31
2059	Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. British Journal of Cancer, 2019, 120, 190-195.	2.9	31
2060	Musculoskeletal Metastasis from Primary Rectal Cancer: Series of Two Cases of a Very Rare Occurrence with a Short Literature Review. Journal of Gastrointestinal Cancer, 2019, 50, 991-996.	0.6	2
2061	Current status of immunotherapy in metastatic colorectal cancer. International Journal of Colorectal Disease, 2019, 34, 13-25.	1.0	106
2062	Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan. JAMA Oncology, 2019, 5, 343.	3.4	280
2063	mFOLFOX6 plus bevacizumab to treat liver-only metastases of colorectal cancer that are unsuitable for upfront resection (TRICC0808): a multicenter phase II trial comprising the final analysis for survival. International Journal of Clinical Oncology, 2019, 24, 516-525.	1.0	18
2064	Treatment patterns and survival outcomes for patients receiving second-line treatment for metastatic colorectal cancer in the USA. International Journal of Colorectal Disease, 2019, 34, 581-588.	1.0	10
2065	Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases. Translational Oncology, 2019, 12, 550-560.	1.7	2
2066	Costâ€“effectiveness analysis of UGT1A1*6/*28 genotyping for preventing FOLFIRI-induced severe neutropenia in Chinese colorectal cancer patients. Pharmacogenomics, 2019, 20, 241-249.	0.6	14
2067	Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemotherapy and Pharmacology, 2019, 83, 123-129.	1.1	26
2068	The changing face of treatment for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 2019, 19, 61-70.	1.1	10
2069	A phase 2 randomised study of veliparib plus FOLFIRIÂ±bevacizumab versus placebo plus FOLFIRIÂ±bevacizumab in metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 183-189.	2.9	38
2070	Is neoadjuvant chemotherapy appropriate for patients with resectable liver metastases from colorectal cancer?. Surgery Today, 2019, 49, 82-89.	0.7	16
2071	Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer. International Journal of Clinical Oncology, 2019, 24, 222-230.	1.0	9
2072	Indolent Nodal Relapse of Colon Carcinoma with Associated Tumor Thrombus Invading the Superior Mesenteric Vein. Journal of Gastrointestinal Cancer, 2019, 50, 660-664.	0.6	1

#	Article	IF	Citations
2073	DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. Future Oncology, 2019, 15, 2349-2360.	1.1	9
2074	Prognostic Value of Knowledge of Cancer and Used Unconventional Therapy Methods on Quality of Life in Advanced, Metastatic Colorectal Cancer in Clinical Practice. Journal of Cancer Education, 2020, 35, 151-158.	0.6	2
2075	Irinotecan toxicity during treatment of metastatic colorectal cancer: focus on pharmacogenomics and personalized medicine. Tumori, 2020, 106, 87-94.	0.6	20
2076	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1-42.	1.0	1,123
2077	Survival outcomes in patients aged 75Âyears and over with peritoneal colorectal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): multicenter study of the Spanish Group of Peritoneal Cancer Surgery (GECOP). Clinical and Translational Oncology, 2020, 22, 130-136.	1.2	3
2078	Utilisation of systemic therapy options in routine treatment of metastatic colorectal cancer in Australia. Internal Medicine Journal, 2020, 50, 165-172.	0.5	1
2079	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectrum, 2020, 4, pkz078.	1.4	22
2080	Locally recurrent rectal cancer; long-term outcome of curative surgical and non-surgical treatment of 447 consecutive patients in a tertiary referral centre. European Journal of Surgical Oncology, 2020, 46, 448-454.	0.5	34
2081	Patient-Derived Colorectal Cancer Organoids Upregulate Revival Stem Cell Marker Genes following Chemotherapeutic Treatment. Journal of Clinical Medicine, 2020, 9, 128.	1.0	38
2082	FOLFOX treatment response prediction in metastatic or recurrent colorectal cancer patients via machine learning algorithms. Cancer Medicine, 2020, 9, 1419-1429.	1.3	27
2083	Model-Based Cost-Effectiveness Analysis of Panitumumab Plus FOLFIRI for the Second-Line Treatment of Patients with Wild-Type Ras Metastatic Colorectal Cancer. Advances in Therapy, 2020, 37, 847-859.	1.3	2
2084	Association of DNA repair gene polymorphisms with colorectal cancer risk and treatment outcomes. Experimental and Molecular Pathology, 2020, 113, 104364.	0.9	15
2085	Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?. Journal of the National Cancer Institute, 2020, 112, 773-778.	3.0	6
2086	Liver Metastases. , 2020, , 846-862.e4.		2
2087	Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 28-34.	0.6	8
2088	Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM). Clinical and Translational Oncology, 2020, 22, 1180-1186.	1.2	3
2089	5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. , 2020, 206, 107447.		449
2091	Maintenance treatment in metastatic colorectal cancer: in search of the best strategy. Clinical and Translational Oncology, 2020, 22, 1205-1215.	1.2	7

#	Article	IF	Citations
2092	Combining Correlated Outcomes and Surrogate Endpoints in a Network Meta-Analysis of Colorectal Cancer Treatments. Cancers, 2020, 12, 2663.	1.7	3
2093	Optimized lowâ€dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. Molecular Oncology, 2020, 14, 2894-2919.	2.1	20
2094	Cost-effectiveness of CapecitabineÂ+ Irinotecan Versus LeucovorinÂ+ FluorouracilÂ+ Irinotecan in the Second-line Treatment of Metastatic Colorectal Cancer in China. Clinical Therapeutics, 2020, 42, 2148-2158.e2.	1.1	7
2095	Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. European Journal of Cancer, 2020, 138, 89-98.	1.3	13
2096	A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer. Journal of International Medical Research, 2020, 48, 030006052092640.	0.4	2
2097	Combinatorial Immunotherapies for Metastatic Colorectal Cancer. Cancers, 2020, 12, 1875.	1.7	19
2098	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 5027.	1.8	7
2099	Statistical Considerations for Trials in Adjuvant Treatment of Colorectal Cancer. Cancers, 2020, 12, 3442.	1.7	2
2100	Apparent Diffusion Coefficient Can Predict Response to Chemotherapy of Liver Metastases in Colorectal Cancer. Academic Radiology, 2020, 28 Suppl 1, S73-S80.	1.3	13
2101	Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease. Journal of Clinical Medicine, 2020, 9, 3889.	1.0	35
2102	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. European Journal of Cancer, 2020, 137, 117-126.	1.3	16
2103	Benefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer. European Journal of Cancer, 2020, 137, 148-160.	1.3	14
2104	Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer. BMC Cancer, 2020, 20, 687.	1.1	9
2105	Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093742.	1.4	5
2106	Construction and optimization of gene expression signatures for prediction of survival in two-arm clinical trials. BMC Bioinformatics, 2020, 21, 333.	1.2	3
2107	Four lines of immunochemotherapy combinations in aÂyoung patient with an aggressive metastatic colorectal cancer. Memo - Magazine of European Medical Oncology, 2020, 13, 337-340.	0.3	1
2108	MTA3 gene expression as potential gene biomarker for epithelial mesenchymal transition (EMT) study in colorectal cancer (CRC) cases. AIP Conference Proceedings, 2020, , .	0.3	0
2109	Simulating Progression-Free and Overall Survival for First-Line Doublet Chemotherapy With or Without Bevacizumab in Metastatic Colorectal Cancer Patients Based on Real-World Registry Data. Pharmacoeconomics, 2020, 38, 1263-1275.	1.7	3

#	Article	IF	Citations
2110	Disturbance of consciousness due to hyperammonemia and lactic acidosis during mFOLFOX6 regimen. Medicine (United States), 2020, 99, e21743.	0.4	2
2111	Fluorouracil Supplemented With Oxaliplatin or Irinotecan for Solid Tumors: Indications From Clinical Characteristics and Health Outcomes of Patients. Frontiers in Oncology, 2020, 10, 1542.	1.3	2
2112	Review of cancer-associated fibroblasts and their microenvironmentÂin post-chemotherapy recurrence. Human Cell, 2020, 33, 938-945.	1.2	10
2113	Predictive and prognostic value of magnesium serum level in FOLFIRI plus cetuximab or bevacizumab treated patients with stage IV colorectal cancer: results from the FIRE-3 (AIO KRK-0306) study. Anti-Cancer Drugs, 2020, 31, 856-865.	0.7	2
2114	Oxaliplatin-associated sarcoid-like reaction masquerading as recurrent colon cancer. BMJ Case Reports, 2020, 13, e229548.	0.2	5
2115	Efficacy of Olanzapine-Triple Antiemetic Regimen in Patients with Gastrointestinal Tumor and High Risk of Chemotherapy-Induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: A Retrospective Study . Cancer Management and Research, 2020, Volume 12, 6575-6583.	0.9	3
2116	Tumor-Derived Exosome-Educated Hepatic Stellate Cells Regulate Lactate Metabolism of Hypoxic Colorectal Tumor Cells via the IL-6/STAT3 Pathway to Confer Drug Resistance . OncoTargets and Therapy, 2020, Volume 13, 7851-7864.	1.0	14
2117	Change in skeletal muscle index and its prognostic significance in patients who underwent successful conversion therapy for initially unresectable colorectal cancer: observational study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482097119.	1.4	3
2118	Targeting EGFR in Esophagogastric Cancer. Frontiers in Oncology, 2020, 10, 553876.	1.3	6
2119	Graft-versus-cancereffect and innovative approaches in the treatment of refractory solid tumors. Turkish Journal of Medical Sciences, 2020, 50, 1697-1706.	0.4	3
2120	Prognostic Relevance of HJURP Expression in Patients with Surgically Resected Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 7928.	1.8	26
2121	A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 2516-2527.	1.9	17
2122	Comparison of Treatment, Cost, and Survival in Patients With Metastatic Colorectal Cancer in Western Washington, United States, and British Columbia, Canada. JCO Oncology Practice, 2020, 16, e425-e432.	1.4	5
2123	Investigation of morphological and functional changes in the liver and pancreas during bevacizumab treatment. Scandinavian Journal of Gastroenterology, 2020, 55, 712-717.	0.6	2
2124	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. Frontiers in Oncology, 2020, 10, 560.	1.3	12
2125	An Animal Model of Colorectal Cancer Liver Metastasis With a High Metastasis Rate and Clonal Dynamics. Anticancer Research, 2020, 40, 3297-3306.	0.5	5
2126	Ascending colon cancer with synchronous right external iliac lymph node metastasis. International Cancer Conference Journal, 2020, 9, 162-167.	0.2	1
2127	Treatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. JCO Global Oncology, 2020, 6, 414-438.	0.8	140

#	Article	IF	Citations
2128	Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 2020, 20, 251-270.	1.1	4
2129	Current and New Predictors for Treatment Response in Metastatic Colorectal Cancer. The Role of Circulating miRNAs as Biomarkers. International Journal of Molecular Sciences, 2020, 21, 2089.	1.8	11
2130	Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial. International Journal of Clinical Oncology, 2020, 25, 1285-1290.	1.0	1
2131	Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy, 2020, 5, 22.	7.1	853
2133	Splenic enlargement induced by preoperative chemotherapy is a useful indicator for predicting liver regeneration after resection for colorectal liver metastases. World Journal of Surgical Oncology, 2020, 18, 139.	0.8	0
2134	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. Expert Opinion on Drug Safety, 2020, 19, 187-204.	1.0	5
2135	Optimal timing for the resection of pulmonary metastases in patients with colorectal cancer. Medicine (United States), 2020, 99, e19144.	0.4	4
2136	Is aflibercept an optimal treatment for wt RAS mCRC patients after progression to first line containing anti-EGFR?. International Journal of Colorectal Disease, 2020, 35, 739-746.	1.0	12
2137	Targeting necroptosis in anticancer therapy: mechanisms and modulators. Acta Pharmaceutica Sinica B, 2020, 10, 1601-1618.	5.7	54
2138	A fast method for the detection of irinotecan in plasma samples by combining solid phase extraction and differential pulse voltammetry. Analytical and Bioanalytical Chemistry, 2020, 412, 1585-1595.	1.9	8
2139	Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study. International Journal of Cancer, 2020, 147, 285-296.	2.3	56
2140	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. BioMed Research International, 2020, 2020, 1-24.	0.9	38
2141	Serum LOX-1 is a novel prognostic biomarker of colorectal cancer. International Journal of Clinical Oncology, 2020, 25, 1308-1317.	1.0	20
2142	An Explorative Analysis of ABCG2/TOP-1 mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial. Cancers, 2020, 12, 977.	1.7	4
2143	Two-part joint model for a longitudinal semicontinuous marker and a terminal event with application to metastatic colorectal cancer data. Biostatistics, 2022, 23, 50-68.	0.9	7
2144	Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations. Briefings in Bioinformatics, 2021, 22, .	3.2	19
2145	A comprehensive review of economic evaluations of therapeutic drug monitoring interventions for cancer treatments. British Journal of Clinical Pharmacology, 2021, 87, 271-283.	1.1	11
2146	An appraisal of emerging second line therapies for metastatic colorectal cancer. Expert Review of Gastroenterology and Hepatology, 2021, 15, 165-179.	1.4	2

#	Article	IF	Citations
2147	Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm. Cancer Treatment Reviews, 2021, 92, 102135.	3.4	2
2148	Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5â€fluorouracil and leucovorin combination as firstâ€or secondâ€line treatment against metastatic colorectal cancer: Results from the International <scp>EORTC</scp> 05011 Trial. International Journal of Cancer, 2021, 148, 2512-2521.	2.3	19
2149	Clinical Validation of a Machine-learningâ€"derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer. Clinical Cancer Research, 2021, 27, 1174-1183.	3.2	28
2150	Multidisciplinary Treatment of Colorectal Cancer. , 2021, , .		2
2151	Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors. Clinical Colorectal Cancer, 2021, 20, e129-e138.	1.0	2
2152	Deep learningâ€based radiomics predicts response to chemotherapy in colorectal liver metastases. Medical Physics, 2021, 48, 513-522.	1.6	32
2153	Emerging trends in colorectal cancer: Dysregulated signaling pathways (Review). International Journal of Molecular Medicine, 2021, 47, .	1.8	50
2154	Hepatic Perfusion for Diffuse Metastatic Cancer to the Liver. Surgical Oncology Clinics of North America, 2021, 30, 175-188.	0.6	0
2155	Intraarterial Chemotherapy for Liver Metastases. Surgical Oncology Clinics of North America, 2021, 30, 143-158.	0.6	5
2156	Effective management of advanced colon cancer genotyping microsatellite stable/microsatellite instable-low with Kirsten rat sarcoma viral oncogene mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report. SAGE Open Medical Case Reports, 2021, 9, 2050313X2110277.	0.2	1
2157	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110205.	1.4	3
2158	Importance of Systemic Chemotherapy in Advanced Peritoneal Metastasis. , 2021, , 239-253.		0
2159	A prospective phase II study of raltitrexed combined with Sâ€1 as salvage treatment for patients with refractory metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 2021, 17, 513-521.	0.7	4
2160	Advances in CpG Island Methylator Phenotype Colorectal Cancer Therapies. Frontiers in Oncology, 2021, 11, 629390.	1.3	11
2161	Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis. BMC Cancer, 2021, 21, 116.	1.1	23
2162	Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatinâ€based or irinotecanâ€based therapy for colorectal cancer. Cancer Science, 2021, 112, 1567-1578.	1.7	5
2163	Synthesis of thiazole linked chalcones and their pyrimidine analogues as anticancer agents. Synthetic Communications, 2021, 51, 1406-1416.	1.1	10
2164	Conventional transarterial chemoembolization combined with systemic therapy versus systemic therapy alone as second-line treatment for unresectable colorectal liver metastases: randomized clinical trial. British Journal of Surgery, 2021, 108, 373-379.	0.1	7

#	Article	IF	Citations
2165	Perspectives in the Treatment of RAS or BRAF Mutated Metastatic Colorectal Cancer Patients. Frontiers in Oncology, 2021, 11, 602596.	1.3	3
2166	Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 3093.	1.8	7
2167	Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 329-359.	2.3	758
2168	Temporal Change in Treatment Patterns of Metastatic Colorectal Cancer and Its Association with Patient Survival: A Retrospective Cohort Study Based on an Intelligent Big-Data Platform. Engineering, 2021, 7, 526-533.	3.2	5
2169	Early liver metastases after â€œfailureâ€•of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy?. Hpb, 2021, 23, 601-608.	0.1	3
2170	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. Cancers, 2021, 13, 1705.	1.7	10
2171	Patient demographics and management landscape of metastatic colorectal cancer in the thirdâ€line setting: Realâ€world data in an australian population. Asia-Pacific Journal of Clinical Oncology, 2022, 18, .	0.7	3
2172	Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women. JAMA Network Open, 2021, 4, e215250.	2.8	13
2173	Induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as neoadjuvant treatment for locally recurrent rectal cancer: study protocol of a multicentre, open-label, parallel-arms, randomized controlled study (PelvEx II). BJS Open, 2021, 5, .	0.7	7
2174	Risk factors of mFOLFOX6-induced hyperammonemia in patients with colorectal cancer: an observational study. International Journal of Clinical Oncology, 2021, 26, 1477-1484.	1.0	4
2175	Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study of Zhejiang Cancer Hospital. Frontiers in Pharmacology, 2021, 12, 632076.	1.6	3
2176	Performance of capecitabine in novel combination therapies in colorectal cancer. Journal of Chemotherapy, 2021, 33, 375-389.	0.7	7
2177	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. Current Medicinal Chemistry, 2021, 28, 3158-3172.	1.2	1
2178	Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center. BMC Cancer, 2021, 21, 630.	1.1	5
2179	Stability of calcium levofolinate, 5-fluorouracil and oxaliplatin (FOLFOX) mixture. Journal of Oncology Pharmacy Practice, 2022, 28, 1303-1314.	0.5	2
2180	Advances in Treatment Selection for Patients with Metastatic Colorectal Cancer. Advances in Oncology, 2021, 1, 297-310.	0.1	0
2181	C677T and A1298C MTHFR gene polymorphisms and response to fluoropyrimidine-based chemotherapy in Mestizo patients with metastatic colorectal cancer. Pharmacogenetics and Genomics, 2021, 31, 191-199.	0.7	5
2182	Current controversies and advances in the management of pancreatic adenocarcinoma. World Journal of Gastrointestinal Oncology, 2021, 13, 472-494.	0.8	9

#	Article	IF	Citations
2183	Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Cancer Chemotherapy and Pharmacology, 2021, 88, 543-553.	1.1	5
2184	Management of Metastatic Colorectal Carcinoma in Older Adults: Balancing Risks and Benefits of Novel Therapies. Drugs and Aging, 2021, 38, 639-654.	1.3	1
2185	All-Trans Retinoic Acid Enhances Chemosensitivity to 5-FU by Targeting miR-378c/E2F7 Axis in Colorectal Cancer. Journal of Oncology, 2021, 2021, 1-10.	0.6	0
2186	Therapeutic Strategy of Colorectal Liver Metastasis Using Modified-JHBPS Nomogram. Anticancer Research, 2021, 41, 3657-3665.	0.5	1
2187	The Outcome of Induction Chemotherapy, Followed by Neoadjuvant Chemoradiotherapy and Surgery, in Locally Advanced Rectal Cancer. Iranian Journal of Pathology, 2021, 16, 266-273.	0.2	1
2188	Optimal Maintenance Strategy for First-Line Oxaliplatin-Containing Therapy with or without Bevacizumab in Patients with Metastatic Colorectal Cancer: A Meta-Analysis. Cancer Research and Treatment, 2021, 53, 703-713.	1.3	1
2189	First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entÃ©rologues Oncologues (AGEO) multicentre study. Digestive and Liver Disease, 2021, , .	0.4	3
2190	Place of regorafenib in treatment of patients with metastatic colorectal cancer: when are all options exhausted? Or in third line?. Medical Alphabet, 2021, , 30-35.	0.0	0
2191	Modern strategy for treatment of metastatic colorectal cancer as key to increasing life expectancy of patients with metastatic colorectal cancer without mutations in RAS genes. Medical Alphabet, 2021, , 54-63.	0.0	1
2192	Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701. International Journal of Clinical Oncology, 2021, 26, 1871-1880.	1.0	1
2193	Systemic chemotherapy combined with anti-epidermal growth factor receptor antibody therapy for RAS wild-type appendiceal signet-ring cell carcinoma: a series of three cases. International Cancer Conference Journal, 2022, 11, 17-22.	0.2	0
2194	Impact of UGT1A1 genotype on the efficacy and safety of irinotecanâ€based chemotherapy in metastatic colorectal cancer. Cancer Science, 2021, 112, 4669-4678.	1.7	8
2195	Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Annals of Oncology, 2021, 32, 959-967.	0.6	102
2196	Influence of first line chemotherapy strategy depending on primary tumor location in metastatic colorectal cancer. Journal of Gastrointestinal Oncology, 2021, 12, 1509-1517.	0.6	3
2197	Effects of Vanadyl Complexes with Acetylacetonate Derivatives on Non-Tumor and Tumor Cell Lines. Molecules, 2021, 26, 5534.	1.7	1
2198	Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513. Clinical Cancer Research, 2021, 27, 6314-6322.	3.2	22
2199	The Prognostic Significance of a Histological Response to Preoperative Chemotherapy in Patients With Synchronous Colorectal Liver Metastases. International Surgery, 2022, 106, 5-17.	0.0	0
2200	Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group. Clinical Colorectal Cancer, 2021, 20, 245-255.	1.0	2

#	Article	IF	Citations
2201	Advances and new frontiers for immunotherapy in colorectal cancer: Setting the stage for neoadjuvant success?. Molecular Therapy - Oncolytics, 2021, 22, 1-12.	2.0	24
2202	Tackling Refractory Metastatic Colorectal Cancer: Future Perspectives. Cancers, 2021, 13, 4506.	1.7	11
2203	Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. Current Problems in Cancer, 2021, , 100793.	1.0	1
2204	Development and validation of a selective SPR aptasensor for the detection of anticancer drug irinotecan in human plasma samples. Analytical and Bioanalytical Chemistry, 2021, 413, 1225-1236.	1.9	10
2205	Radiomics Texture Analysis for the Identification of Colorectal Liver Metastases Sensitive to First-Line Oxaliplatin-Based Chemotherapy. Annals of Surgical Oncology, 2021, 28, 2975-2985.	0.7	19
2206	Colorectal Cancer: Metastatic (Palliation). , 2007, , 462-481.		1
2207	Targeted Therapy in Colorectal Cancer. , 2008, , 101-123.		2
2209	Modern Locoregional Treatment of Colorectal Cancer Liver Metastases. , 2016, , 67-109.		1
2210	Cetuximab: Appraisal of a Novel Drug Against Colorectal Cancer. Recent Results in Cancer Research, 2007, 176, 135-143.	1.8	10
2211	Liver Metastases. , 2008, , 885-923.		2
2214	A cutaneous metastasis of unresectable rectal adenocarcinoma: A case report and literature review. International Journal of Surgery Case Reports, 2020, 71, 95-101.	0.2	8
2215	Recent developments in the clinical activity of topoisomerase-1 inhibitors. Cancer Chemotherapy and Biological Response Modifiers, 2005, , 61-100.	0.5	1
2216	Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. Seminars in Interventional Radiology, 2017, 34, 116-120.	0.3	3
2217	Distinct Genomic Profiles are Associated With Conversion to Resection and Survival in Patients With Initially Unresectable Colorectal Liver Metastases Treated With Systemic and Hepatic Artery Chemotherapy. Annals of Surgery, 2022, 276, e474-e482.	2.1	15
2219	Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1017-1024.	3.2	22
2220	Colorectal liver metastases: radiopathological correlation. Insights Into Imaging, 2020, 11, 99.	1.6	18
2221	Pulmonary Edema Caused by Levofolinate Treatment in Patients with Liver Metastases from Colorectal Cancer. Journal of Nippon Medical School, 2013, 80, 460-466.	0.3	1
2222	Percutaneous Cryoablation of Pulmonary Metastases from Colorectal Cancer. PLoS ONE, 2011, 6, e27086.	1.1	38

#	Article	IF	Citations
2223	A Novel and Selective Poly (ADP-Ribose) Polymerase Inhibitor Ameliorates Chemotherapy-Induced Painful Neuropathy. PLoS ONE, 2013, 8, e54161.	1.1	50
2224	Hospital-Based Colorectal Cancer Survival Trend of Different Tumor Locations from 1960s to 2000s. PLoS ONE, 2013, 8, e73528.	1.1	25
2225	Oxaliplatin-Based Chemotherapy Is More Beneficial in KRAS Mutant than in KRAS Wild-Type Metastatic Colorectal Cancer Patients. PLoS ONE, 2014, 9, e86789.	1.1	18
2226	High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer. PLoS ONE, 2017, 12, e0182512.	1.1	27
2227	Predictors of Irinotecan Toxicity and Efficacy in Treatment of Metastatic Colorectal Cancer. Acta Medica (Hradec Kralove), 2012, 55, 153-159.	0.2	13
2228	Multiple Subcutaneous Nodules Leading to Diagnosis of Colon Cancer. Middle East Journal of Digestive Diseases, 2018, 10, 188-191.	0.2	5
2231	First-line irinotecan combined with 5-fluorouracil and leucovorin for high-grade metastatic gastrointestinal neuroendocrine carcinoma. Tumori, 2013, 99, 57-60.	0.6	6
2233	MicroRNA profiles involved in trifluridine resistance. Oncotarget, 2017, 8, 53017-53027.	0.8	14
2234	Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis. Oncotarget, 2018, 9, 10272-10283.	0.8	7
2235	Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. Oncotarget, 2019, 10, 5510-5522.	0.8	13
2236	PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancer. Oncotarget, 2015, 6, 14385-14398.	0.8	36
2237	Prognostic factors for transarterial chemoembolization combined with sustained oxaliplatin-based hepatic arterial infusion chemotherapy of colorectal cancer liver metastasis. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 36-44.	0.7	9
2238	First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab. OncoTargets and Therapy, 2009, 2, 73.	1.0	4
2239	Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature.. Reviews on Recent Clinical Trials, 2013, 8, 101-109.	0.4	9
2240	Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. Anticancer Research, 2016, 36, 4715-4724.	0.5	5
2241	TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR Research Protocols, 2019, 8, e11545.	0.5	27
2242	Effects of ABCC2 and SLCO1B1 Polymorphisms on Treatment Responses in Thai Metastatic Colorectal Cancer Patients Treated with Irinotecan-Based Chemotherapy. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2757-2764.	0.5	7
2243	The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): Combined analysis of efficacy. Acta Chirurgica Iugoslavica, 2008, 55, 11-16.	0.0	6

#	Article	IF	Citations
2244	Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites - case report and a literature review.. Folia Histochemica Et Cytobiologica, 2011, 48, 597-602.	0.6	6
2245	Liver dysfunction associated with oxaliplatin-based chemotherapy: evaluation with enhanced computed tomography. Acta Hepatologica Japonica, 2020, 61, 358-366.	0.0	1
2246	Metastatic chest wall tumor after resection of primary rectal cancer: A case report. The Journal of the Japanese Association for Chest Surgery, 2013, 27, 594-599.	0.0	2
2247	Thermal Ablation for Colorectal Liver Metastases. Thermal Medicine, 2008, 24, 83-89.	0.0	6
2248	The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technology Assessment, 2008, 12, iii-ix, xi-162.	1.3	60
2249	Cetuximab for the first-line treatment of metastatic colorectal cancer. Health Technology Assessment, 2010, 14, 1-8.	1.3	14
2250	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technology Assessment, 2010, 14, 47-53.	1.3	5
2251	Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer. Health Technology Assessment, 2010, 14, 47-53.	1.3	17
2252	KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis. Health Technology Assessment, 2014, 18, 1-132.	1.3	66
2253	Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion. Health Technology Assessment, 2015, 19, 1-322.	1.3	29
2254	The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Health Technology Assessment, 2017, 21, 1-294.	1.3	24
2255	PERITONEAL COLORECTAL CARCINOMATOSIS. APPROACHES TO TREATMENT (REVIEW). Koloproktologia, 2016, , 69-79.	0.1	7
2256	Colorectal cancer: from epidemiology to current treatment. Libyan Journal of Medicine, 2006, 1, 42-59.	0.8	1
2257	Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. Global Health & Medicine, 2020, 2, 240-246.	0.6	4
2259	Role of Oxaliplatin Combined with 5-Fluorouracil and Folinic Acid in the First- and Second-Line Treatment of Advanced Colorectal Cancer. Current Oncology, 2006, 13, 173-184.	0.9	12
2260	Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer. Current Oncology, 2010, 17, 3-17.	0.9	63
2261	Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World Journal of Gastroenterology, 2009, 15, 289.	1.4	37
2262	Secondary hepatic resection as a therapeutic goal in advanced colorectal cancer. World Journal of Gastroenterology, 2009, 15, 3855.	1.4	19

#	Article	IF	Citations
2263	Limited influences of chemotherapy on healthy and metastatic liver parenchyma. World Journal of Gastroenterology, 2005, 11, 5322.	1.4	2
2264	Evolution in the treatment of metastatic colorectal carcinoma of the liver. World Journal of Gastroenterology, 2006, 12, 3253.	1.4	6
2265	Metastatic colorectal cancer-past, progress and future. World Journal of Gastroenterology, 2007, 13, 3806.	1.4	64
2266	Surveillance of patients following surgery with curative intent for colorectal cancer. World Journal of Gastroenterology, 2007, 13, 3816.	1.4	25
2267	Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World Journal of Gastroenterology, 2007, 13, 6231.	1.4	18
2268	Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World Journal of Gastroenterology, 2010, 16, 3133.	1.4	100
2269	Primary site resection is superior for incurable metastatic colorectal cancer. World Journal of Gastroenterology, 2010, 16, 3561.	1.4	14
2270	Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World Journal of Gastroenterology, 2013, 19, 8474.	1.4	9
2271	Role of cetuximab in first-line treatment of metastatic colorectal cancer. World Journal of Gastroenterology, 2014, 20, 4208.	1.4	25
2272	Palliative care and end-stage colorectal cancer management: The surgeon meets the oncologist. World Journal of Gastroenterology, 2014, 20, 7602.	1.4	53
2273	Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World Journal of Gastroenterology, 2014, 20, 9775.	1.4	105
2274	Successful resection of metachronous para-aortic, Virchow lymph node and liver metastatic recurrence of rectal cancer. World Journal of Gastroenterology, 2015, 21, 12722.	1.4	3
2275	Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis. World Journal of Gastroenterology, 2015, 21, 1982.	1.4	11
2276	Predictive effects of bilirubin on response of colorectal cancer to irinotecan-based chemotherapy. World Journal of Gastroenterology, 2016, 22, 4250.	1.4	8
2277	Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World Journal of Gastroenterology, 2017, 23, 1406.	1.4	22
2278	FOLFOX-4 Regimen as a First-line Therapy for Cuban Patients with Metastatic Colorectal Cancer. MEDICC Review, 2009, 11, 34.	0.5	2
2279	A Long-term Survival Case of Far Advanced Colon Cancer with Virchow Lymph Node and Liver Metastases that Responded to Multidisciplinary Therapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2007, 60, 412-416.	0.1	4
2280	Irinotecan, Continuous 5-Fluorouracil, and Low dose of Leucovorin (modified FOLFIRI) as First Line of Therapy in Recurrent or Metastatic Colorectal Cancer. Korean Journal of Internal Medicine, 2005, 20, 205.	0.7	3

#	Article	IF	Citations
2281	Efficacy and Safety of Hepatic Arterial Infusion of Fluorouracil with Leucovorin as Salvage Treatment for Refractory Liver Metastases from Colorectal Cancer. Korean Journal of Internal Medicine, 2011, 26, 82.	0.7	5
2282	The impact of primary tumor location in patients with metastatic colorectal cancer: a Korean Cancer Study Group CO12-04 study. Korean Journal of Internal Medicine, 2019, 34, 165-177.	0.7	20
2283	Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean Journal of Internal Medicine, 2019, 34, 1188-1196.	0.7	3
2284	FOLFOX-4 Combination Chemotherapy as a First-line Treatment in Patients with Advanced Gastric Cancer. Korean Journal of Medicine, 2012, 82, 37.	0.1	2
2285	Role of Bevacizumab as Post-Progression Maintenance Therapy in Metastatic Colon Cancer. Journal of Medical Sciences (Faisalabad, Pakistan), 2008, 8, 452-460.	0.0	2
2286	Review of systemic therapies for locally advanced and metastatic rectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 185-200.	0.6	45
2287	Hepatic resection, hepatic arterial infusion pump therapy, and genetic biomarkers in the management of hepatic metastases from colorectal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 699-708.	0.6	19
2288	Sequence of treatment in locally advanced and metastatic renal cell carcinoma. Translational Andrology and Urology, 2015, 4, 310-25.	0.6	16
2289	Chemotherapy for advanced cancers. Annals of Palliative Medicine, 2014, 3, 203-28.	0.5	11
2290	Safety and efficacy of cetuximab-chemotherapy combination in Saudi patients with metastatic colorectal cancer. Indian Journal of Cancer, 2007, 44, 56.	0.2	3
2291	Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian Journal of Cancer, 2013, 2, 179.	0.2	25
2292	A Phase II Study of Irinotecan, 5-Fluorouracil and Leucovorin for Treatment in Patients with Previously Untreated Advanced Colorectal Cancer. Cancer Research and Treatment, 2006, 38, 72.	1.3	3
2293	A Retrospective Study of First-Line Combination Chemotherapy in Advanced Colorectal Cancer: A Korean Single-Center Experience. Cancer Research and Treatment, 2011, 43, 96-101.	1.3	2
2294	Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Research and Treatment, 2011, 43, 148-153.	1.3	12
2295	Novel Methods for Clinical Risk Stratification in Patients with Colorectal Liver Metastases. Cancer Research and Treatment, 2015, 47, 242-250.	1.3	8
2296	A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine. Cancer Research and Treatment, 2017, 49, 706-716.	1.3	17
2297	Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer. Cancer Research and Treatment, 2018, 50, 283-292.	1.3	4
2298	Recent Advances in Molecular Targeted Therapy for advanced Colorectal Cancer and Nonâ€“Small Cell Lung Cancer. , 2012, 02, .		1

#	Article	IF	Citations
2299	Oxaliplatin and pH. , 2012, 02, .		1
2300	Multicenter Phase II Study of FOLFOX6 for Previously Untreated Unresectable Metastatic Colorectal Cancer. Journal of Integrative Oncology, 2014, 03, .	0.3	1
2301	Outcomes after Surgery for Spinal Metastasis of Colorectal Origin: Case Series. Asian Spine Journal, 2014, 8, 267.	0.8	5
2302	Multidrug Delivery Systems with Single Formulationâ€"â€"Current status and Future Perspective. Journal of Biomaterials and Nanobiotechnology, 2012, 03, 50-60.	1.0	24
2303	Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer. Journal of Cancer Therapy, 2011, 02, 675-682.	0.1	4
2304	Recent Advances in the Management of Stage IV Colon Cancer. Journal of Cancer Therapy, 2012, 03, 1104-1118.	0.1	5
2305	Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer. Modern Chemotherapy, 2012, 01, 5-10.	0.5	2
2306	Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer. World Journal of Gastrointestinal Oncology, 2020, 12, 604-618.	0.8	9
2307	Advances in therapeutics for liver metastasis from colorectal cancer. World Journal of Gastrointestinal Oncology, 2010, 2, 380.	0.8	2
2308	Surgical treatment of hepatic metastases from colorectal cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 1.	0.8	14
2309	Is there diversity amongUGT1A1polymorphism in Japan. World Journal of Gastrointestinal Oncology, 2012, 4, 170.	0.8	9
2310	Cetuximab in colon cancer. International Journal of Biological Markers, 2007, 22, 62-70.	0.7	2
2311	Phenotype of peripheral blood leukocytes and survival of patients with metastatic colorectal cancer. International Journal of Biological Markers, 2005, 20, 126-133.	0.7	4
2312	Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World Journal of Clinical Oncology, 2019, 10, 75-85.	0.9	7
2313	Colorectal liver metastases: Current management and future perspectives. World Journal of Clinical Oncology, 2020, 11, 761-808.	0.9	98
2314	FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World Journal of Clinical Oncology, 2018, 9, 110-118.	0.9	9
2315	Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumor.. Canadian Urological Association Journal, 2015, 9, 204.	0.3	9
2316	Review of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in solid tumors excluding breast cancer. World Journal of Transplantation, 2016, 6, 675.	0.6	5

#	Article	IF	Citations
2317	Hepatic arterial infusion in colorectal carcinoma: is anatomical targeting still relevant in an era of molecularly targeted therapy?. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 81-92.	0.2	8
2318	Cost-minimization Analysis of S-1 Plus Irinotecan (IRIS) versus Oxaliplatin or Irinotecan Plus Fluorouracil and Folinic Acid (mFOLFOX6 or FOLFIRI) in Patients with Advanced Colorectal Cancer. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2015, 41, 153-162.	0.0	1
2319	Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1059-1063.	0.5	24
2320	Serum miR-19a Predicts Resistance to FOLFOX Chemotherapy in Advanced Colorectal Cancer Cases. Asian Pacific Journal of Cancer Prevention, 2013, 14, 7421-7426.	0.5	86
2321	Efficacy and Safety of Raltitrexed Combinations with Uracil-Tegafur or Mitomycin C as Salvage Treatment in Advanced Colorectal Cancer Patients: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO). Asian Pacific Journal of Cancer Prevention, 2014, 15, 1845-1849.	0.5	5
2322	Predictive Significance of VEGF and HIF-1Î± Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab. Asian Pacific Journal of Cancer Prevention, 2015, 16, 6149-6154.	0.5	16
2323	Factors Affecting Prognosis in Metastatic Colorectal Cancer Patients. Asian Pacific Journal of Cancer Prevention, 2015, 16, 3015-3021.	0.5	23
2324	GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Review of Precision Medicine and Drug Development, 2021, 6, 117-129.	0.4	6
2325	Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Liver Metastases from Colorectal Cancer: a Multicenter, Propensity Scoreâ€“Matched Cohort Study. Journal of Gastrointestinal Surgery, 2022, 26, 772-781.	0.9	5
2326	Effects of an elemental diet to reduce adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil: a phase III randomized controlled trialâ€”EPOC 2 (JFMC49-1601-C5). ESMO Open, 2021, 6, 100277.	2.0	6
2327	Association between Fusobacterium nucleatum and patient prognosis in metastatic colon cancer. Scientific Reports, 2021, 11, 20263.	1.6	11
2328	A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI â€“ Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results. Oncology, 2021, , 1-11.	0.9	1
2329	Phase II Study of Irinotecan, 5-Fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as First-line Therapy. Cancer Research and Treatment, 2004, 36, 235.	1.3	5
2331	The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) patients. Journal of Clinical Oncology, 2004, 22, 3564-3564.	0.8	0
2332	Chemotherapy for Metastatic Rectal Cancer. , 2005, , 243-251.		0
2333	Trends in the Treatment of Colorectal Cancer. Oncology & Hematology Review, 2005, 00, 1.	0.2	0
2334	Phase II Study of Oxaliplatin, 5-fluorouracil, and Leucovorin in Relapsed or Metastatic Colorectal Cancer as Second Line Therapy. Cancer Research and Treatment, 2006, 38, 201.	1.3	0
2335	A Case of Advanced Rectal Cancer with Extended Lymph Node Metastasis Responding to Multi-modality Therapy. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2006, 31, 880-884.	0.0	0

#	Article	IF	Citations
2336	A Case Report of Advanced Gastric Cancer Effectively Treated with Chemotherapy. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2006, 31, 693-697.	0.0	1
2337	Evaluation of Pamphlets Used to Give Patients Instruction on Cancer Chemotherapy That Are Applicable to All Drug Regimens. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and) Tj ETQq1 1 0.784314 rgBT /Ove	0.0	2
2338	Multimodal treatment of metastatic colorectal cancer. Acta Chirurgica Iugoslavica, 2006, 53, 51-55.	0.0	1
2339	Kolorektales Karzinom. , 2006, , 3787-3937.		1
2340	A GIANT ENDOCRINE CELL CANCER OF THE RECTUM THAT REMAINED PROGRESSION FREE FOR 20 MONTHS WITH MULTIDISCIPLINARY TREATMENT. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.0	12
2341	PREOPERATIVE COMBINED MODALITY THERAPY IN PATIENT WITH INOPERABLE SIGMOID COLON CANCER-CASE REPORT-. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2006, 67, 1342-1346.	0.0	0
2342	Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the Liver. Human Gene Therapy, 2006, .	1.4	0
2343	Pharmacological Background. , 2007, , 19-28.		0
2344	åˆ‡é™¤è¸ƒï½ãƒ»å†ç™ºå§è…,ç™Œã«å¯¾ã•—, 2æ¬¡æ²»ç™‚ã«é™¤ã«è¡Œã£ãŸmFOLFOX6ç™‚æ³•ã®æ²»ç™‚æˆ¸¾. Nihon Gekakei Rengo G 125-130.	0.0	0
2345	Hepatic Lymph Node Involvement in Patients with Synchronous Liver Metastasis of Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2007, 60, 392-397.	0.1	0
2346	A Case Report of Non-Recurred Long-Term Survival After Resection for Undifferentiated Rectal Cancer with Systemic Multiple Lymph Node Metastases Successfully Treated by Preoperative Chemotherapy. Japanese Journal of Gastroenterological Surgery, 2007, 40, 504-509.	0.0	2
2347	Chemotherapy of Liver Tumors. , 2007, , 1298-1311.		0
2348	Sensitivity to CPT-11 and platinum derivatives of stage II/III node-positive gastric cancer with occult neoplastic cells in lymph node sinuses. Annals of Cancer Research and Therapy, 2007, 15, 22-26.	0.1	1
2349	Intra-arterial Chemotherapy for Liver Tumors. , 2007, , 1321-1337.		1
2350	Treatment outcome and local control of radiofrequency ablation for colorectal liver metastases. Journal of Microwave Surgery, 2007, 25, 131-135.	0.3	0
2351	SçŠ¶çuè…,ç™Œã®åµå·£è»¢ç§»ã«ã‚ˆã‚Špseudo-Meigsç—‡å€™ç¾¤ã‚’å‘ˆã—ãŸ1ä¾‹. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese C 778-782.	0.0	2
2352	Traitement des cancers bronchique, colorectal, du sein et de l'ovaire. , 2008, , 621-644.		0
2353	Role of Thymidylate Synthase Gene Variations in Colorectal Cancer Patients. , 2008, , 151-172.		0

#	Article	IF	Citations
2354	Long-term Survival of a Case with Brain and Lung Metastases from Rectal Cancer Treated by Gamma Knife Radiosurgery and Chemotherapy. Nihon Daicho Komonbyo Gakkai Zasshi, 2008, 61, 169-174.	0.1	0
2355	Prognosis analysis and treatment strategy for patients with Dukes D stage rectal cancer. World Chinese Journal of Digestology, 2008, 16, 3844.	0.0	1
2356	Multicenter Trial on Hypersensitivity Reactions following Treatment with FOLFOX Regimens. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2008, 34, 919-926.	0.0	3
2357	Nonurological Cancers Affecting the Urinary Tract. , 2008, , 576-595.		0
2358	A Case of Rectal Cancer with Simultaneous Liver Metastasis and Heterochronous Ovarian Metastasis. Yamaguchi Medical Journal, 2008, 57, 209-215.	0.1	1
2359	A Case of Pinch-off Syndrome caused by Clavicular Fracture. Japanese Journal of Gastroenterological Surgery, 2008, 41, 368-371.	0.0	1
2361	Systemic Therapy for Non-operable Colorectal Cancer Metastases. , 2009, , 1-8.		0
2362	Personalized Medicine in the Clinical Management of Colorectal Cancer. , 2009, , 1-18.		0
2363	Oncosurgical Strategies for Unresectable Liver Metastases. , 2009, , 1-13.		0
2365	Oxaliplatin-Based Chemotherapy for Colon Cancer. , 2009, , 271-284.		0
2366	Progress in the treatment of colorectal cancer: the impact of new drugs. , 2009, , 176-190.		0
2367	A Case of Ascending Colon Cancer accompanied by Suspected Portal Vein Tumor Thrombosis with Long-Term Survival who received Systemic Chemotherapy followed by Resection of Primary Lesion. Japanese Journal of Gastroenterological Surgery, 2009, 42, 112-117.	0.0	4
2368	The Usefulness of De-escalation Chemotherapy for Advanced Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2009, 62, 207-213.	0.1	0
2369	A Case of Poorly Differentiated Rectal Adenocarcinoma Causing Disseminated Intravascular Coagulation Syndrome Due to Carcinomatosis of Bone Marrow after a Modified FOLFIRI-induced Pathological CR. Nihon Daicho Komonbyo Gakkai Zasshi, 2009, 62, 65-71.	0.1	6
2370	å•Œæ™‚æ€§è„³è»¢ç§»ã«å¯¾ã—ã¦é›†å¦çš„æ²»ç™‚ã•Œæœ‰åŠ¹ã§ã‚ã£ãŸç›´è…¸ç™Œã®ï¼'ä¾‹. Nihon Gekakei Rengo Gakkaishi (Journa	0.0	1
2371	Le traitement mÃ©dical des cancers colorectaux mÃ©tastatiques en 2009: quels traitements pour quels patients?. , 2009, , 56-64.		0
2374	Title is missing!. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2009, 34, 871-877.	0.0	1
2375	Liver Metastases in Colorectal Cancer. Journal of the Korean Society of Coloproctology, 2009, 25, 63.	0.2	0

#	Article	IF	Citations
2376	First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients. , 2009, , 285-293.		0
2377	Combination Therapy with S-1 and CPT-11 for Metastatic Colorectal Cancer: Prognostic Factors for Patient Survival. Nihon Daicho Komonbyo Gakkai Zasshi, 2009, 62, 147-153.	0.1	0
2378	Colorectal Cancer: Optimization of the Combination of 5-Fluorouracil and Irinotecan. , 2009, , 105-117.		0
2379	å§è…ç™Œå•Œæ™‚æ€§å¤µå·£è»¢ç§»ã®ï¼"ä¾‹. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2009, 34, 10	0.0	0
2381	Chemotherapy Trials for Colorectal Cancer in Advanced Disease: Whatâ€™s the Current Hypothesis?. , 2010, , 27-54.		0
2382	è…¹è…"å‹•è„ˆå"¨å›²ãƒªãƒ³ãƒ'ç¯€è»¢ç§»ã'ä¼´ã£ãŸçµè…ç™Œç•°æ™‚æ€§å‰¯è…Žè»¢ç§»ã®ï¼'ä¾‹. Nihon Gekakei Rengo Gakkaishi (Jou	0.0	0
2383	Factors Associated with Neurotoxicity in Patients Receiving FOLFOX 4. Iryo Yakugaku (Japanese Journal) Tj ETQq0 0 0 rgBT /Overlock 10	0.0	2
2384	A CASE OF ADVANCED RECTAL CARCINOMA WITH SURROUNDING ORGAN INVASION WHICH ON PATHOLOGY WAS FOUND TO HAVE COMPLETELY RESPONDED TO NEOADJUVANT CHEMOTHERAPY. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2010, 71, 2676-2681.	0.0	2
2386	Surgical and Ablative Management of Liver Metastases. , 2010, , 131-150.		0
2387	Chemotherapie und systemische Therapie bei Lebermetastasen. , 2010, , 386-409.		0
2388	Cetuximab for the first-line treatment of metastatic colorectal cancer. Health Technology Assessment, 2010, 14, 1-8.	1.3	562
2389	Preoperation Chemotherapy. Updates in Surgery Series, 2011, , 75-100.	0.0	0
2390	Liver Metastases. , 2011, , 311-319.		0
2391	Colorectal Cancer with Multiple Metastases: Is Palliative Surgery Needed?. Journal of the Korean Society of Coloproctology, 2011, 27, 226.	0.9	2
2392	Clinical Analysis of Bevacizumab Plus FOLFIRI Regimen as Front-Line Therapy for Chinese Patients with Advanced Colorectal Cancer. Journal of Cancer Therapy, 2011, 02, 470-474.	0.1	0
2393	A Rare Case of Pathologically Complete Response of Locally Advanced Colorectal Cancer after Systemic Chemotherapy with mFOLFOX6. Nihon Daicho Komonbyo Gakkai Zasshi, 2011, 64, 510-515.	0.1	1
2394	Colorectal Carcinoma Liver Metastasis: Surgical Clinical Perspective. Cancer Metastasis - Biology and Treatment, 2011, , 353-380.	0.1	0
2395	A Case of Advanced Rectal Cancer Treated with FOLFIRI with Bevacizumab Therapy Leading to Histological Complete Response. Nihon Daicho Komonbyo Gakkai Zasshi, 2011, 64, 178-184.	0.1	0

#	Article	IF	Citations
2396	Beyond First-Line Therapy: Combining Chemotherapy and Radioembolization for Hepatic Colorectal Metastases. Journal of Nuclear Medicine & Radiation Therapy, 2011, 01, .	0.2	5
2397	Colorectal Cancer: Metastatic (Palliation). , 2011, , 783-802.		0
2398	Biotherapy in the Adjuvant Treatment of Colorectal Cancer. Gastroenterology Research, 2011, 4, 162-167.	0.4	0
2399	Clinical development of chemotherapy for advanced gastric or colorectal cancer. Journal of Microwave Surgery, 2011, 29, 45-49.	0.3	0
2400	Advances in the surgical treatment of colorectal liver metastases. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2011, 57, 215-222.	0.3	1
2401	Phase II study of RO4929097 in metastatic colorectal cancer.. Journal of Clinical Oncology, 2011, 29, e14058-e14058.	0.8	1
2402	Systemic Treatment in Recurrent and Metastatic Unresectable Rectal Cancer. , 0, , .		0
2403	New Option for Metastatic Colorectal Cancer: Oxaliplatin and Novel Oral S-1 Combination Chemotherapy. , 0, , .		0
2405	The Treatment of Metastatic Liver Disease of Colorectal Origin. , 0, , .		0
2407	Adjuvant Therapy for Resectable Colorectal Cancer Liver Metastases. , 0, , .		0
2408	A Case of Cecal Cancer Recurrence Survival with Trousseau Syndrome Postoperatively Combined Multimodality Treatment. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2012, 37, 795-801.	0.0	1
2409	Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody. Journal of Cancer Therapy, 2012, 03, 902-911.	0.1	0
2410	Serum Chlorine Level as a Possible Predictive Factor for Oxaliplatin-Induced Peripheral Neuropathy. Pharmacology & Pharmacy, 2012, 03, 44-51.	0.2	0
2411	Hepatic Resection After Neoadjuvant Chemotherapy for Colorectal Liver Metastases. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2012, 37, 696-701.	0.0	0
2412	Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared with Infusional Fluorouracil, Levcovorin, and Irinotecan (FOLFIRI) as First-Line Treatment for Metastatic Colorectal Cancer. Journal of Cell Science & Therapy, 2012, 03, .	0.3	0
2413	Neoadjuvant Chemotherapy for Colorectal Liver Metastases. , 0, , .		0
2414	Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Cancer and Clinical Oncology, 2012, 1, .	0.2	0
2415	Palliative Care for the Elderly with Colorectal Cancer. , 2013, , 183-199.		0

#	Article	IF	Citations
2416	Clinical Study of the Correlation between Histological Types and the Efficacy of mFOLFOX6 ^|^plusmn; Bevacizumab in Patients with Metastatic Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2013, 66, 80-85.	0.1	0
2417	Resistance to the Anti-EGFR Therapy, Beyond KRAS, in Patients with Metastatic Colorectal Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2013, , 125-141.	0.1	0
2418	Study of Appropriate Surgical Timing for Liver Metastasis of Colon Cancerâ€"From Tumor Shrinkage Speed by Chemotherapyâ€". Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2013, 38, 746-752.	0.0	0
2419	Post-face Vers une nouvelle recherche adaptÃ©e Ã une mÃ©decine personnalisÃ©e. , 2013, , 405-414.		0
2420	Feasibility and Efficacy Study of Biweekly Irinotecan Combined with Oral Tegafur/Uracil in Advanced Colorectal Cancer. Journal of Cancer Therapy, 2013, 04, 8-14.	0.1	0
2421	What is the Optimal Treatment for Metastatic Colorectal Cancer? Controversial Points. Journal of Cancer Science & Therapy, 2013, 05, .	1.7	0
2422	Prognostic Factors of Patients Who Underwent Primary Tumor Resection in Stage IV Colorectal Cancer with Non-resectable Synchronous Metastasis. Nihon Daicho Komonbyo Gakkai Zasshi, 2013, 66, 585-590.	0.1	0
2423	Role of Surgery in the Diagnosis and Management of Metastatic Cancer. , 2013, , 381-399.		0
2424	æ¶ˆåŒ–å™¨ç™ŒåŒ–å¦ç™‚æ³•ã«ãŠã'ã‚‹å£å†…ç‚Žã«å¯¾ã™ã‚‹ã‚¨ãƒ¬ãƒ³ã‚¿ãƒ¼ãƒ«ï¼ˆEDï¼‰ã®æœ‰ç"¨æ€§ã®æ¤œè¨Ž. The Japanese		0
2425	Adenocarcinoma of the Colon and Rectum. , 2013, , 2051-2074.		0
2427	Carcinomatosis: Cytoreduction and Heated Intraperitoneal Chemotherapy (HIPEC) Versus Palliation. , 2014, , 63-89.		1
2428	Medical Oncology. , 2014, , 71-82.		0
2429	Adjuvant therapy for colorectal cancer. , 2014, , 82-94.		0
2430	Perioperative Chemotherapy for Liver Metastases from Colorectal Cancer. Nihon Daicho Komonbyo Gakkai Zasshi, 2014, 67, 877-887.	0.1	0
2431	Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies. World Journal of Gastroenterology, 2014, 20, 10288.	1.4	3
2432	Acute large bowel obstruction secondary to stage 4 colonic carcinoma in an elderly man with severe aortic stenosis: a therapeutic challenge. BMJ Case Reports, 2014, 2014, bcr2013201186-bcr2013201186.	0.2	0
2433	Management of Colorectal Hepatic Metastases: Time for Targeted Patient Care. Gastroenterology & Hepatology (Bartlesville, Okla), 2014, 1, .	0.0	0
2434	Presentation and outcome of twenty patients with synchronous stage IV rectal carcinoma. International Journal of Cancer Therapy and Oncology, 2014, 2, 020313.	0.2	1

#	Article	IF	Citations
2436	FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer. Turkish Journal of Gastroenterology, 2014, 25, 198-204.	0.4	0
2437	Non-Urological Cancers Affecting the Urinary Tract. , 2015, , 857-878.		0
2438	Metastatic Rectal Cancer. , 2015, , 287-310.		0
2439	Zosteriform metastasis of rectal adenocarcinoma: a case report. Dermatology Online Journal, 2015, 21, .	0.2	2
2440	Designs for Evaluating Precision Medicine Trials. , 2015, , 113-131.		0
2441	Targeted Therapies for Colorectal Cancer. Current Clinical Pathology, 2015, , 147-162.	0.0	0
2442	Osteopontin Gene Expression is Inversely Regulate 5-Fluorouracil Drug Resistance in Colon Cancer. Cancer Research Journal, 2015, 3, 42.	0.0	0
2444	Multimodality Management of Oligometastatic Colorectal Cancer. , 2015, , 311-350.		0
2445	Colorectal and Anal Tumors. Pediatric Oncology, 2017, , 319-333.	0.5	0
2446	Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India. Indian Journal of Cancer, 2017, 54, 631.	0.2	2
2447	Regional chemotherapy for liver tumors. , 2017, , 1470-1487.e3.		0
2448	Basics of Chemotherapy. , 2017, , 1-10.		0
2449	Utility of Primary Tumor Resection in Asymptomatic, Unresectable Metastatic Colon and Rectal Cancer. Difficult Decisions in Surgery: an Evidence-based Approach, 2017, , 139-152.	0.0	1
2450	A clinical case of perineal invasion from rectal carcinoma. Giornale Di Chirurgia, 2017, 38, 199.	0.5	1
2453	Weekly High-dose 5-Fluorouracil as 24-hour Infusion Combined with Sodium Folinic Acid (AIO regimen) Plus Irinotecan in Second-line and Sequential Therapy of Metastatic Colorectal Cancer (CRC). Anticancer Research, 2017, 37, 3771-3779.	0.5	2
2454	Clinicoepidemiological Study and Survival Analysis of Right versus Left Sided Colon Cancer Patients. The Egyptian Journal of Hospital Medicine, 2017, 69, 1723-1737.	0.0	0
2455	CHEMOTHERAPY IN THE MANAGEMENT OF LOCALIZED AND METASTATIC COLON CANCER: NEW AND YET UNFORGOTTEN APPROACHES. Meditsinskiy Sovet, 2017, , 67-76.	0.1	2
2456	Stellenwert der systemischen Chemotherapie bei fortgeschrittener peritonealer Metastasierung. , 2018, , 245-260.		0

#	Article	IF	Citations
2457	Penile and multiple cutaneous metastases over the pubic region from a rectal adenocarcinoma: An uncommon case. Tzu Chi Medical Journal, 2018, 30, 44.	0.4	1
2458	Hepatic Arterial Therapy for Colorectal Cancer Liver Metastases. , 2018, , 217-231.		0
2460	Results of using tegafur in combination with irinotecan and oxaliplatin in patients with advanced colorectal cancer. Meditsinskiy Sovet, 2018, , 42-49.	0.1	1
2461	ConventÄ±onal and targeted therapy in metastatÄ±c colorectal cancer. Journal of Cancer Prevention & Current Research, 2018, 9, .	0.1	1
2463	Clinical value of an adenosine triphosphate-based chemotherapy response assay in resectable stage III colorectal cancer. Annals of Surgical Treatment and Research, 2019, 97, 93.	0.4	1
2464	Prognostic Factors in Geriatric Patients with Metastatic Colon Cancer. Journal of Cancer Therapy, 2019, 10, 779-788.	0.1	0
2465	Metastatic Colorectal Cancer. , 2019, , 135-160.		0
2466	AnÃ¡lise da toxicidade de uma Fluoropirimidina em Protocolo QuimioterÃ¡pico. SaÃºde, 2018, 3, .	0.1	1
2467	Importance of autophagy in colorectal cancer: A cross-sectional study. Journal of Surgery and Medicine, 0, , .	0.0	1
2468	Early Recurrence After Initial Hepatectomy for Colorectal Liver Metastases. International Surgery, 2019, 104, 375-382.	0.0	2
2470	Sequencing of Systemic Chemotherapy for Unresectable CRLM. , 2020, , 297-312.		0
2471	Surgical Results for Synchronous Colorectal Cancer Liver Metastases. , 2020, , 345-354.		0
2472	Management of Disappearing Liver Metastasis Following Preoperative Chemotherapy. , 2020, , 229-238.		0
2473	Adenocarcinoma of the Colon and Rectum. , 0, , .		0
2474	Results of using 3-component regimen TEGOXIRI (tegafur, oxaliplatin, irinotecan) Â± Leucovorin in patients with advanced colorectal cancer. Meditsinskiy Sovet, 2019, , 92-102.	0.1	0
2475	Resection of the Primary in Unresectable Colorectal Cancer Liver Metastases â€“ Is It Worth?. , 2020, , 445-453.		0
2476	Role of Hepatic Artery Infusion Pump Chemotherapy for Unresectable Colorectal Cancer Liver Metastases. , 2020, , 313-327.		1
2477	Retrospective Analysis of S-1 plus Bevacizumab as Maintenance Therapy after Induction of S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer. Journal of Cancer Therapy, 2020, 11, 35-43.	0.1	0

#	Article	IF	Citations
2478	Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. World Journal of Gastrointestinal Oncology, 2020, 12, 301-310.	0.8	9
2479	Current perspective on the treatment of advanced/metastatic colorectal cancer. Onkologie (Czech) Tj ETQq1 1 0.784314 rgBT /Overlock	0.0	0
2480	Oxaliplatin-Induced Thrombocytopenia: A Case Report and Review of Pathophysiology of Various Speculative Mechanisms. Cureus, 2020, 12, e9929.	0.2	0
2481	Selective Vascular Endothelial Growth Factor Receptor Inhibitors Provide Limited Benefits for Metastatic Colorectal Cancer: A Meta-Analysis. Current Pharmaceutical Design, 2020, 26, 3171-3186.	0.9	0
2482	Phase I Dose-Escalation Trial of an Innovative Chemotherapy Regimen Combining a Fractionated Dose of Irinotecan Plus Bevacizumab, Oxaliplatin, 5-Fluorouracil, and Folinic Acid (bFOLFIRINOX-3) in Chemorefractory Metastatic Colorectal Cancer. Cancers, 2021, 13, 5472.	1.7	0
2484	Monosialotetrahexosylganglioside in the treatment of chronic oxaliplatin-induced peripheral neurotoxicity: TJMUCH-GI-001, a randomised controlled trial. EClinicalMedicine, 2021, 41, 101157.	3.2	3
2485	Role of plant derived bioactive compounds against cancer. South African Journal of Botany, 2022, 149, 1017-1028.	1.2	17
2486	Understanding Colorectal Cancer: The Basics. Diagnostics and Therapeutic Advances in GI Malignancies, 2020, , 93-115.	0.2	0
2487	Drug Repurposing in Oncotherapeutics. , 0, , .		1
2488	A phase 1b expansion study of TASâ€102 with oxaliplatin for refractory metastatic colorectal cancer. Cancer, 2021, 127, 1417-1424.	2.0	5
2489	Rapid and Sensitive Detection of UGT1A1 Polymorphisms Associated with Irinotecan Toxicity by a Novel DNA Microarray. Yamaguchi Medical Journal, 2020, 69, 161-168.	0.1	0
2490	5HT₃RA plus dexamethasone plus aprepitant for controlling delayed chemotherapyâ€induced nausea and vomiting in colorectal cancer. Cancer Science, 2021, 112, 744-750.	1.7	10
2491	Novel approaches to treatment of locally advanced rectal cancer. OnkologiÄeskaÃ¢ KoloproktologiÃ¢, 2020, 10, 73-83.	0.1	0
2492	A Case of Rectal Cancer with Peritoneal Dissemination Wrho Responded to Combination Chemotherapy afterPlacement of a Self-expandable Metallic Stent. Nihon Daicho Komonbyo Gakkai Zasshi, 2020, 73, 58-63.	0.1	0
2493	Significance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases. Anticancer Research, 2021, 41, 5539-5547.	0.5	7
2494	Treatment strategy for resectable colorectal cancer liver metastases from the viewpoint of time to surgical failure. Langenbeck's Archives of Surgery, 2021, , 1.	0.8	2
2495	Colorectal Cancer: From Epidemiology to Current Treatment. Libyan Journal of Medicine, 2006, 1, 42-59.	0.8	1
2499	A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). Investigational New Drugs, 2006, 24, 343.	1.2	0

#	Article	IF	Citations
2501	Cytotoxic Chemotherapy for Metastatic Colorectal Cancer. , 2007, , 69-84.		1
2502	Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment. , 2007, , 85-98.		1
2503	Second-Line Strategies in the Treatment of Patients With Metastatic Colorectal Cancer. , 2007, , 119-130.		0
2504	Adjuvant Chemotherapy for Colon Cancer. , 2007, , 131-154.		0
2506	Kolorektales Karzinom. , 0, , 747-817.		0
2508	The conversion of RAS status in metastatic colorectal cancer patients after firstâ€line biological agent treatment. Colorectal Disease, 2021, 23, 206-212.	0.7	0
2509	SystemÄ±c Chemotherapy in Colorectal Cancer. , 2021, , 693-705.		0
2510	Aberrant Partial Chromosomal Instability With Chemotherapeutically Resistant Metachronous Colorectal Cancer Following a Synchronous Primary Colorectal Cancer: A Case Report. Cureus, 2020, 12, e11308.	0.2	2
2511	Chemotherapy and Targeted Drugs for Patients with Metastatic Colorectal Cancer. , 2021, , 187-202.		0
2512	The emerging role of neoadjuvant chemotherapy for rectal cancer. Journal of Gastrointestinal Oncology, 2014, 5, 362-73.	0.6	29
2513	Management of oxaliplatin-induced peripheral neuropathy. Therapeutics and Clinical Risk Management, 2005, 1, 249-58.	0.9	96
2514	Predictive and prognostic markers in colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 237-46.	0.8	9
2515	Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointestinal Cancer Research: GCR, 2007, 1, 146-54.	0.8	26
2516	Second-line therapy for advanced colorectal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 57-63.	0.8	10
2517	Looking ahead: what will change in colorectal cancer treatment?. Gastrointestinal Cancer Research: GCR, 2009, 3, S16-8.	0.8	3
2518	Cetuximab in the management of colorectal cancer. Biologics: Targets and Therapy, 2007, 1, 77-91.	3.0	13
2519	Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics: Targets and Therapy, 2009, 3, 429-41.	3.0	3
2520	Current status of treatment of metastatic colorectal cancer with special reference to cetuximab and elderly patients. OncoTargets and Therapy, 2009, 2, 17-27.	1.0	3

#	Article	IF	Citations
2521	Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Transactions of the American Clinical and Climatological Association, 2010, 121, 21-32; discussion 32-3.	0.9	2
2522	Evolving role of cetuximab in the treatment of colorectal cancer. Cancer Management and Research, 2009, 1, 79-88.	0.9	5
2523	Panitumumab: the evidence of its therapeutic potential in metastatic colorectal cancer care. Core Evidence, 2007, 2, 81-8.	4.7	1
2524	Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Current Oncology, 2011, 18 Suppl 2, S5-S10.	0.9	11
2525	Prognostic factors for metastatic colorectal cancer patients undergoing irinotecan-based second-line chemotherapy. Gastrointestinal Cancer Research: GCR, 2011, 4, 168-72.	0.8	13
2526	Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia. The Malaysian Journal of Medical Sciences, 2011, 18, 32-43.	0.3	7
2527	Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer. Current Oncology, 2006, 13, 173-84.	0.9	9
2528	A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. Journal of Gastrointestinal Oncology, 2012, 3, 90-6.	0.6	17
2529	Rectal adenocarcinoma: proposal for a model based on pretreatment prognostic factors. Puerto Rico Health Sciences Journal, 2012, 31, 52-8.	0.2	0
2530	Optimal timing of systemic therapy in resectable colorectal liver metastases. American Surgeon, 2013, 79, 414-21.	0.4	3
2531	Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. Journal of Gastrointestinal Oncology, 2014, 5, 99-103.	0.6	4
2532	A 39-year-old female patient with metastatic rectal cancer develops thrombocytopenia. Gastrointestinal Cancer Research: GCR, 2014, 7, 55-8.	0.8	1
2533	Colorectal cancer and NF-Î°B signaling pathway. Gastroenterology and Hepatology From Bed To Bench, 2011, 4, 127-32.	0.6	48
2534	Efficacy of chemotherapy plus bevacizumab as first-line therapy in patients with metastatic colorectal cancer: a meta-analysis and up-date. International Journal of Clinical and Experimental Medicine, 2015, 8, 1434-45.	1.3	10
2535	Saudi Oncology Society clinical management guideline series. Colorectal cancer 2014. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1538-44.	0.5	5
2536	The challenge of using biomarkers and molecularly targeted drugs to improve cure rate in early stage non-small cell lung cancer. Journal of Thoracic Disease, 2015, 7, 230-4.	0.6	2
2537	Palliative oxaliplatin-based chemotherapy after exposure to oxaliplatin in the adjuvant setting for colon cancer. Journal of Gastrointestinal Oncology, 2015, 6, 487-91.	0.6	3
2538	Gemcitabine plus S-1 versus cetuximab as a third-line therapy in metastatic colorectal cancer: an observational trial. International Journal of Clinical and Experimental Medicine, 2015, 8, 21159-65.	1.3	4

#	Article	IF	Citations
2539	Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer. Advanced Biomedical Research, 2016, 5, 10.	0.2	2
2540	Natural killer cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p. American Journal of Cancer Research, 2018, 8, 824-834.	1.4	9
2541	Photothermal therapy technology of metastatic colorectal cancer. American Journal of Translational Research (discontinued), 2020, 12, 3089-3115.	0.0	7
2542	Cutaneous metastasis of a colon adenocarcinoma presenting as an unusual manifestation: a report of one case. International Journal of Clinical and Experimental Pathology, 2020, 13, 1897-1901.	0.5	0
2543	Serious Adverse Events Reporting in Phase III Randomized Clinical Trials of Colorectal Cancer Treatments: A Systematic Analysis. Frontiers in Pharmacology, 2021, 12, 754858.	1.6	2
2544	Economic Evaluation of Monoclonal Antibodies in Metastatic Colorectal Cancer: A Systematic Review. Molecular Diagnosis and Therapy, 2021, 25, 715-734.	1.6	6
2546	Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases. Cancers, 2022, 14, 241.	1.7	14
2547	Development and validation of a coding framework to identify severe acute toxicity from systemic anti-cancer therapy using hospital administrative data. Cancer Epidemiology, 2022, 77, 102096.	0.8	5
2548	Predictive Value of UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity and Therapeutic Efficacy in Colorectal Cancer Patients. Journal of Cancer Treatment & Diagnosis, 2020, 4, 39-46.	0.9	2
2549	Locally Advanced Rectal Cancer: What We Learned in the Last Two Decades and the Future Perspectives. Journal of Gastrointestinal Cancer, 2022, , 1.	0.6	5
2550	Early detection of treatment futility in patients with metastatic colorectal cancer. Oncotarget, 2022, 13, 61-72.	0.8	7
2551	Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer. Investigational New Drugs, 2022, 40, 340-348.	1.2	4
2552	A comprehensive framework for early-onset colorectal cancer research. Lancet Oncology, The, 2022, 23, e116-e128.	5.1	49
2553	Precision medicine for metastatic colorectal cancer in clinical practice. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110727.	1.4	23
2554	CHFR-Promoter-Methylation Status Is Predictive of Response to Irinotecan-based Systemic Chemotherapy in Advanced Colorectal Cancer. Anticancer Research, 2022, 42, 697-707.	0.5	2
2555	FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592110687.	1.4	9
2556	Immune subtypes and neoantigen-related immune evasion in advanced colorectal cancer. IScience, 2022, 25, 103740.	1.9	4
2557	A multicenter phase II trial evaluating the efficacy of bevacizumab plus mFOLFOX6 for R0 surgical resection in advanced colorectal liver metastases harboring mutant-type KRAS: NEXTO-mt trial. Hpb, 2022, 24, 1245-1251.	0.1	1

#	Article	IF	Citations
2558	Efficacy and Safety of Systemic Treatments Among Colorectal Cancer Patients: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Oncology, 2021, 11, 756214.	1.3	7
2559	Treatment of metastatic colorectal cancer in the year 2020. Onkologie (Czech Republic), 2021, 14, 258-261.	0.0	0
2560	The sequence of antiVEGF(R) preparations in the treatment of metastatic colorectal carcinoma in 2020. Onkologie (Czech Republic), 2021, 14, 263-267.	0.0	0
2561	Immunotherapy in the Treatment of Advanced Colorectal Cancer. , 2022, , 113-137.		0
2562	Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial. Cancer Control, 2022, 29, 107327482210803.	0.7	0
2564	Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis. Signal Transduction and Targeted Therapy, 2022, 7, 54.	7.1	84
2565	Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. Cancer Management and Research, 2022, Volume 14, 821-842.	0.9	2
2566	Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RASâ€mutant metastatic colorectal cancer. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 531-538.	0.7	3
2567	Efficacy and toxicity of aflibercept and bevacizumab in combination with FOLFIRI in secondâ€line therapy for metastatic colon cancer: a retrospective multicenter study. Pelvic Surgery and Oncology, 2022, 11, 11-17.	0.2	0
2568	Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer. Journal of Cancer Research and Clinical Oncology, 2022, , .	1.2	0
2569	The Efficacy and Tolerability of Xeliri-Aflibercept Combination in A Metastatic Colorectal Cancer Patient After 5-Fu- Induced Symptomatic Bradycardia: A Case Report and A Brief Review of Literature. OsmangazÄ° Journal of Medicine, 0, , .	0.1	0
2570	Surgery, Chemotherapy and Radiotherapy May Promote Cancer Growth Speeds and Shorten Patient Lives. Global Journal of Cancer Therapy, 2022, 8, 046-049.	0.4	2
2571	Inoperable deÂnovo metastatic colorectal cancer with primary tumour inÂsitu: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre). Molecular and Clinical Oncology, 2021, 16, 40.	0.4	0
2572	Transcriptomic profiling of adjuvant colorectal cancer identifies three key prognostic biological processes and a disease specific role for granzyme B. PLoS ONE, 2021, 16, e0262198.	1.1	4
2573	Advances in liver transplantation for unresectable colon cancer liver metastasis. World Journal of Gastrointestinal Surgery, 2021, 13, 1615-1627.	0.8	0
2574	Mining Cancer Cell Line-Based Drugs to Benefit KRAS^(G12D) Pancreatic Adenocarcinoma Patients. , 2021, , .		0
2576	Results of Cytoreduction followed by HIPEC in Carcinomatosis of Colorectal Origin. , 2007, 134, 291-301.		1
2594	A case of long-term survival after repeated response to oxaliplatin-based chemotherapy and repeated thermoablation of liver metastases from colorectal cancer. Should we introduce the concept of oxaliplatin-resistant tumors?. Tumori, 2013, 99, e91-5.	0.6	1

#	Article	IF	Citations
2595	Hepatic arterial infusion chemotherapy prior to standard systemic chemotherapy in patients with highly advanced unresectable liver metastases from colorectal cancer: a report of three patients. Acta Medica Okayama, 2011, 65, 49-53.	0.1	0
2600	Bevacizumab plus FOLFOX or FOLFIRI regimens on patients with unresectable liver-only metastases of metastatic colorectal cancer. Advanced Biomedical Research, 2016, 5, 10.	0.2	4
2601	Multimodal immune activation abilities and characteristics of reovirus.. American Journal of Translational Research (discontinued), 2021, 13, 14176-14185.	0.0	0
2602	A Comprehensive Review of Management of Colorectal Liver Mets in the Current Era.. , 2022, 5, 46-57.		0
2603	Nanotherapeutics for colon cancer. , 2022, , 251-268.		0
2605	A Nutritional Approach for the Management of Chemotherapy-Induced Diarrhea in Patients with Colorectal Cancer. Nutrients, 2022, 14, 1801.	1.7	5
2606	Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen. Anticancer Research, 2022, 42, 2675-2681.	0.5	0
2607	Multiple Criteria Decision Analysis (MCDA) for evaluating cancer treatments in hospital-based health technology assessment: The Paraconsistent Value Framework. PLoS ONE, 2022, 17, e0268584.	1.1	5
2608	Simple systemic index associated with oxaliplatinâ€induced liver damage can be a novel biomarker to predict prognosis after resection of colorectal liver metastasis. Annals of Gastroenterological Surgery, 2022, 6, 813-822.	1.2	3
2609	Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm. JCO Clinical Cancer Informatics, 2022, , .	1.0	3
2610	Regional Therapy for Colorectal Cancer Liver Metastases: Which Modality and When?. Journal of Clinical Oncology, 2022, 40, 2806-2817.	0.8	9
2611	Zebrafish Patient-Derived Xenograft Model to Predict Treatment Outcomes of Colorectal Cancer Patients. Biomedicines, 2022, 10, 1474.	1.4	7
2612	Role of Ginseng, Quercetin, and Tea in Enhancing Chemotherapeutic Efficacy of Colorectal Cancer. Frontiers in Medicine, 0, 9, .	1.2	8
2613	Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment. Journal of Gastrointestinal Cancer, 0, , .	0.6	0
2614	Coptidis Rhizoma Suppresses Metastatic Behavior by Inhibiting TGF-Î²-Mediated Epithelial-Mesenchymal Transition in 5-FU-Resistant HCT116 Cells. Frontiers in Pharmacology, 0, 13, .	1.6	4
2616	Randomized phase II trial of FOLFIRI-panitumumab compared with FOLFIRI alone in patients with RAS wild-type circulating tumor DNA metastatic colorectal cancer beyond progression to first-line FOLFOX-panitumumab: the BEYOND study (GEMCAD 17-01). Clinical and Translational Oncology, 2022, 24, 2155-2165.	1.2	6
2617	A Systematic Review of Conversion to Resectability in Unresectable Metastatic Colorectal Cancer Chemotherapy Trials. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	0.6	1
2618	The survival impact of palliative chemotherapy dose modifications on metastatic colon cancer. BMC Cancer, 2022, 22, .	1.1	2

#	Article	IF	Citations
2619	Baseline serum uric acid level is associated with progression-free survival, disease control rate, and safety in postoperative patients with colorectal cancer treated by FOLFOX, FOLFIRI, or XELOX. Frontiers in Oncology, 0, 12, .	1.3	0
2620	Survival after hepatectomy for metastatic colorectal cancer in the presence of resectable extrahepatic disease. Ibnosina Journal of Medicine and Biomedical Sciences, 2014, 06, 67-74.	0.2	0
2621	Is There a Place for Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer?. Current Oncology, 2022, 29, 5223-5237.	0.9	5
2622	ISPARTA BURDUR YÃ–RESÄ°NDEKÄ° KOLON KANSERÄ° HASTALARININ DEMOGRAFÄ°K VE KLÄ°NÄ°K Ã–ZELLÄ°KLERÄ°. SÃ¼leyman Demirel Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 2022, 29, 386-389.	0.0	0
2623	Perioperative Chemotherapy for Liver Metastasis of Colorectal Cancer: Lessons Learned and Future Perspectives. Current Treatment Options in Oncology, 2022, 23, 1320-1337.	1.3	7
2624	Optimizing the Personalized Care for the Management of Rectal Cancer: A Consensus Statement. , 2022, 33, 627-663.		0
2625	Clinical outcomes of targeted therapies in elderly patients aged â‰¥ 80 years with metastatic colorectal cancer. World Journal of Clinical Cases, 0, 10, 10066-10076.	0.3	0
2626	Provider imaging practices and outcomes of advanced colorectal cancer. Cancer Treatment and Research Communications, 2022, 32, 100624.	0.7	0
2627	Polypharmacology in Clinical Applicationsâ€”Anticancer Polypharmacology. , 2022, , 73-132.		0
2628	The role of chemotherapy in the treatment of advanced appendiceal cancers: summary of the literature and future directions. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211124.	1.4	5
2629	Generalized pairwise comparisons for censored data: An overview. Biometrical Journal, 2023, 65, .	0.6	5
2630	The optimal first-line treatment for patients with left-sided RAS wild-type metastatic colorectal cancer: Double-drug regimen or triple-drug regimen therapy. Frontiers in Pharmacology, 0, 13, .	1.6	2
2631	Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers, 2022, 14, 4340.	1.7	1
2632	Palliative primary tumor resection in minimally symptomatic patients with colorectal cancer and synchronous unresectable metastases: when is it necessary? (systematic review). Koloproktologia, 2022, 21, 99-110.	0.1	0
2633	Evaluation of survival of the patients with metastatic rectal cancer by staging 18F-FDG PET/CT radiomic and volumetric parameters. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2023, 42, 122-128.	0.1	0
2634	Combined Therapy for the Treatment of Cancer. , 2022, , 27-55.		0
2636	Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity. Cancer Medicine, 2023, 12, 4294-4305.	1.3	3
2637	Small Bowel Adenocarcinoma: 10-Year Experience in a Cancer Centerâ€”The Ottawa Hospital (TOH). Current Oncology, 2022, 29, 7439-7449.	0.9	3

#	Article	IF	Citations
2639	Colorectal Cancer Liver Metastases. Surgical Oncology Clinics of North America, 2023, 32, 119-141.	0.6	7
2640	A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenibÂin previously treated metastatic colorectal cancer patients (REARRANGE trial). European Journal of Cancer, 2022, 177, 154-163.	1.3	4
2641	Efficacy of Adjuvant Chemotherapy Following Curative Resection of Colorectal Cancer Liver Metastases. Anticancer Research, 2022, 42, 5497-5505.	0.5	2
2642	A Multicenter Phase 1 Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery for Patients with Peritoneal Surface Disease. Annals of Surgical Oncology, 0, , .	0.7	1
2644	Treatment Refractory Metastatic Colorectal Cancer. , 2022, , 287-292.		0
2645	Initial Systemic Chemotherapy for Metastatic Colorectal Cancer. , 2022, , 279-286.		0
2646	Infusional Therapy: American Experience. , 2022, , 341-351.		0
2647	Perioperative Chemotherapy: Review of Randomized Trials and Recommended Approach. , 2022, , 197-209.		0
2648	Adjuvant Systemic Chemotherapy. , 2022, , 301-308.		0
2649	FDA Should Re-evaluate All mRNA Vaccines and Revoke Their Use Authorizations (The Short Version).. International Journal of Coronaviruses, 2022, 4, 16-66.	0.8	0
2650	Screening prognostic genes related to leucovorin, fluorouracil, and irinotecan treatment sensitivity by performing co-expression network analysis for colon cancer. Frontiers in Genetics, 0, 13, .	1.1	0
2651	Hepatectomy is associated with improved oncologic outcomes in recurrent colorectal liver metastases: A propensity-matched analysis. Surgery, 2023, 173, 1314-1321.	1.0	6
2652	Association of HLA-G 3â€²UTR Polymorphisms with Response to First-Line FOLFIRI Treatment in Metastatic Colorectal Cancer. Pharmaceutics, 2022, 14, 2737.	2.0	4
2655	Trifluridineâ€“tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study. The Lancet Gastroenterology and Hepatology, 2023, 8, 133-144.	3.7	11
2656	Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis. International Journal of Colorectal Disease, 2023, 38, .	1.0	0
2657	AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway. BMC Cancer, 2023, 23, .	1.1	13
2658	Oncotherapeutic Strategies in Early Onset Colorectal Cancer. Cancers, 2023, 15, 552.	1.7	4
2659	Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study. Cancer Communications, 0, , .	3.7	0

#	Article	IF	Citations
2660	Serum CCL7 Is a Novel Prognostic Biomarker of Metastatic Colorectal Cancer. Anticancer Research, 2023, 43, 105-114.	0.5	5
2661	Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. World Journal of Gastroenterology, 0, 29, 926-948.	1.4	4
2662	Safety of Early Bevacizumab Administration after Central Venous Port Placement for Patients with Colorectal Cancer. Cancers, 2023, 15, 2264.	1.7	2
2664	Is the combination of immunotherapy with conventional chemotherapy the key to increase the efficacy of colorectal cancer treatment?. World Journal of Gastrointestinal Oncology, 0, 15, 251-267.	0.8	6
2665	CACA guidelines for holistic integrative management of rectal cancer. , 2023, 2, .		0
2666	Vertical level of blood cell division cycle 42 predicts response and survival benefits to PD-1 inhibitor-based regimen in metastatic colorectal cancer patients. Scandinavian Journal of Clinical and Laboratory Investigation, 2023, 83, 103-110.	0.6	1
2667	Complete resolution of rectal cancer with liver metastases after palliative chemoradiotherapy and unplanned surgical resectionâ€”a case report. Journal of Surgical Case Reports, 2023, 2023, .	0.2	0
2668	Bayesian estimation of twoâ€part joint models for a longitudinal semicontinuous biomarker and a terminal event with INLA: Interests for cancer clinical trial evaluation. Biometrical Journal, 2023, 65, .	0.6	1
2669	Stage IV Colorectal Cancer Management and Treatment. Journal of Clinical Medicine, 2023, 12, 2072.	1.0	18
2670	Effectiveness of Standard Treatment for Stage 4 Colorectal Cancer: Traditional Management with Surgery, Radiation, and Chemotherapy. Clinics in Colon and Rectal Surgery, 2024, 37, 062-065.	0.5	0
2671	The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) â€“ a real- life data report 2013â€“2018. Radiology and Oncology, 2023, 57, 103-110.	0.6	1
2672	Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201. Journal of Gastrointestinal Oncology, 2023, 14, 676-691.	0.6	1
2687	Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance. , 2023, , 207-221.		0
2699	Editorial: Molecular targets for the treatment of metastatic colorectal cancer. Frontiers in Oncology, 0, 13, .	1.3	0
2705	Current drug therapy for colorectal cancer. , 2024, , 115-148.		0